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ABSTRACT 
Bioactive Poly( ethylene glycol)-based Hydrogels for Angiogenesis in 
Tissue Engineering 
by 
Jennifer Elaine Saik 
Because engineered tissue constructs are inherently limited by their lack of 
microvascularization, which is essential to provide oxygen for cell survival, this thesis 
presents rationally designed materials and cell culture techniques capable of supporting 
functional tubule formation and stabilization. Combining a synthetic scaffold material 
with cells and their cell-secreted signals instigated tubule formation throughout the 
scaffold Poly( ethylene glycol) (PEG) based hydrogels, biocompatible polymers which 
resist protein adsorption and subsequent nonspecific cellular adhesion, were modified to 
induce desired cell characteristics. Human umbilical vein endothelial cells were used as a 
reproducible and readily available cell type. Several tubule-stabilization signals, 
including platelet derived growth factor-BB (PDGF-BB) and ephrinAl, were covalently 
immobilized via conjugation to PEG to enable prolonged bioactive signaling and 
controlled local delivery. All hydrogels were further tested in a mouse cornea 
micropocket angiogenesis assay, a naturally avascular tissue for easy imaging in a 
reproducible and quantifiable assay. Hydrogels containing soluble growth factors induced 
vessel formation in the hydrogel, and the resulting vessel morphology was modulated 
using different growth factor concentrations. Immobilized PDGF-BB led to tubule 
111 
formation in two dimensions, three dimensions, and in the mouse cornea while 
immobilized ephrinAl stimulated secretion of extracellular matrix proteins laminin and 
collagen IV to stabilize the newly formed tubules. Finally, a co-culture of endothelial 
and pericyte cells encapsulated into hydrogels formed tubules that anastomosed to the 
host vasculature and contained red blood cells. PEG-based hydrogels represent a 
promising technique to induce microvascular formation in engineered constructs, leading 
to stable and functional vessel formation using covalently immobilized growth factors 
and encapsulated cells. These materials can be used for replacement of damaged or 
diseased tissues as the current supply of cadaveric donations cannot meet the demand of 
tissues for the 110,000 people awaiting an organ in the US. 
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Chapter 1: Introduction 
A significant portion of this chapter is from JE Saik, MK McHale, and JL West. 
"Biofunctional Materials for Directing Vascular Repair." Curr Vas Phama. Submitted 
2011. 
1.1 The Need for Therapeutic Angiogenesis 
While organ transplantation saves thousands of lives each year, over 110,000 
people are currently waiting on the organ transplant list, eighteen patients die every day 
awaiting an organ, and a person is added to the transplant wait list every thirteen minutes 
(UNOS, 2011). The increasing demand for donated organs to replace damaged or 
diseased tissues cannot be met by the current supply from cadaveric and living donors. 
The field of tissue engineering aims to meet this demand by replacing injured and 
diseased tissues with functional engineered counterparts (Saik et al., 2011). The first US 
Food and Drug Administration approved success in tissue engineering was Apligraf® to 
replace the epidermis in burn patients (Falanga et al., 1999). Despite the success of 
Apligraf®, successfully engineered tissues have been to date limited to thin or avascular 
tissues, including skin, cartilage, and bladder (Jain et al., 2005; Atala et al., 2006). In 
these thin tissues, oxygen, nutrients, and waste can diffuse through the tissue without 
requiring a functional microvascular system. 
Development of more complex tissues, such as lung, liver, or heart, will require a 
better understanding of how to induce vascularization in tissues, especially capillaries. 
Therapeutic angiogenesis attempts to induce capillary formation in tissues. This chapter 
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will first outline the basic biology of blood vessels and neovessel formation. Since tissue 
engineering mimics the body's natural process by using three basic components to create 
new tissues: (I) growth factors, (2) biomaterials, and (3) cells, this chapter will review 
the role of growth factors involved in angiogenesis, the biomaterials used, and in vivo 
assays to demonstrate the material's functionality. Finally, current work involving 
biomaterials releasing growth factors and encapsulated cells is reviewed. Using the three 
basic components of cells, growth factors, and biomaterials, this thesis demonstrates the 
formation of functional and stable tubule networks in tissue engineering scaffolds which 
can be used for fabrication of more complex engineered tissues. 
1.2 Biology of the Microvasculature 
Capillaries are composed of endothelial cells, pericytes, and a basement 
membrane. The thrombo-resistant monolayer of endothelial cells forms a selectively 
permeable barrier and function to control leukocyte and platelet interactions, blood flow, 
and vessel tone (Seifalian et al., 2002). The walls of capillaries are lined with a single 
layer of pericytes, a type of mural cell analogous to the smooth muscle cells found in 
larger vessels (Edelman et al., 2006). Similar to their mural cell counterpart, pericytes 
function to contract in order to regulate blood flow and permeability. Unlike smooth 
muscle cells, pericytes primarily function in the production of basement membrane. Each 
pericyte covers several endothelial cells in an "umbrella-like" manner as seen in Figure 
1-1. With less than 20 nm between pericytes and endothelial cells, pericytes regulate 
permeability but also support general microvascular integrity (Edelman et al., 2006). 
Furthermore, vessels lacking pericytes exhibit abnormal features, such as leakage and 
impaired perfusion due to abnormal endothelial junctions, endothelial hyperplasia, and 
hypervariable diameter (Betsholtz et al., 2005). Based on the importance ofpericytes, 
this thesis researched confirmed the presence of pericyte coverage around induced 
vessels. 
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The presence of pericytes is not only important to existing capillary networks, but 
also to neovessel formation. As the body undergoes healing and maintenance of 
homeostasis, new capillaries must form. These new capillaries arise from either 
vasculogenesis or angiogenesis (Figure 1-1). Vasculogenesis is de novo formation of 
vessels from bone marrow-derived endothelial progenitor cells. Alternatively, in the 
angiogenesis pathway, sprouts from pre-existing capillaries extend to form new vessels. 
Finally, pericytes are recruited to the endothelial cells, derived from either endothelial 
progenitor cells of pre-existing capillaries, to stabilize vessels. This thesis used both of 
these natural processes for neovessel formation. Specifically, a co-culture of endothelial 
cells and pericytes were encapsulated into hydrogels to mimic vascologenesis, and 
various growth factors were used in soluble and immobilized forms to mimic 
angiogenesis. 
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A Vasculogenesis B Angiogenesis 
Endothelial progenitors Capillary 
Lumen formation 
Vascular sprouting 
C ' Poricyte """''men! 
EC 
Blood vessel stabilization and maturation 
Figure 1-1: Capillary Formation. Capillaries arise from either endothelial progenitor recruitment 
as in vasculogenesis (A) or new vessel sprouting from pre-existing endothelial cells as in 
angiogenesis (B). The resultant capillaries are stabilized by pericyte recruitment (C). Figure 
adapted from (Moon et al., 2008). 
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1.3 The Process of Angiogenesis 
A more detailed understanding of the angiogenic process is necessary in order to mimic 
the body's natural 
process. Angiogenesis 
occurs in four steps as 
seen in Figure 1-2: (A) 
plasma proteins (often 
vascular endothelial 
growth factor), released 
Figure 1-2: The process of angiogenesis. (A) A growth factor 
gradient is detected by an endothelial cell, and the endothelial cell 
becomes activated. (B) The activated tip endothelial cell degrades 
the basement membrane in order to migrate down the growth factor 
gradient. (C) Large vacuoles form and merge to make tubule lumen. 
(D) Pericytes are recruited and stabilize newly formed vessels with 
deposition of basement membrane. Figure from (Phelps et al., 
2009). 
during vasodilation and 
extravasation, signal 
endothelial cells via a 
concentration gradient; 
(B) the connection 
between endothelial 
cells and pericytes is 
interrupted, and 
endothelial cells detach 
from the basement membrane; (C) endothelial cells migrate and extend filapodia in 
response to the released proteins; vacuoles form and fuse to create tubule lumen; and (D) 
stabilizing pericytes are recruited to lay basement membrane proteins (Madeddu, 2005). 
The resulting vessels are stabilized and remodeled as necessary, and endothelial cells 
return to their normal quiescent state. Based on the natural process of angiogenesis, this 
thesis research used growth factors, such as VEGF, to establish a concentration gradient. 
Furthermore, the presence of vacuoles and pericytes was confirmed using staining as an 
indicator of remodeling and stable capillary formation. 
1.4 The Role of Growth Factors in Angiogenesis 
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In the process of angiogenesis, growth factors play an important role in the 
development of neovessels. Vascular endothelial growth factor (VEGF), considered the 
key angiogenic factor, stimulates endothelial cells to migrate, proliferate, and 
differentiate (Nomi et al., 2006). VEGF-A, the most characterized VEGF molecule, is 
composed of five isoforms as a result of alternative splicing: VEGF 121 is completely 
soluble; VEGF 165 is mostly soluble but also has affinity for heparin sulfate proteoglycans 
on cell surfaces; and VEGF14s, VEGF1s9, and VEGF2o6 all remain sequestered on the cell 
surface due to their high affinity for heparin (Park et al., 1993). Gene knockout mice 
confirm the importance of VEGF in that a mouse lacking even one VEGF gene fails to 
develop past early embryonic stages (Carmeliet et al., 1996). Several VEGF receptors 
have also been identified, with all VEGF isoforms binding VEGFR-1 and VEGFR-2. 
Hypoxia is the most important inducer ofVEGF expression, mediated by HIF-1 and HIF-
2 along with an increase in mRNA stability (Marti, 2005). However, VEGF-induced 
vessel formation is often leaky and tumor-like (Jain et al., 2005). In this thesis, VEGF 
was initially used as an established method to induce angiogenesis. 
In addition to VEGF, fibroblast growth factor (FGF) is also known for its ability 
to initiate angiogenesis. FGF was the first angiogenic growth factor to be discovered and 
represents a family consisting of over 20 molecules, of which FGF -2 or basic FGF is 
involved in angiogenesis. FGF-2 stimulates endothelial cell proliferation and migration, 
and FGF-2 regulates expression ofkey angiogenic molecules, such as collagenases, PI 
integrins, and urokinase type plasminogen activator (Bikfalvi et al., 1997). FGF-2 also 
induces migration and proliferation of smooth muscle cells (Jackson et al., 1993). 
Hypoxia induces macrophages to release FGF -2 to stimulate growth of endothelial cells. 
This thesis used FGF as an alternative to VEGF to initiate angiogenesis, especially in 
combination with stabilizing factors such as platelet derived growth factor. 
As compared to early stage growth factors like FGF and VEGF known to initiate 
angiogenesis, platelet-derived growth factor (PDGF) is involved in the later stages of 
angiogenesis involving stabilization and remodeling. PDGF was identified as a key 
protein secreted from platelets in the 1970s. PDGF forms homo- and heterodimers of A-
and B-polypeptide chains. The three-dimensional structure and amino acid sequence 
show great similarity to VEGF, as well as to nerve growth factor and transforming 
growth factor p (Heldin et al., 1999). Two PDGF receptors exist, and ligand-induced 
receptor dimerization initiates receptor autophosphorylation. 
PDGF receptor autophosphorylation induces widespread activities throughout the 
body, especially in the development of the kidneys, lungs, CNS, and blood vessels. 
Specific to the vascular system, endothelial cells not only produce PDGF but also display 
PDGF receptors (Bar et al., 1989). Although PDGF is not involved in initial vessel 
formation, PDGF-BB is involved in neovessel stabilization and functionalization by 
inducing functional anastomoses and recruiting pericytes. Mice lacking the PDGF-B 
chain exhibited defective blood vessel development and microaneurysms, likely as a 
result ofthe inability ofneovessels to attract stabilizing pericytes (Lindahl et al., 1997). 
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PDGF also induces pericyte production of extracellular matrix (ECM) proteins, including 
fibronectin, collagen, and proteoglycans, necessary for the basement membrane of 
capillaries. Furthermore, PDGF stimulates fibroblasts to produce and secrete 
collagenases. This thesis research presents PDGF in an immobilized form for its 
involvement in anastomosis formation and collagenase secretion. 
Similar to PDGF, ephrins are involved in the later remodeling and stabilization 
stages of capillary network formation. Eph receptors and their ephrin ligands are a family 
of receptor tyrosine kinases involved in growth, differentiation, and patterning of tissues. 
Ephrin ligands are categorized as type A for having a glycophosphatidylinositol-anchor 
or type B for having a transmembrane domain. Signaling can occur in a forward manner 
by ephrin ligands activating eph receptors or in reverse by eph receptors activating ephrin 
ligands (Heroult et al., 2006). Unlike other receptor tyrosine kinases, ephrins mediate 
cell adhesion, repulsion, and migration rather than proliferation. Expression of ephrinAl 
is induced by tumor necrosis factor-a, interleukin-1 beta, and VEGF (Cheng, Brantley, 
and Chen, 2002). These factors lead to activation of ephrinAl and its EphA2 receptor, 
which has been shown to be involved in angiogenesis by initiating endothelial cell 
migration and capillary invasion (Brantley et al., 2002). An immobilized form of 
ephrinA 1 was used in this thesis research for its ability to modulate angiogenesis from the 
role of cell adhesion. 
Angiogenesis requires coordinated expression of several key growth factors. A 
single factor such as VEGF is not sufficient to form functional vasculature, and in fact, 
presentation ofVEGF alone can lead to induction oftortuous and leaky vessels (Marti, 
2005). In addition, spatial and temporal regulation of growth factor expression ensures 
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accurate vessel growth and remodeling. For example, when combined with FGF, PDGF 
receptors are upregulated, causing proliferation of smooth muscle cells and stabilization 
ofneovessels (Hollinger et al., 2008). Growth factors, such as VEGF, FGF, and PDGF, 
can be incorporated both individually and in combination in natural and synthetic 
biomaterials. 
1.5 In vivo Angiogenic Assays 
Three in vivo angiogenesis 
assays, including the 
chorioallantoic membrane (CAM) 
assay, dorsal skinfold assay, and 
cornea micropocket, are 
commonly used to evaluate the 
response of vessels to externally 
applied stimuli. The 
A B CAM 
Figure 1-3: The CAM assay for testing angiogenic 
activity of biomaterials. (A) Image of the egg with 
vessels at day 10 and (B) location ofthe CAM (in red) 
around the chick embryo. Adapted from (Vargas et al. , 
2007). 
chorioallantoic membrane, or CAM, is an extra-embryonic membrane used as a gas 
exchange surface during the 21 days prior to chick hatching (Figure 1-3). The CAM 
assay was originally developed to study embryonic tissue grafts and involves breaking 
open an egg and applying the experimental substance to the membrane surface. 
Advantages of the CAM assay include low cost, ease of access to chick embryos, and low 
immunogenicity due to the lack of a complete immune system. However, angiogenic 
efficacy in the CAM assay is limited to ten days due to the developing chick, background 
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vessels must be distinguished from new angiogenesis in response to treatment, and 
genetic modifications to chicks is limited (Vargas et al., 2007). 
In order to study angiogenesis in rodents, which are amenable to genetic 
modification, the dorsal skinfold chamber can be used. In this technique, the experiment 
is carried out within a transparent backpack chamber that is placed over the skinfold, 
providing ease of visualization for the duration of study (Figure 1-4) (Laschke et al., 
2006). On the other hand, experimental protocols are limited in that any implants are 
restricted in size to 5 mm in diameter and 1 mm in height, and background vessels must 
be subtracted from induced vessels. 
Figure 1-4: The dorsal skinfold chamber for studying in vivo angiogenesis. (A) skinfold 
chamber seen on a hamster. (B) The observation window allows imaging of large microvessels. 
(C) Intravital microscopy can be used to image arterioldes (arrows), capillaries (arrowheads), and 
venules (double arrows). Figure from (Laschke et al. , 2006). 
A third in vivo angiogenesis assay is conducted in the mouse cornea, which is a 
reproducible and quantifiable assay in an otherwise avascular tissue and will be used for 
all in vivo work in this thesis. The cornea consists of three cell layers: the outer 
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epithelium, the thick stroma, and the inner endothelium. The thick stromal layer is 
composed of type I collagen fibers and keratinocytes. The endothelium is a monolayer of 
mitrochondria-rich endothelial cells lined with Descemet's membrane, a modified 
basement membrane. The cornea is a continuous layer with the connective tissue sclera, 
and therefore limbic vessels surround the edge ofthe cornea. The cornea functions, along 
with the lens, to refract light and focus the eye. In fact, the cornea represents greater than 
60% of the eye's focusing power (Beebe, 2008). As a result of the cornea's functional 
role, the cornea is a transparent tissue. To maintain transparency, the cornea is both an 
angiogenic and immune privileged site, in which transport of nutrients and oxygen occurs 
through diffusion. 
A vascularity ofthe cornea is maintained by three key molecules: (1) a soluble 
VEGF receptor, (2) pigment epithelium-derived factor (PEDF), and (3) thrombospondins. 
The soluble VEGF receptor Flt-1 binds and sequesters any VEGF present in the cornea 
(Ambati et al., 2007). The importance of sFltl was established when reduction of sFltl 
expression in genetically modified mice led to corneal neovascularization, and Florida 
manatees with vascularized corneas exhibited decreased sFlt1 expression (Beebe, 2008). 
Pigment ephithelium derived factor was identified in avascular cartilage, and inhibition of 
PEDF activity induces corneal neovascularization (Beebe, 2008). The third molecule that 
maintains avascularity is thrombospondins (TSP), a family of four secreted molecules. 
Thrombospondin 1 and 3 were also identified in asvacular cartilage, and TSP-1 and -2 are 
expressed in the cornea. Genetically modified mice lacking TSP-1 showed reduction of 
corneal neovascularization in response to inflammation, and mice lacking TSP-2 
developed vascularized irises (Cursiefen et al., 2004). Even though the cornea normally 
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remains avascular, neovascularization can be induced in response to injury or 
implantation (Muthukkaruppan et al., 1979). The cornea micropocket angiogenesis assay 
takes advantage ofthe potential to induce neovascularization in the cornea by stimulating 
limbic vessels to branch and invade the cornea stroma in response to implantation of a 
biomaterial (Figure 1-5) (Rogers et al., 2007). 
Similar to the angiogenic privilege nature of the cornea, the cornea is also an 
"immune privileged" tissue in order to maintain transparency. The immune privileged 
state is actively maintained by the reduced expression of major histocompatibility 
complex (MHC) class I expression and reduced numbers of immune cells expressing 
MHC class II. Furthermore, an immunosuppressive environment is maintained by the 
presence of soluble factors such as a.-melanocyte-stimulating hormone and vasoactive 
intestinal polypeptide (Cursiefen, 2007). Due to the cornea's avascular nature, nutrient 
and oxygen transport occur by diffusion. Nutrient transport is from the aqueous humor, 
interstitial fluid, and tear film of the eye. Oxygen diffusion occurs from the air through 
the epithelium and stroma. Normal tissues are considered hypoxic when the oxygen 
concentration is below 5%, but the cornea normally has 2% oxygen (Helbig et al., 1993). 
Due to the cornea's unique features of visibility, accessibility, and avascularity 
(Kenyon et al., 1996), the mouse cornea has been used as an optimal in vivo site to study 
angiogenesis since the 1970s and was used for the work in this thesis (Muthukkaruppan 
et al., 1979). In an otherwise avascular tissue, all vessels induced to invade the cornea 
stroma are in response to the bioactive hydrogel. The cornea enables visualization of the 
developing vasculature over time by allowing imaging of live animals. Although the 
cornea restricts implant size, this assay provides a well established, quantitative, and 
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reproducible technique (Rogers et al., 2007) . Based on the ease of imaging over time and 
lack of background vessels, the mouse cornea micropocket was used for the presented 
thesis research. 
D 
B 
monitor 
angiogenic response 
c 
hydrogel 
E 
Figure 1-5: The mouse cornea micropocket. The eye is anesthetized 
(A) and a partial-thickness incision is made (B). A micropocket is 
created (C) and the hydrogel is placed in the micropocket (D). Bioactive 
hydrogels promote natural limbic vessels surrounding the cornea to 
invade the cornea stroma in response to angiogenic stimulation (E). 
Figure adapted from (Rogers et al. , 2007). 
1.6 Biomaterials for Guiding Vessel Growth 
Many biomaterials have been investigated to induce and guide vessel growth 
because biomaterials provide a scaffold for delivery of growth factors and cell seeding. 
Natural materials are commonly used, including collagen and its gelatin derivatives, 
fibrin, and alginate, because they are either components of or similar to components of 
the natural ECM. Collagen is the most abundant ECM consitutent, representing about 
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25% of the total protein mass in the body. Collagen is naturally degraded by cell-
secreted matrix metalloproteinases (MMPs), specifically collagenases and serine 
proteases, allowing cellular infiltration via host degradation. Furthermore, mechanical 
properties of collagen matrices can be enhanced with the addition of chemical 
crosslinkers (Drury et al., 2003). Similar to collagen, fibrin is a natural component of the 
body, found in clots formed during the wound healing cascade. Fibrin provides both 
structural and biochemical cues (Patel et al., 2004). Furthermore, fibrin is capable of 
providing a reservoir for growth factors, which induce endothelial cell tubulogenesis in 
vitro. Alginate and chitosan are hydrophilic, linear polysaccharides commonly used in 
vivo. Alginate, commonly isolated from brown seaweed and bacteria, is readily available 
and forms gels under gentle conditions to allow optimal bioactivity (Drury et al., 2003). 
While natural materials incorporate ECM components, synthetic polymers are 
often used as scaffolds because they allow precise modification of various parameters, 
such as mechanical properties, degradation rates, and drug delivery rates based on 
alteration of molecular weights, chemical structures, and crosslinking modes. Three 
commonly used synthetic biomaterials include poly(lactide-co-glycolide), polyurethane, 
and poly( ethylene glycol). The most highly researched synthetic polymer is poly(lactide-
co-glycolide) (PLGA) because it combines glycolic acid and lactic acid in various ratios 
to design specific degradation and drug release rates. Additionally, PLGA degrades by 
hydrolysis into two biocompatible components (Patel et al., 2004). Polyurethanes are 
another type of synthetic biomaterial used for their biocompatibility and versatility. 
Although polyurethanes are commonly used as biomaterials for heart valves and dialysis 
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membranes, they have only recently been used in angiogenesis applications due to issues 
surrounding their biodegradation (Patel et al., 2004 ). 
This thesis used poly( ethylene glycol) diacrylate (PEGDA), an FDA approved 
biocompatible polymer. PEGDA resists protein absorption and subsequent nonspecific 
cell adhesion, thus providing a "blank slate" which can be modified with bioactive 
ligands to create desired characteristics, such as cell adhesion and possibly differentiation 
(DeLong et al., 2005). PEGDA hydrogels are biocompatible, hydrophilic materials with 
tunable mechanical properties (Figure 1-6) (Hahn et al., 2007). Fully hydrated polymers 
mimic the mechanical properties of soft tissues (West et al., 1999). The polymer can be 
photopolymerized via light by incorporating a photosensitive chemical into the polymer 
solution. Mild crosslinking conditions enable cellular encapsulation into the material 
500 
400 
" .. 
300 
M 200 
100 
0 
50 100 lSO 200 
Figure 1-6: Tunable mechanical properties of PEGDA hydrogels. Increased PEGDA 
concentration allows increasing Young's modulus (E) and ultimate tensile stress (UTS) to mimic 
various tissues in the body (Gunn et al. , 2005). 
while maintaining cell viability. Bioactivity is commonly incorporated into PEG 
materials by attaching the free amine or carboxyl group of a peptide or protein to a 
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bifunctional PEG molecule, leaving the other end to crosslink into the hydrogel. For 
example, several bioactive oligopeptides known to interact with cell surface receptors 
have been incorporated into the hydrogel, including RGDS, showing the concentration of 
RGDS conjugated to the surface of the gel affected cell adhesion (Gunn et al., 2005; Hem 
et al., 1997). Based on these ideal characteristics, PEG-based hydrogels were used for 
the presented research. 
1. 7 Growth Factor Release from Biomaterials 
Biomaterials have provided a delivery vehicle for growth factors involved in 
angiogenesis, including VEGF, FGF, and PDGF. These materials can be designed to 
provide various release profiles of growth factors, enabling controlled response. VEGF 
released increased viability of ischemic flats in rat dorsal skin (Mittermayr et al., 2008) 
and increased human umbilical vein endothelial cell (HUVEC) proliferation (King et al., 
2000). Similarly, FGF-2 release has been used to enhance angiogenesis (Miyoshi et al., 
2005; Fujita et al., 2007; Chinen et al., 2003) and induced more smooth muscle cell 
mitogenicity (Guan et al., 2007; Gou et al., 2008). Similar to FGF, PDGF-BB has been 
released from PLGA microspheres on a nanofibrous scaffold, which resulted in increased 
blood vessel number in an in vivo soft tissue wound repair model (Jin et al., 2008). 
In order to better mimic the natural angiogenic process, combinations of growth 
factors have been released from biomaterials (Wong et al., 2003) (Nillesen et al., 2006) 
(Lee et al., 2003). For example, an in vivo Matrigel plug assay was used to elicit the 
effects of a combination ofFGF-2 and VEGF, finding that VEGF enhances endothelial 
PDGF-B expression, and that FGF-2 enhances mural PDGF receptor f3 (PDGFR-f3) 
expression. The combinations of the factors induce significant mural cell recruitment, 
necessary for a functional vessel (Kano et al., 2005). The combination ofVEGF and 
PDGF is not used based on evidence that VEGF-mediated activation ofVEGFR-2 
suppresses PDGFR-~ expression in mural cells, thereby limiting the vascular response 
(Greenberg et al., 2008). This interaction is confirmed when VEGF-R2 is inhibited. 
17 
Seminal work in the mouse cornea and ischemic hindlimb models investigated 
three combinations of growth factors including VEGF and FGF-2, VEGF and PDGF-BB, 
and FGF-2 and PDGF-BB (Cao et al., 2003). Cao's study found a synergistic effect of 
FGF-2 and PDGF-BB (Figure 1-7), which was further investigated on a molecular level, 
suggesting that vascular endothelial cells are unresponsive to PDGF until FGF activation. 
The synergistic response results because FGF transcriptionally turns on PDGF receptor 
expression in endothelial cells, and PDGF-BB then induces a positive feedback signal by 
amplifying FGF-2 expression in vascular mural cells (Cao et al., 2008). Based on the 
work of Cao et al. illustrating this synergistic angiogenic response, this thesis research 
used a combination ofFGF-2 and PDGF-BB. 
18 
1.8 Controlled Delivery of Growth Factors Using Biomaterials 
Since growth factors have such substantial effects in the body, many growth 
factors have been examined in clinical trials which showed varied results. However, the 
same desirable biological effects also have the potential to create significant 
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Figurel-7: Synergistic effects ofFGF-2 and PDGF-BB as seen in the mouse cornea 
micropocket model. Notice the synergistic vessel formation in response to the combination of 
PDGF-BB and FGF-2. Also, vessels are stable for at least 210 days. Adapted from (Cao et al. , 
2003). 
complications. Even in slow-release applications, high levels of growth factors circulate 
in the body, potentially inducing harmful side effects. Release of growth factors can lead 
to unintended angiogenesis, as seen in pathologies including retinopathy, rheumatoid 
arthritis, and tumor growth (Patel et al. , 2004). Since VEGF induces vascular 
permeability, circulating VEGF has been associated with transient edema in 34% of 
patients (Baumgartner et al. , 2000) and multi-organ edema leading to death in a high 
percentage of animals (Epstein et al., 200 I). Systemic VEGF was also found to promote 
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atherosclerotic lesion growth and instability of atherosclerotic plaques. The combination 
ofVEGF and FGF has been shown to produce vasodilation and hypotension through the 
nitric-oxide-mediated pathway, resulting in death of 50% of pigs tested (Epstein et al., 
2001 ). In clinical trials, delivery of growth factors showed initial promise, but 
subsequent phase II trials failed to show efficacy (Semenza, 2006). Therefore, 
biomaterials have been used to provide a more controlled delivery system of potent 
growth factors and covalent linkage of growth factors to biomaterial matrices offers the 
promise oflocal bioactivity without the unintended systemic effects. 
To improve the cellular response to releasable factors, biomaterials can be 
designed to control both spatial and temporal characteristics of angiogenic factor release. 
Control over spatial release is critical because undirected growth factor release leads to 
many pathological side effects. Many growth factors including FGF-2 and VEGF have a 
half life of less than one hour when released into the body due to cellular degradation 
(Lee et al., 2000). Control over temporal release can thus better mimic the natural 
process of angiogenesis, leading to more stable and functional vessel formation. Ennet et 
al. examined temporal VEGF release kinetics by combining PLGA scaffolds with PLG 
microspheres. In order to obtain sustained, local VEGF release for 21 days, VEGF 
release was tailored based on alterations in polymer composition, matrix composition, 
and scaffold size (Ennett et al., 2006). This system was improved upon by temporally 
controlling the release ofboth VEGF and PDGF-BB from PLGA (Figure 1-8) 
(Richardson et al., 2001). Both spatial and temporal release kinetics ofVEGF and 
PDGF-BB were controlled using a similar porous PLGA scaffold to first deliver VEGF in 
one spatial region with subsequent release ofPDGF-BB in an adjacent spatial region, 
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thereby leading to more mature vessels in vivo (Chen et al. , 2007). VEGF was also 
released from biomaterials based on mechanical signals. Since blood vessels and many 
other tissues operate under a mechanically dynamic environment, alginate hydrogels 
were used as a matrix to 
mechanically control growth 
factor release by reversibly 
binding the growth factor to 
the hydrogel carrier (Lee et 
al., 2000). While biomaterials 
have enabled controlled 
growth factor delivery, many 
challenges still face growth 
factor delivery in the body. 
To overcome these 
Figure 1-8: Spatial and Temporal Control ofVEGF and 
PDGF Release. Temporal release ofVEGF followed by 
PDGF was achieved by mixing VEGF with the polymer 
solution and pre-encapsulating PDGF into polymer 
microspheres. VEGF was subject to rapid release due to 
association with the surface of the polymer in contrast to 
PDGF release, which was regulated by the degradation of 
the polymer used to form the microspheres. Adapted from 
(Richardson et al. , 2001 ). 
challenges, growth factors can be covalently bound to the hydrogel, and this technique is 
used for this thesis research. 
1.9 Immobilized Growth Factors 
Growth factors covalently attached to matrices enable prolonged delivery and 
bioactivity in a local, controlled manner. Heparan sulfate proteoglycans and fibrin 
naturally bind certain growth factors in order to deliver them during wound healing. For 
example, heparan sulfate proteoglycans regulate the biological activities of certain 
growth factors including VEGF and FGF -2. Heparan sulfate stabilizes these growth 
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factors by protecting them from proteolytic degradation thereby creating long-term 
reservoirs. VEGF has been the most highly studied, with covalent incorporation via both 
fibrin attachment (Ehrbar et al., 2008) and heparan attachment (Steffens et al., 2004) 
leading to significantly more vessel growth in vivo. Similar to the effects ofVEGF, 
neovascularization was enhanced when sustained delivery ofFGF-2 was achieved by 
allowing FGF-2 to bind to covalently incorporated heparan sulfate in collagen matrices 
(Pieper et al., 2002). Maynard et al. created a synthetic sulfated tetrapeptide which 
mimics heparin binding to VEGF in order to improve upon natural heparin, which is 
often heterogeneous and difficult to modify (Maynard et al., 2005). Covalent attachment 
can also be achieved via synthetic means, such as VEGF attachment to collagen matrices 
via a disuccinimidyldisuccinatepolyethyleneglycol (SS-PEG-SS) linker (Koch et al., 
2006). 
Another synthetic 
method to covalently attach 
proteins is poly( ethylene 
glycol), which represents an 
optimal method to covalently 
incorporate growth factors due 
to improved solubility, 
decreased immunogenicity, 
and increased stability. Due to 
PEG's hydrophilicity, proteins 
Figure 1-9: Schematic representation of a PEGylated 
protein. The protein is surrounded by long hydrophilic 
PEG chains with circles representing the cloud of water 
around the ether-oxygen groups of the polymer. Adapted 
from (Veronese et al., 2008). 
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conjugated to PEG are surrounded by a water cloud which decreases degradation by 
proteolytic enzymes and cells (Figure 1-9) (Veronese, 200 I; Veronese et al., 2008). 
Furthermore, the water cloud causes an increase in protein size, leading to slower kidney 
filtration and longer blood circulation (Roberts et al., 2002). Based on these desirable 
characteristics, many drugs have been PEGylated and used in clinical therapy. Since the 
development of the first PEGylated drug in the 1970s, PEGylated pharmaceuticals are 
now used in the treatment of many chronic diseases including leukemia, rheumatoid 
arthritis, and hepatitis C. A summary of FDA-approved PEGylated pharmaceuticals is 
listed in Table 2. 
Table 1-1: FDA approved PEGylated proteins. Table from (Veronese et al., 2008). 
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The first example of an immobilized protein via PEG conjugation was epidermal 
growth factor (EGF) in 1996. Prolonged EGF delivery is particularly important because 
a constant dose ofEGF signaling is required over several hours to affect DNA synthesis. 
While use of slow-release polymers would prolong EGF delivery, maintaining constant 
levels ofEGF is challenging. Ideal delivery systems account for cellular uptake and 
proteolytic degradation to ensure adequate levels ofEGF are present while continuing to 
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allow cell surface events including signal transduction to occur. By PEGylating EGF, the 
growth factor maintained bioactivity in a nonendocytosible and nondiffusable form which 
maintained efficacy in eliciting DNA synthesis (Kuhl et al., 1996). Other growth factors 
have since been PEGylated, including bone morphogenic protein-2 (BMP-2) (Liu et al., 
2007), TGF-JH (Mann et al., 2001), TGF-f32 (Bentz et al., 1998), and FGF-2 (DeLong et 
al., 2005). Two PEGylated factors, VEGF and ephrinA1, have been specifically studied 
for their angiogenic effects. PEG-ephrinA 1 induced endothelial tubulogenesis with 
luminal diameters in the range of 5-30 J.Ull (Moon et al., 2007). PEGylated VEGF not 
only increased endothelial cell tubulogenesis, but also increased endothelial cell motility 
14-fold and cell-cell connections 3-fold in a 3D biodegradable gel (Leslie-Barbick et al., 
2009). Based on these significant results, PEGylated growth factors were used during the 
thesis work to induce neovessel formation. 
1.10 Cellular Encapsulation for Angiogenesis in Biomaterials 
Another approach to creating vascularized tissues is the use of cells, which 
naturally secrete angiogenic growth factors. Cells can be seeded on the surface of 
biomaterials or encapsulated in biomaterials. Cell-based approaches eliminate the time-
delay inherent in releasing growth factors to stimulate host angiogenesis and also 
eliminate the need to optimize dose and release of growth factors. For example, Chen et 
al. allowed a co-culture of human umbilical vein endothelial cells (HUVECs) and 
fibroblasts to form tubes in vitro for seven days before in vivo implantation. Scaffolds 
containing pre-formed tubes led to anastamosis with the host vasculature within 5 days as 
compared to 14 days for scaffolds without pre-formed tubes. Additionally, the number 
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and area of perfused lumens was significantly higher in prevascularized scaffolds (Chen 
et al., 2008). 
A wide variety of cell sources has been investigated from mesenchymal stem 
cells, adipose stem cells, endothelial progenitor cells, and human embryonic stem cells. 
Nor et al. showed the feasibility of this approach when human dermal microvascular 
endothelial cells (HDMEC) seeded on poly L-lactic acid (PLLA) scaffolds formed 
functional vessels, which anastomosed with the host vasculature (Nor et al., 2001). The 
response was enhanced when HDMECs were cocultured with human osteoblasts on a 3D 
bone biomaterial composed of hydroxyapatite, calcium phosphate, and nickel titanium 
(Unger et al., 2007). A co-culture using three cell types, keratinocytes, fibroblasts, and 
endothelial cells, decreased the response time to form capillary-like structures in a skin-
substitute from fourteen days to four days (Tremblay et al., 2005). Koike et al. formed 
long-term stable vessels when HUVECs were used alone and in combination with 
pericyte precursor cells (IOTI/2) on a fibronectin-type I collagen matrix (Koike et al., 
2004). HUVECs alone formed vessels with minimal perfusion, but HUVECs and lOTl/2 
cells formed a functional vascular network capable of anatosmosing with host circulatory 
system up to one year later as seen in Figure 1-10 (Au et al., 2007). When HUVECs 
were cocultured with IOTI/2 cells, IOTI/2 cells displayed a smooth muscle cell 
morphology and began expressing pericyte markers, such as a-smooth muscle actin, 
smooth muscle myosin, and calponin (Hirschi et al., 1998). 
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Figure 1-10: Engineered blood vessels using HUVECs and 10T1/2 cells. (A) Vacuoles (arrows) 
resembling the lumen of capillaries were seen four days after implantation, but were not perfused 
(indicated by the absence of red). (B) Engineered vessels were functional and stable four months after 
implantation. Figure adapted from (Koike et al. , 2004). 
Endothelial progenitor cells, identified in 1997 in human peripheral blood as a 
key player in adult neovascularization, have also been used in therapeutic angiogenesis. 
Endothelial progenitor cells begin as mononuclear hematopoietic progenitor cells capable 
of differentiating into endothelial cells as part of vasculogenesis when released from the 
bone marrow into peripheral circulation upon a physiological stimulus. Human 
embryonic stem cells, differentiated into platelet/endothelial cell adhesion molecule-1 
(PECAM-1) expressing endothelial-like cells, showed an angiogenic response in SCID 
mice and an ischemic hindlimb (Levenberg et al. , 2002; Cho et al. , 2007). When the 
differentiated endothelial-like cells were combined with 10Tl/2 cells, the tubule 
structures were observed after only two days in vivo (Wang et al. , 2007). Other stem 
cells sources, including hematopoietic stem cells and mesenchymal stem cell in the bone 
marrow have also shown a vascular response (Moioli et al. , 2008). 
Cellular response has been enhanced with the addition of growth factors. Lower 
doses of growth factors than currently used in clinical trials can be used to act upon the 
transplanted vessel-forming cells, promoting survival, proliferation, and differentiation. 
Peters et al. showed that functional vessels were formed after seven days when human 
microvascular endothelial cells were seeded with VEGF in PLG (Peters et al., 2002). 
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The combination of dermal fibroblasts and HUVECs showed significantly more capillary 
formation in response to FGF-2 and VEGF (Hudon et al., 2003). Frerich et al. enhanced 
capillary formation by combining two cell types, HUVECs and stromal cells from 
adipose tissue, along with two growth factors, VEGF to stimulate angiogenesis and 
insulin-like growth factor (IGF)-1, to stabilize the capillary structures (Frerich et al., 
2001). Others have even transfected cells to overexpress angiogenic growth factors in 
order to ensure prolonged, local growth factor delivery (Ikeda et al., 2004; De Coppi et 
al., 2005; Rinsch et al., 2001 ). A co-culture of endothelial cells and pericytes was 
encapsulated into PEG hydrogels along with soluble factors in order to induce 
anastomosis formation between cell-formed tubules and host vasculature. This thesis 
research is further discussed in Chapter 5. 
1.11 Innovative Biomaterial Design 
Alternative methods to induce neovascularization involve using patterning 
techniques such as microchannel designs to mimic capillary networks and allow 
biomaterials to guide neovascularization (Hoffmann et al., 201 0). Endothelial cells can 
then be seeded along the microchannels, providing a vasculature in the scaffold capable 
of connecting with the host vasculature. This method eliminates time delays involved in 
inducing angiogenesis. For example, a fibrin gel containing a polyurethane mesh 
releasing VEGF was grown in a CAM angiogenic assay to enable prevascularization. 
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Once the polyurethane mesh contained capillary networks through the scaffold, it 
underwent a freeze-thaw cycle and was implanted in vivo. Revascularization of the 
networks occurred within three days of implantation, possibly due to enhanced adhesion 
from ECM proteins such as collagen IV and laminin from prevascularization or a 
chemotactic effect from cell remnants attracting host macrophages, which secrete 
endothelial signals (Sanders et al., 2003). Using a similar technique, polyvinyl alcohol 
matrices releasing FGF-2 were implanted into the rat mesentery and allowed to 
prevascularize for one week before seeding hepatocytes onto the scaffolds. 
Prevascularization increased the mean number of vessels and survival of hepatocytes, 
probably due to improved oxygen transport (Ogawa et al., 2001). Stosich et al. created 
cylindrical channels within hydrogel networks and examined the effects of patterned 
networks when combined with FGF-2 release. Hydrogels with channels but without 
FGF-2 showed host infiltration only in the microchannels, and hydrogels with FGF-2 but 
without microchannels showed random and isolated areas of vessel infiltration. 
Hydro gels containing both FGF -2 and microchannels showed significant infiltration in 
channels (Stosich et al., 2007). While the thesis work presented does not use a 
prevascularization technique, future research could combine a prevascularization 
technique with immobilized growth factors and encapsulated cells as presented in this 
thesis. 
1.12 Summary 
Although much research has been performed to induce angiogenesis, significant 
work remains before a tissue engineering scaffold containing a functional 
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microvasculature system can be utilized in a clinical setting. Poly( ethylene glycol) based 
hydrogels act as a biocompatible scaffold to deliver growth factors in both soluble and 
immobilized forms. The hydrogels were rendered biodegradable by incorporating an 
MMP-degradable sequence into the polymer backbone (West et al., 1999). Finally, mild 
crosslinking conditions enable cellular encapsulation into the matrix. This thesis includes 
several novel techniques and combinations of growth factors and cells to improve upon 
the existing work to promote neovessel formation in poly( ethylene glycol) hydrogels. 
Specifically, PDGF -BB and ephrinAl were covalently immobilized to the hydro gels and 
shown to promote angiogenesis. Furthermore, for the first time PEG hydro gels were 
tested in an in vivo model of the mouse cornea micropocket. Bioactive hydrogels with 
releasable growth factors were shown to induce angiogenesis. The response was then 
tailored using rational design ofhydrogels. Finally, encapsulated cells forming tubule 
networks throughout the hydrogels were implanted and shown to anastomse to host 
vasculature. These fundamental contributions bring ever closer the reality of using 
biomaterials containing a microvascular system in a clinical setting. 
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Chapter 2: Biomimetic Poly( ethylene glycol) Hydrogels Promote 
Angiogenesis in a Mouse Model 
Portions of this chapter were obtained from: 
RA Poche, JE Saik, JL West, ME Dickinson. "The mouse cornea as a transplantation site 
for live imaging of engineered tissue constructs." Cold Spring Harbor Protocols. 
doi:10.1101/pdb.prot5416. (cover) 
JJ Moon, JE Saik, RA Poche, JE Barbick, SH Lee, AA Smith, ME Dickinson, JL West. 
"Biomimetic hydrogels with pro-angiogenic properties" Biomaterials. 14:3840-7,2010. 
RA Poche, IV Larina, ML Scott, JE Saik, JL West, ME Dickinson. "Flkl-myr::mCherry 
mouse as a useful reporter to characterize multiple aspects of ocular blood vessel 
development and disease." Developmental Dynamics. 238:2318-2326, 2009. (cover) 
2.1 Introduction 
Biomaterials can provide a local, controlled delivery system for release of 
angiogenic growth factors as potential treatments for ischemic disease or to improve 
blood supply to engineered tissues. Precise control over delivery of growth factor 
concentrations is necessary to induce the desired cellular responses (Tayalia et al., 2009). 
Current methods to deliver growth factors to induce angiogenesis in vivo rely on bolus 
injections. However, clinical trials examining bolus injections of these agents highlight 
the concern of harmful side effects resulting from systemic injection, including 
hypotension, edema, and vasodilation (Epstein et al., 2001 ). Many of these side effects 
may be mitigated by achieving precise control oflocal growth factor delivery over the 
time scale necessary to produce the desired biological response. For instance, growth 
factors can be incorporated into the precursor solution, thus entangling the signals into 
the scaffold following polymer crosslinking. Growth factors are then released from the 
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scaffold via diffusion, establishing a concentration gradient. Growth factor delivery for 
angiogenesis has been achieved using natural scaffolds (Mittermayr et al., 2008; Miyoshi 
et al., 2005; Fujita et al., 2007; Chinen et al., 2003; Nillesen et al., 2006) as well as 
synthetic polymers (Lee et al., 2000; Guan et al., 2007; Ennett et al., 2006; Richardson et 
al., 2001). Scaffolds delivering vascular endothelial growth factor (VEGF) have been 
used to induce dose dependant, pro-angiogenic responses including increased 
vascularization, pericyte coverage, and vessel perfusion (Davies et al., 2008). VEGF 
dose and temporal distribution was also found to govern endothelial cell phenotype in an 
in vitro model and optimal angiogenic sprouting in vivo (Silva et al.). 
Although many growth factors have been shown to have angiogenic properties, 
the majority of work has focused on three growth factors as discussed in chapter 1 : 
vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF-BB), 
and fibroblast growth factor (FGF-2). VEGF, released in response to hypoxia, stimulates 
endothelial cells to migrate, proliferate, and differentiate (Nomi et al., 2006). Hypoxia 
also induces macrophages to release FGF -2, which stimulates endothelial cell 
proliferation and migration, and regulates the expression of key angiogenic molecules, 
such as collagenases and ~1 integrins (Bikfalvi et al., 1997). PDGF-BB is involved in the 
stabilization of developing capillaries by recruiting pericytes and inducing them to 
produce the extracellular matrix proteins that constitute the basement membranes of 
functional blood vessels. In addition, PDGF-BB has been implicated as a key factor in 
anastamosis formation (Betsholtz et al., 2005; Khachigian et al., 1995). 
VEGF has been widely used to induce angiogenesis, but VEGF -induced vessels 
have been shown to be unstable, leaky and hemorrhagic (Jain, 2005; Jain et al., 2005). 
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Cao et al. used Hydron pellets to deliver VEGF, PDGF-BB, or FGF-2 alone and in 
combinations to the mouse cornea. Analysis of resulting vessel formation in response to 
either PDGF-BB or VEGF alone indicated total vessel regression by 24 days and by 70 
days for FGF-2-induced vessels (Cao et al., 2003). Notably, vessels formed in response 
to the combination ofFGF-2 and PDGF-BB was stable for over 210 days. Hydron pellets 
containing growth factors were also removed from the eye 6 days after implantation, 
causing total vessel regression within one week of all samples but those containing 
PDGF-BB and FGF-2. As compared to VEGF-induced vessels which were highly leaky, 
vessels formed in response to PDGF-BB and FGF-2 remodeled into well-defined 
branching and organized structures that were not leaky when perfused with fluorescent 
dextran (Cao et al., 2003). As an indicator of vessel maturity 25 days after implantation, 
70% ofvessels formed in response to PDGF-BB and FGF-2 were desmin positive as 
compared to only 40% for FGF-2 induced vessels (at this point all PDGF-BB induced 
vessels had regressed). The addition ofVEGF antagonists confirmed the VEGF-
independent vessel formation using PDGF-BB and FGF-2 (Cao et al., 2003). Findings 
were corroborated in the hind limb ischemia model, which shows that PDGF-BB and 
FGF-2 increased collateral vessel growth and paw blood perfusion, and vessels were well 
organized and stable for over 60 days. The synergistic response was later found to result 
because FGF-2 transcriptionally turns on PDGF-BB receptor expression in endothelial 
cells and PDGF-BB then induces a positive feedback signal by amplifying FGF-2 
expression in vascular mural cells (Cao et al., 2008). 
In light of the data showing that the combination ofFGF-2 and PDGF-BB 
promote the formation of more stable vessel structures than VEGF, there is a tremendous 
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interest in using these factors to promote tissue repair and to induce angiogenesis and 
perfusion of biomaterial scaffolds for tissue engineering. The combination of these 
factors is a powerful tool for controlling the angiogenic response, and in this study a 
range of responses to concentrations ofthese factors was determined in order to tune the 
angiogenic response to these factors and to control angiogenesis in vivo. 
This thesis research used poly( ethylene glycol) (PEG) diacrylate, a 
photocrosslinkable and biocompatible polymer, to deliver angiogenic growth factors in a 
local, controlled manner. Hydrogels were further modified with an immobilized RGD 
peptide (a sequence commonly found in fibronectin and other cell-adhesive proteins) 
(Gunn et al., 2005; DeLong et al., 2005) and rendered them proteolytically degradable by 
incorporating matrix metalloproteinase (MMP) sensitive cleavable peptide sequences into 
the polymer backbone (Moon, 2008; West et al., 1999) to allow for invading cells to 
degrade the material (Moon, Saik, Poche et al., 201 0). The photocrosslinking process 
enables inclusion of releasable growth factors prior to crosslinking for local, controlled 
delivery to induce host vessel invasion (Leslie-Barbick et al., 2009). In this manner, 
releasable factors and covalently bound adhesive factors can work in concert to induce 
rapid and stable vascularization of these constructs. This research demonstrates a slow-
release profile of growth factors from these materials enabling prolonged, local delivery 
of the encapsulated agents. This release was modulated by adjusting the polymer 
molecular weight and solution concentration and by incorporating the proteins either 
before or after hydrogel crosslinking. 
Through the adjustment of growth factor concentrations, this thesis research has 
induced a microvasculature which is morphologically similar to target tissues, including 
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skin and skeletal muscle. Normal tissues require a precise and unique vessel pattern to 
maintain an equilibrium between growth and cellular demands (Jain et al., 2005; Jain, 
2003). Each tissue possess a unique microvascular morphology (Humphrey et al., 2001) 
related to initial development, metabolic need, physiological function and ultrastructural 
shape and dynamics (Caplan, 1985). For example, skeletal muscle contains uniquely 
shaped vessels for delivery of nutrients while allowing for the linear application of forces 
(Carlson, 1973; Tong et al., 2004). In fact, Jain postulated that skeletal muscle is 
incredibly difficult to recapitulate due to its dense perfusion and high metabolic rate (Jain 
et al., 2005). This system combines tailored, local delivery of growth factors in 
angiogenic scaffolds along with quantification of induced vessel morphological and space 
filling parameters. 
The mouse cornea serves as the in vivo implantation site because induced vessels 
can be quantitatively examined microscopically (Gaudric et al., 1992; Auerbach et al., 
2003), enabling high resolution imaging over time, and the external nature of the cornea 
allows for facile surgical implantation and analysis. The cornea is a transparent tissue 
covering the outer surface of the eye which, together with the lens, functions to transmit 
and refract light. The mature cornea consists of an outer stratified epithelial cell layer, an 
inner collagenous stroma with a sparse population ofkeratocytes, and an inner endothelial 
cell monolayer (for descriptions of eye anatomy and histology, see (Zieske, 2004)). For 
efficient transmittance of light, the cornea has evolved as an avascular tissue. 
Nevertheless, the cornea is still capable of experiencing substantial neovascularization in 
response to severe physical, chemical, and thermal injury, implantation of tumors and 
other physiological insults (Muthukkaruppan et al., 1979; Gimbrone et al., 1973; 
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Langham, 1953). The mouse corneal micropocket angiogenesis assay has capitalized 
upon this property and is often considered the gold standard to determine whether 
signaling peptides, drugs, etc. function as proangiogenic or anti-angiogenic factors in 
vivo (Kenyon et al., 1996; Rogers et al., 2007). This assay has several advantages. For 
example, because the cornea is normally avascular, there are no background vessels 
present. Thus, the researcher does not have to make any assumptions as to whether the 
observed changes in vascular structure are the result of remodeling ofpreexisting vessels 
or neovascularization (Kenyon et al., 1996; Rogers et al., 2007). Another major 
advantage of this system is that the cornea is a relatively immune privileged site and is 
externally located (Streilein, 2003, 2003). These properties lend themselves to minimally 
invasive and high-throughput transplantation of experimental tissue constructs and also 
allow live imaging of construct vascularization in vivo (Poche et al., 201 0). The mouse 
cornea also provides a well established and reproducible assay (Kenyon et al., 1996). 
By correlating the resulting vessel formation to the growth factor dose delivered, 
this thesis research induced a vascular structure with a desired fractal dimension. 
Importantly, in only tuning for the appropriate fractal dimension, the desired diameters 
and branch points as well as density and lacunarity of target vessel networks were also 
recreated. This robust system is capable of characterization of vessel morphology and the 
study of angiogenesis, for applications in tissue engineering, ischemic disease and tumor 
vessel biology. 
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2.2 Materials and Methods 
2.2.1 Synthesis and Purification of Poly (ethylene glycol) Diacrylate (PEGDA) 
Poly (ethylene glycol) (PEG) (MW = 6000 Da; Fluka, Milwaukee, WI) was 
acrylated by reacting dry PEG with acryloyl chloride (Sigma, St. Louis, MO) and triethyl 
amine (TEA; Sigma, St. Louis, MO) in anhydrous dichloromethane (DCM; Sigma, St. 
Louis, MO) under argon gas overnight at 1 :4 PEG:acryloyl chloride and 1 :2 PEG:TEA 
molar ratios. The resulting solution was purified using 2 M K2C03 to separate the 
solution into aqueous and organic phases. After allowing the solution to separate 
overnight, PEGDA, in the organic phase, was further purified using anhydrous MgS04 to 
remove residual aqueous solution. MgS04 was removed via filtration before precipitating 
PEGDA, using diethyl ether. PEGDA was separated via filtration and dried overnight 
under vacuum. PEGDA powder was stored at -20°C under argon gas. 
+ 
Acryloyl 
Chloride 
Figure 2-1: Synthesis ofPEGDA. 
1. TEA, DCM 
PEGDA 
2.2.2 Synthesis and Purification ofPEG-succinimidyl carbonate (PEG-SMC) 
PEG (Fluka/Sigma, MW = 3400 Da ) was reacted with Ag20 (Sigma, St. Louis, 
MO), acryloyl chloride (Sigma, St. Louis, MO), and KI (Sigma, St. Louis, MO) in 
anhydrous dichloromethane (DCM; Sigma, St. Louis, MO) at 4°C overnight, at molar 
excess ratios of 1.5, 1.1, and 0.3 respectively. Silver was removed by filtering the 
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solution through Celite 521 (Spectrum Chemical Mfg Corp, Gardena, CA). A Rotovap 
was used to dry the solution prior to dissolution in di H20. Using HCl, pH was adjusted 
to 3, and the solution was heated to 35°C for one hour. Iodine was removed by adding 
activated charcoal (Fisher, Pittsburg, PA), and the solution was filtered through Celite 
521. NaCl and DCM were added, followed by DCM extraction. Phase separation with 2 
M K2C03 was used to remove any acid and chloride ions. Sodium sulfate (Fisher) was 
used to dry the monoacrylated PEG, and a Rotovap was used to concentrate the solution. 
Ethyl ether was used to precipitate monoacrylated PEG followed by vacuum filtration. A 
four molar excess of disuccinimidyl carbonate (Sigma) was reacted with the 
monoacrylated PEG in anhydrous acetonitrile (Sigma) and pyridine (Sigma) under argon 
gas overnight. A Rotovap was used to dry the resulting product prior to dissolving in 
anhydrous DCM. The solution was filtered and PEG-SMC was purified in acetate buffer 
(0.1 M, pH 4.5, 15% NaCl) via phase separation. The purified PEG-SMC was dried 
using anhydrous MgS04• Ethyl ether was used to precipitate out PEG-SMC which was 
filtered and dried overnight under vacuum. Proton nuclear magnetic resonance 
spectroscopy eH-NMR, A vance 400Hz; Broker, Billerica, MA, USA) and matrix-
assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF; 
Broker Daltonics, Dillerica, MA, USA) were used to characterize synthesized PEG-SMC. 
The final PEG-SMC product was stored at -80°C under argon gas. 
2.2.3 Synthesis and Purification ofPEG-RGDS 
Sodium bicarbonate buffer (50mM, pH of8.5) was used to dissolve both 
synthesized PEG-SMC and the cell-adhesive peptide Arg-Gly-Asp-Ser (RGDS, Figure, 
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American Peptide, Sunnyvale, CA) separately. PEG-SMC solution was added to the 
RGDS solution in a 1.1:1 PEG-SMC: RGDS molar ratio. Under gentle rocking, the 
mixture was allowed to react at 4°C for four 
days, followed by a final four hours at 25°C. 
The reacted solution was dialyzed against four 
liters di H20 via a 1000 Da molecular weight 
cutoff dialysis membrane (Spectrum 
Laboratories, Rancho Dominguez, CA) for 24 
Figure 2-2: Chemical Structure ofRGDS hours with repeated di H20 changes. The 
resulting PEG-RGDS solution was lyophilized 
and stored at -80°C under argon gas. Coupling efficiency ofPEG-RGDS was analyzed 
by a gel permeation chromatography (GPC) system equipped with a PLgel column (5J.I.Ill, 
500A, Polymer Laboratories, Amherst, MA) and an evaporative light scattering (ELS) 
detector (Polymer Laboratories). The PEG-RGDS was dissolved in 0.1% ammonium 
acetate in dimethylformamide (DMF) solvent and tested against a PEG-SMC standard. 
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Figure 2-3: Peptide coupling to PEG monoacrylate. 
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Fluorescent PEG-RGDS was synthesized by reacting PEG-RGDS with alexa fluor 488 
carboxylic acid (Invitrogen) with 10-fold dye molar excess in DMF. The solution was 
reacted on a rocker for two hours, lyophilized, and stored under argon in a -80°C freezer 
until use. 
2.2.4 Synthesis of hydrogels to vary FGF release 
An ELISA was also used to quantify the release of FGF from hydrogel 
formulations that differed in polymer molecular weight and percent composition. 3.4 
kDa and 35 kDa PEGDA hydrogels (10% w/v) with 27 ng/gel FGF were synthesized in a 
manner similar to that described above (n=3). Additional 3.4 kDa hydrogels were 
formulated with the same concentration ofFGF, but with PEGDA solution concentrations 
of 5% and 20% (n=3). 
To quantify the influence of protein loading procedures on the release of growth 
factors, FGF was first fluorescently labeled by reaction with Alexa Fluor® 350 
carboxylic acid, succinimidyl ester (Invitrogen, Carlsbad, CA) at a 1:10 molar ratio in 
HBS. Fluorescently-labeled FGF was incorporated into hydrogels before crosslinking by 
mixing into the prepolymer solution at a concentration of 58 ng/gel (n=6) or after 
crosslinking by soaking hydrogels for 4 h in a growth factor-rich solution at a 
concentration of 0.4 Jlg/ 111 (n=5). The hydrogel soak solution was read on a Fluorolog 
(Horiba, Edison, NJ) plate reader at designated time points and compared to a standard 
curve. 
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2.2.5 Synthesis of Degradable Hydrogels 
Hydrogels were rendered degradable based on a collagenase-sensitive sequence 
GGGPQGIWGQGK (abbreviated PQ). The PQ peptide was synthesized using Fmoc 
chemistry on an APEX 396 solid phase peptide synthesizer (Aapptec) and characterized 
using MALDI-TOF. The PQ peptide was used to link two PEG chains, in order to create 
PEG-PQ-PEG. PEG-PQ-PEG was synthesized by dissolving the PQ peptide into 
anhydrous dimethyl sulfoxide (DMSO) and adding diisopropylethylamine (DIPEA). 
Similarly, acrylol-PEG-SCM (Laysan) was dissolved into DMSO. The PEG-SCM 
solution was dripped into the PQ-peptide solution with a 2.1 molar excess of PEG-SCM. 
This mixture was placed on a rocker overnight before being dialyzed in a regenerated 
cellulose membrane to remove unwanted products. After dialysis, the solution was 
lyophilized and characterized with gel permeation chromatography. 
2.2.6 Incorporation and quantification ofVEGF, PDGF, and FGF in hydrogels 
Hydrogels were prepared to a final concentration of 10% PEG-PQ-PEG and 3.5 
J.UllOl!ml PEG-RGDS. The photoinitiator 2-dimethoxy-2-phenylacetophenone 
(acetophenone, Sigma) was prepared as a stock solution by dissolving 300 mg 
acetophenone in 1 ml N-vinylpyrrolidone (NVP) and used at a concentration of 10 J.tl/ml 
polymer solution. Growth factors were added to the liquid prepolymer solution at 
concentrations of320 ng/gel for VEGF and PDGF and 80 ng/gel for FGF. These 
concentrations correspond to doses necessary to induce in vivo vascular responses. 
Hydrogels were polymerized between two glass slides separated by a 0.005 inch thick 
poly(tetra fluoroethylene) spacer. 0.12 Jll polymer solution was injected between slides 
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using a Hamilton syringe and exposed to UV light (B-200SP UV lamp, UVP, 365 nm, I 0 
m W /cm2) for two min. Hydro gels were immediately placed in HEPES buffered saline 
(HBS) with 0.1% bovine serum albumin and kept in a 3 7 °C incubator. Buffer was 
collected and replenished at desired time points. Three hydrogels were analyzed for FGF, 
4 for VEGF, and 5 for PDGF. Growth factor release was quantified using ELlS As (R&D 
Systems, Minneapolis, MN for VEGF and PDGF and Ray Biotech, Norcross, GA for 
FGF). 
2.2.7 Degradation ofPEG-PQ-PEG 
Degradation ofPEG-PQ-PEG hydrogels was monitored using the tryptophan 
absorbance peak (280 nm). Since the PQ-peptide contains a tryptophan, its degradation 
was examined by quantifying tryptophan in the surrounding solution over time. A 
collagenase buffer was created by mixing 0.2 mg/ml collagenase IV, 0.2 mg/ml sodium 
azide, and 1 OmM calcium chloride in HEPES-buffered saline (HBS). A proteinase K 
buffer was used as a positive control and made by mixing 0.2 mg/ml proteinase K with 
0.2 mg/ml sodium azide in HBS. The polymer solution was created by dissolving 10% 
(weight/volume) PEG-PQ-PEG and 10 J.1l/ml2,2-dimethoxy-2-phenylacetophenone in 
HBS. The polymer solution was sterile filtered. Five J.!L droplets were formed at the 
bottom of200 J.!L sterile cuvettes by exposing to UV light (B-200SP UV lamp, UVP, 365 
nm, 10 m W /cm2) for two minutes. Hydro gels were covered in sterile PBS overnight to 
enable swelling. PBS was then exchanged with either collagenase or proteinase K buffer. 
Absorbance measurements at 280 nm were taken for all samples at multiple timepoints 
using a UV spectrophotometer (Varian). 
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2.2.8 Synthesis of Hydrogels 
Six kDa PEGDA or degradable PEG-PQ-PEG was dissolved in HBS. Polymer 
solution varied from 5% to 15% polymer weight percentage solutions. The photoinitiator 
acetophenone was dissolved with N-vinylpyrrolidone (NVP) (300 mg!mL) and added to 
the polymer solution at a concentration of 10 11LimL. The solution was vortexed and 
sterile filtered. Hydrogels were polymerized between two glass sides separated by a 
0.005 inch thick poly(tetra fluoroethylene) (PTFE) spacer. The glass slides and spacer 
were secured using clips. Growth factors were mixed into the polymer solution to create 
desired concentrations ofVEGF, PDGF-BB, and FGF-2 per gel. Growth factor 
concentrations were used based on previously established optimal concentrations in the 
mouse cornea (Rogers et al., 2007). 0.12 JlL polymer solution was inserted in between 
glass slides using a Hamilton syringe. Hydrogels made with acetophenone were exposed 
to UV light (B-200SP UV lamp, UVP, 365 nm, 10 mW/cm2) for two minutes while 
hydrogels formed with Irgacure 2959 were exposed to the same light for 7 minutes. 
Hydrogels synthesized with eosin Y were exposed to white light for 40 seconds. After 
exposure, crosslinked hydrogels were immediately inserted into the cornea micropocket. 
2.2.9 FLKl-myr::mCherry Mice 
Mice expressing the mCherry fluorophore via the Flkl promoter have previously 
been characterized (Larina, 2009). Mice used in this study were from the colony 
established in the Dickinson lab at Baylor College of Medicine containing fluorescently 
labeled endothelial cells, and all experiments were in accordance with an IACUC and 
AALAS approved animal protocol at Baylor College of Medicine. These mice allowed 
for facile visualization and imaging of blood vessels for this study. 
2.2.10 Hydrogel Implantation into the Mouse Cornea Micropocket Angiogenesis 
Assay 
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Using a modified version of the previously described corneal micropocket 
angiogenesis assay (Rogers et al., 2007), hydrogels were implanted into a mouse cornea, 
and corneal angiogenesis was imaged 7 days post-implantation. The novel Flkl-
myr::mCherry transgenic mouse line was used to enable in vivo imaging of angiogenesis 
via fluorescently labeled endothelial cells (Larina et al., 2009). Mice were anesthetized 
by intraperitoneal injection of Avertin (0.2 mlllOg body weight of a 1.25% solution) and 
maintained on a pad heated to 37 °C. As a local anesthetic, one drop ofproparacaine 
(0.5%, Bausche and Lomb) was applied to the eye immediately before the surgery. Next, 
a partial thickness incision was made into the mouse cornea, and the micropocket was 
created using a von Graef knife. Using a number 5 forceps, hydrogels were implanted 
into the micropocket immediately after cross-linking. Subsequently, a bacitracin 
zinc/polymyxin B sulfate antibiotic ointment (Bausch and Lomb) was applied to the 
corneal surface upon which the mouse was returned to the heated cage for recovery. 
A. Proptose eye 
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E. Live .imaging 
Figure 2-4: Modified corneal micropocket assay. (A-E) Shown here is an illustration detailing the 
steps involved in surgical implantation of fluorescently labeled hydrogel discs into the mouse cornea. 
By incorporating a fluorescent dye such as fluorescein isothiocyanate (FITC), the hydrogel is easily 
observed within the corneas of live mice (E, arrowhead) (Poche et al. , 201 0). 
Seven days post-implantation, the mice were sacrificed using C02 inhalation. 
The eyes were enucleated and fixed in 4% paraformaldehyde for one hour at 4°C. Fixed 
eyes were washed with phosphate buffered saline (PBS, pH 7 .3) and corneal flat-mount 
preparations were made (Figure 2-5). Imaging was performed using a Zeiss LSM 510 
MET A inverted microscope system (Carl Zeiss Inc) equipped with a Zeiss Plan-
Apochromat 20x/0.75 NA objective. 543-nm and 488-nm lasers were used to excite the 
Flkl-myr: :mCherry and fluorescent PEG-RGDS, respectively. 
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A corneal flat mount 
Figure 2-5: Corneal Oat mounts from implanted Flkl-myr::mCberry transgenic mice. (A) Schematic 
depiction of a corneal flat mmmt showing how the tissue is separated into quadrants, with one quadrant 
containing the implanted hydrogel and induced host vessels. (B) Blown-up view of the boxed region in panel 
A. ( C,D) Tiled, confocal images of an actual corneal flat mount show a green fluorescently labeled hydrogel 
(containing VEGF) sitting adjacent to the limbic region (C) and Flkl-myr: :mCheny+ (magenta) neovessels 
extending toward the hydrogel (D) (Poche et al., 201 0). 
2.2.11 Analysis of Angiogenic Response 
At designated timepoints, eyes were excised from euthanized mice, and the 
cornea was dissected and flatmounted by cutting the cornea in four locations 90 degrees 
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apart, creating a relatively flat corneal surface. Confocal images ofFlkl-myr::mCherry 
labeled vessels were acquired from flatmounted corneas containing the tissue constructs 
using an LSM 510 META (Carl Zeiss) confocal microscope and a C-Apochromat 
40x/1.2NA water immersion lens. A 543 nm laser was used to excite the mCherry 
fluorophore, and 22 micron thick z-stacks of vessels labeled by mCherry directly on the 
scaffolds were collected such that the step size between two successive images in z-
stacks was 1.1 microns. This thickness was chosen because previous studies of 
vasculature were similar parameters were measured used these dimensions for tissue 
imaging (Gould et al., 2011). Each 8-bit image in the z-stacks consists of512 x 512 
pixels. 
2.2.12 Vessel Branch Points and Diameters 
The branching was quantified, using the LSM image browser to count the total 
number of branch points per three dimensional image field in each image of vessels. 
Diameters were likewise quantified, and the results were compared using ANOV A with 
post hoc Tukey test. 
2.2.13 Image processing 
Images of the vascular beds were processed in similar fashion to what was 
reported previously (Gould et al., 2011). Briefly, stacks of the vessels were projected then 
thresholded in order to create binary images for processing. Thresholds were kept 
constant between images ofvessel beds to ensure comparison methods. Images of 
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vessels were first converted to projections using Image J and then converted to 8-bit 
grayscale. These projections were opened in adobe and had an unsharp mask applied to 
them, which serves as a high-pass filter to remove haziness from around the vessels while 
preserving vessel diameters. The finished grayscale image was opened in MA TLAB and 
a threshold of90 in all cases was applied and determined to be the most useful at 
recreating the appearance of the original vessels. 
A 
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Figure 2-6: Image Processing. Raw LSM images z-stacks of 22 microns are formulated into a 
3D projection. Next, ImageJ is used to form a maximum intensity project. An unsharp mask is 
applied in Adobe Photoshop, followed by thresholding in MA TLAB. The final images are used 
for quantification of vessel parameters. 
2.2.14 Fractal Dimension, Lacunarity, and Multifractal Spectra 
Induced vessel morphology was assessed by imaging vessels and applying 
algorithms developed and described in Gould et al. (Gould et al., 2011) to determine 
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vessel density, diameter, fractal dimension, and lacunarity (Figure 2-7). Also, the 
programs used to extract these parameters are available online through the MA TLAB 
central file exchange (Vadakkan, 2009, 2009). 
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Figure 2-7: Measurement of the Fractal Dimension Using a Box-counting Algorithm. Here, A 
demonstrates the application of a grid to the image of engineered vessels. After applying a grid, 
positive boxes (containing at least one white pixel) are counted. B shows the plot of positive box 
number versus box size. C shows the log (positive boxes) versus log (box size) plot. The slope of 
this line is the fractal dimension. 
2.2.15 Statistical Analysis 
A one-way ANOVA was used to quantify differences in VEGF, PDGF, and FGF 
release at 7 days. A student' s t-test was used to quantify differences in FGF release at 
final time points. P-values less than 0.05 were considered significant. 
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2.3 Results and Discussion 
2.3.1 Characterization of PEG-materials 
Gel permeation chromatography was used to confirm attachment ofPEG-SMC to 
the cell adhesive peptide RGDS and MMP-sensitive peptide PQ. Figure 2-8 shows a GPC 
analysis ofPEG-RGDS with peak 1 representing PEG-RGDS and peak 2 representing 
unreacted PEG-SMC. Figure 2-9 shows GPC analysis ofPEG-PQ-PEG with the blue 
line representing PEG-SMC, the black line representing PEG-PQ-PEG, and the red line 
as the UV absorbance from the PEG-PQ-PEG sample. UV absorbance was seen due to 
inclusion of tryptophan into the degradable PQ sequence and confirmed the presence of 
the PQ sequence. Decrease in the PEG-SMC peak on the PEG-PQ-PEG sample 
confirmed the presence of mostly reacted PEG-SMC. 
tZ 
11 
10 
9 
> 
.... 
• Vi 8 s::: 
OJ 
.... 
2 
c 
- 7 
7ii 
s::: 
bO 6 Vi 
5 
.4 
3 
2 
n "l 10 1? 
Figure 2-8: GPC data confirming conjugation of PEG-RGDS. Peak 1 represents the 
PEG-RGDS peak and peak 2 represents unreacted PEG-SMC. 
~b 
24 
22 
20 
18 
> 
.1::: 16 
"' c:; 
cu 
- 14 .E 
n; 
c:; 12 1:1.0 
v; 
10 
8 
6 
4 
2 
0 2 6 8 
black: PEG-peptide-PEG 
blue: PEG-SMC 
red: tryptophan 
10 12 
49 
Figure 2-9: Conjugation of PEG-PQ-PEG. The blue line shows PEG-SMC; the black line shows the 
PEG-PQ-PEG; and the red line shows the tryptophan peak from the PQ sequence in the PEG-PQ-PEG. 
Degradation ofPEG-PQ-PEG was evaluated because the rate of degradation of 
implants is critical to the implant's success. A scaffold that degrades too slowly will 
impede cell motility and proliferation. On the other hand, a scaffold that degrades too 
quickly may lack structural integrity necessary at the site of implantation. The ideal rate 
of degradation is based on native cell ingrowth via cell-secreted proteases. Cell 
migration is critical to inflammation, wound healing, and tumorigenesis and is controlled 
by degradation of the extracellular matrix. The collagenase sensitive sequence 
GGGPQGIWGQGK (abbreviated PQ) was incorporated into the polymer backbone to 
render the hydrogels sensitive to cell-secreted MMPs. The collagenase sensitive 
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sequence was synthesized and its molecular weight was confirmed at 1141 grams/mol via 
MALDI-TOF in Figure 2-10. 
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Figure 2-10: MALDI-TOF conformation of PQ molecular weight at 1141 grams/mol. 
Degradation of hydro gels was measured via spectrophotometer measurements at 
280 nm into the hydrogel. Absorbance at 280 nm remained relatively unchanged for 
control gels in buffer while absorbance in both the collagenase and proteinase K buffers 
increased, indicating degradation in response to specific cellular enzymes, such as 
collagenases as seen in Figure 2-11. Proteinase K was used as a positive control, 
therefore the reading at 48 hours was considered 100% degraded and all other readings 
were compared to the 48 hour proteinase K value. Control gels showed a slight increase, 
probably from unconjugated PEG-PQ-PEG chains being released from the hydrogel. 
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Control gels were used to indicate that hydrogels do not undergo nonspecific degradation 
in normal buffer conditions. 
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Figure 2-11: Degradation ofPEG-PQ-PEG. Absorbance readings ofPEG-PQ-PEG hydrogels 
in collagenase (blue) and proteinase K (red) solutions showing degradation via release of 
tryptophan into the solution over time. Control gels (green) confirm gels do not undergo 
nonspecific degradation. 
2.3.2 Growth Factor Release from Hydrogels 
PEG-based hydro gels were evaluated for the release of the angiogenic growth 
factors VEGF, PDGF, and FGF. All factors follow the same profile with an initial burst 
release, similar to that needed to initiate an angiogenic response in vivo, followed by slow 
release for over seven days (Figure 2-12). The subsequent slow diffusion from hydrogels 
is advantageous for maintaining prolonged local growth factor action at the site of 
delivery. VEGF-loaded hydrogels demonstrated the highest total protein delivery with a 
release of 92% of the theoretically loaded amount. This is statistically higher than the 
releases of both PDGF and FGF, which were measured at 66% and 52%, respectively 
(p<0.05). Since the diffusion of growth factors within a hydrogel matrix depends on 
specific protein characteristics including molecular weight, folding structure, 
dimerization, and charge distribution, any of these characteristics may have contributed 
to the release profiles seen here. For example, the similarity between the release curves 
ofPDGF and FGF could be attributed to the fact that these proteins have similar 
molecular weights and dimerizations. 
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Figure 2-12: Growth factor release from degradable PEG-PQ-PEG hydrogels. An initial burst 
release during the first 30 min is followed by consistent delivery over the next 7 days. This growth 
factor release profile is well suited to the establishment of an angiogenic response where an initial 
response can be stimulated followed by prolonged signaling. 
To adjust the amount ofFGF released from PEG hydrogels, polymer molecular 
weight, polymer weight percentage, and protein incorporation methods were varied. The 
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amount ofFGF released form 35 kDa PEG hydrogels was statistically greater than that 
released from 3.4 kDa hydrogels (Figure 2-13A). 35 kDa PEGDA has longer polymer 
chains in between crosslinkable acrylate groups, leaving more space for diffusion of 
growth factors than the smaller 3.4 kDa polymer. Similarly, the loose hydrogel mesh 
formed from less densely packed 5% PEGDA gels also led to a statistically significant 
increase in amount ofFGF released at 8 hours when compared to 20% hydrogels (Figure 
2-13B). 
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Figure 2-13: Methods to vary FGF release. (A) More FGF is released from 35 kDa PEGDA hydrogels 
than 3.4 kDa hydrogels (p=0.02). (B) 5% (w/v) polymer gels release more FGF than 20% hydrogels 
(p=0.003). (C) Incorporating FGF after crosslinking hydrogels results in more FGF release than 
incorporating FGF before crosslinking (p<<O.Ol). 
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The method of soluble factor loading was also shown to influence the protein 
release. Hydrogels for which the growth factors were soaked in after crosslinking 
exhibited higher release than those formed with the signaling molecules present during 
polymerization (Figure 2-13C). This effect may be due to the fact that incorporation after 
crosslinking relies solely on diffusion of growth factors into the matrix, and as such any 
molecule that is able to migrate in, should also be free to release from the hydrogel at 
later time points. On the other hand, incorporation before crosslinking may physically 
entangle some growth factors making them unavailable for subsequent release. These 
data indicate that the protein loading method is an important consideration when 
designing the appropriate hydrogel formulation for in vivo use. 
2.3.3 Confirmation of Hydrogel Placement 
In order to verify proper placement ofhydrogels in between layers of cornea 
stromal tissue, hydrogels were labeled with fluoroscein-o-acrylate and imaged. Proper 
placement was confirmed based on images of the eye (A) and histology of the cornea as 
seen in both white light (B) and fluorescence (C). 
-200J.1m 
Figure 2-14: Proper placement of the hydrogel in a cornea micropocket is confirmed with 
fluorescein-o-acrylate labeled hydrogels. (A) llistology further confirms creation of a 
micropocket containing a hydrogel under white light (B) and fluorescence (C). 
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Histological sections were 
Figure 2-15: DAPI staining shows placement 
of the hydrogel in between the cornea layers. 
stained with DAPI to enable 
visualization of the nuclei in the 
cornea layers. The 80 !J.m thick 
cornea contains a pocket large 
enough for the hydrogel and heals 
itself after implantation of the 
hydrogel as seen in Figure 2-15. 
Rehydration of the section 
allowed the hydrogel to swell to 
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its original size. Hydrogel shift resulted from the rehydration procedure. 
2.3.4 Bioactive Hydrogels Stimulate a Vascular Response in vivo 
VEGF-releasing hydrogels were used to confirm that implanted hydrogels 
stimulate a vascular response. Dextran (MW 70,000 Da) was injected in a mouse tail 
vein to visualize perfused vessels. Limbic vessels were seen in the control PEGDA gel 
(Figure 2-16) while VEGF-releasing hydrogel promoted limbic vessels branching into the 
cornea toward the hydrogel six days after implantation. Perfusion of vessels with dextran 
validates functionality of resultant vessels. In another view, dextran-perfused vessels can 
be seen surrounding the hydrogel itself (Figure 2-17). 
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Figure 2-16: VEGF-releasing Hydrogels Induce Angiogenesis in the Cornea. Natural limbic 
vessels with no enhanced vascularization as a result of PEGDA hydrogel without VEGF are 
seen in the control as compared to the enhanced vascular response to PEGDA hydrogels 
releasing VEGF. Functionality of the vessels is suggested by perfusion· with fluorescent 
dextran. 
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Figure 2-17: Newly formed blood vessels in hydrogels are functional. A,B) Small incision was 
made in cornea and photopolymerized hydrogels were implanted into the micropocket. C). Blood 
vessels formed in the hydrogels were perfused with Dextran-Texas red (70 KDa MW) injected 
intravenously into mice (Moon, Saik, Poche et al. , 2010). 
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The Flkl-myr: :mCherry genetically modified mouse labels the membrane of 
endothelial cells with a red fluorescence. This transgenic mouse line creates a novel 
system for neovascular imaging with subcellular resolution (Poche et al. , 2009). 
Furthermore, the angiogenic response to implanted hydrogels can be monitored in vivo 
over time. An extensive vascular network ofmyr::mCherry+ vessels can been seen in 
response to a VEGF -releasing PEGDA hydrogel six days after implantation (Figure 2-18 
A-B). 
Control PEG-VEGF hydrogel 
Figure 2-18: VEGF-releasing PEGDA gels stimulate myr::mCherry+ vessels (B) as 
compared to control gels without VEGF (A). Image from (Poche et al. , 2009). 
Red blood cells can be seen in the newly formed cherry+ vessels, suggesting functionality 
of the vessels (Figure 2-19). 
Figure 2-19: Perfused Vessels. (A) Fluorescent endothelial cells showed the angiogenic 
response to VEGF -releasing hydrogels. Red blood cells were seen in these vessels (B), and an 
overlay ofthe images (C) confirmed the presence of red blood cells inside the cherry+ vessels. 
Image from (Poche et al., 2009). 
While VEGF induces a substantial vascular response, the response can be 
enhanced by releasing both PDGF-BB and FGF-2, which is a previously established 
synergistic combination (Rogers et al., 2007). After 11 days in vivo, PEGDA gels 
releasing the combination ofPDGF-BB and FGF-2 induce a cherry+ neovascular 
response on both the gel surface (Figure 2-20A) and gel bottom (Figure 2-20B). 
However, the neovascular response to VEGF-releasing hydrogels was seen only on the 
hydrogel surface (Figure 2-20C) and not the bottom of the gel (Figure 2-20D). 
Another method to confirm successful perfusion of engineered vessels involved 
injecting fluorescent microspheres into the bloodstream. Vessels were successfully 
perfused and the rate of perfusion was quantified to be 980 !Jmlsec (Figure 2-21 ). 
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Figure 2-20: PEGDA gels releasing PDGF-BB and FGF-2 (A: top of gel; B: bottom of gel) 
enhance the neovascular response as compared to gels releasing VEGF (C: top; D: bottom). 
Furthermore, vessels formed in response to the combination ofPDGF-BB and FGF-2 appear 
more stable and organized. 
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Figure 2-21: High-speed confocal imaging of circulating fluorescent microspheres among an 
implanted corneal hydrogel. Images were acquired at 50 frames/sec using a Zeiss LSM 5 LIVE 
high-speed confocal microscope with a Zeiss Plan-Neofluar SX/0.15 NA objective lens, resulting in 
a movie showing the circulation of microspheres through the newly induced vessels surrounding the 
hydrogel. (A) A single frame taken from the image series. Bright green microspheres are located 
within the induced vessels and surrounding the hydrogel in the cornea of a live animal. (B-D) 
Images from the Imaris software in which individual spheres (yellow and blue arrows) are tracked in 
successive frames in an area of interest (white box in A). The tracks shown represent the trajectories 
of23 microspheres imaged over 15.62 sec (753 images) and are shown as colored lines. The time 
stamp shows that the elapsed time between each frame (B to D) is 100 msec. The velocities of 
fluorescent spheres that were tracked ranged from 0.65 to 1.15 mm/sec (Average= 980.58±147.89 
1-!rnlsec) (Poche et al., 201 0). 
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PEG-VEGF and MMP-sensitive hydrogels were combined to enhance the 
neovascular response. The first column of Figure 2-21 outlines the hydrogel by using 
fluorescent PEG-RGDS. The middle column shows cherry+ neovessels, and the third 
column shows the merge of hydrogel and vessels. Degradable gels without any VEGF 
acted as control gels and caused no vascular response (Figure 2-21 ). 
Merge 
Figure 2-21: Hydrogels without growth factors do not stimulate a vascular response. 
Fluorescently-labeled RODS outlines the area of the hydrogel (A) and no vessels are seen in (B). 
C) An overlay confirms that hydrogels do not stimulate a vascular response without growth 
factors. 
These gels confirm that degradable gels alone cannot stimulate a response. Non 
degradable 6 kDa PEGDA gels with both PEG-VEGF and releasable VEGF stimulated a 
response with vessels covering the gel surface (Figure 2-23 A-D). Degradable gels with 
both releasable and covalently-immobilized VEGF enabled degradation of the matrix as 
vessels penetrated into the matrix (Figure 2-23 E-H). Degradation was seen in areas of 
substantial vessel growth. 
The effects of tunable mechanical properties were also investigated using a 15% 
polymer weight percentage degradable gel. The increase in polymer percentage alters 
hydrogel mechanical properties, creating a stiffer gel with smaller mesh sizes. Previous 
work has confirmed that increasing polymer weight percentage significantly increases the 
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compressive moduli ofthe hydrogels and slows degradation time (Moon, 2008). Lutolf 
et al. has shown that the rate of fibroblast migration into 3D hydrogels is inversely related 
to polymer crosslinking density (Lutolf et al., 2003). Furthermore, the mechanical 
properties also affect cell phenotype, as an increase in matrix stiffuess was shown to 
decrease cardiomyocyte contraction (Shapira-Schweitzer et al., 2007). 15% polymer 
weight percentage gels were fabricated with both PEG-VEGF and releasable VEGF, and 
the in vivo response was evaluated seven days after implantation. After seven days, a 
vascular response was seen on the gel surface, and the early stages of scaffold 
degradation were seen as vessel ingrowth, highlighted by the depth profile image (Figure 
2-23 1-L). These studies confirm that the degradation rate can be controlled using tunable 
mechanical properties, allow precise design ofhydrogels for various in vivo applications. 
Moreover, the angiogenic response can also be controlled by altering mechanical 
properties. 
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Figure 2-23: Proteolytically-degradable PEG hydrogels promote neovascularization in murine 
cornea. Hydrogels incorporated with soluble and immobilized forms of VEGF via PEG linkage 
were implanted into cornea in Flkl-myr: :mCherry transgenic mice. Newly formed blood vessels 
were visualized by confocal microscopy, and depth profiles of the vessels were generated to reveal 
their Z position with respect to the hydrogels. A-D) Non-degradable hydrogels releasing soluble 
VEGF supported angiogenesis adjacent to the hydrogels, but the depth decoding graph indicates lack 
of vessel penetration into the hydrogels. E-H) MMP-sensitive PEG hydrogels with 10% polymer 
weight promoted robust neovascularization adjacent to the hydrogels and extensive infiltration of 
host vasculature into the hydrogels. The arrow in E) indicates a portion hydrogel undergoing active 
degradation, and the arrow in H) points to regions within hydrogels with vessel infiltration. 1-L) 
MMP-sensitive PEG hydrogels with 15% polymer weight had blood vessel growth on surface of 
hydrogels as pointed by the arrow in L ), but the hydrogels remained mostly intact (I) without any 
significant vessel infiltration into the core. Scale bars = 100 Jlm in A-L) (Moon, Saik, Poche et al. , 
2010). 
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Finally, three different doses ofPDGF-BB and/or FGF-2 were used to induce 
vessel formation on PEG-based hydrogels implanted into a cornea micropocket using 
transgenic mice expressing Flkl-myr: :mCherry to facilitate characterization of the 
angiogenic response (Poche, 2009; Poche et al., 2010). Growth factors were used 
individually to parse out individual effects and in combination to investigate synergistic 
effects. Resulting vessels were imaged 7 and 14 days after implantation and space-filling 
morphological parameters including fractal dimension, vessel density, and lacunarity 
were used to quantify resulting vessel morphology (Gould et al., 2011). Vessel 
morphology varied based on dose, where high doses of individual factors and 
combinations of factors induced vessel beds with high vessel density (Figure 2-25 A, B), 
greater fractal dimension and a higher lacunarity parameter b, reflecting less lacunae or 
open space between vessels versus lower dose treatments (Figure 2-25 D). These trends 
were confirmed using statistical tests (ANOV A and Tukey post hoc analysis), which 
confirmed a significant difference between high and low dose groups at 7 and 14 days in 
all treatment groups, (p<0.05) when using the vessel density and fractal dimension 
analysis. Amongst the various dose and treatment groups, three key findings were 
present: (1) significant differences existed in all cases between high and low dose groups, 
indicating a dynamic range of vessel morphology (p<0.01), (2) the PDGF-BB I FGF-2 
combination group alone at 14 days exhibited significant differences between high, 
medium and low dose groups using vessel density, fractal dimension, and lacunarity 
(p<0.05), and (3) other groups showed some differentiation between groups, but lacked 
the same level of differentiation between all groups. At the 7 day timepoints, lacunarity 
proved significantly different amongst all dose groups. However, at 14 days the 
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differences between high and low dose groups were not significant except in the PDGF-
BB I FGF-2 combination group, which showed differences between all three dose groups 
(p<0.01) at 7 and 14 days. In all treatment cases, the high dose groups were significantly 
higher in vessel density and fractal dimension, while in some, the medium dose groups 
were significantly different from either the low or the high dose groups, but not both. 
Differences were observed within groups, and examined for trends which might 
indicate morphological changes from 7 to 14 days. The high dose in all treatment groups 
exhibited vessel densities of around 40% at 7 days and near 35% at 14 days. Although 
these trends suggest remodeling, no significant difference within groups and doses in the 
density from 7 to 14 days was observed. In comparison to the 7 day vessels, the 14 day 
vessels were visually observed to have lower diameters, and the branching was similarly 
observed to be slightly lower in some groups (Figure 2-26 A,B). 
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Figure 2-24: Growth Factor Dose Induces Differing Vessel Morphology. 7 days (A) and 14 
days (B) after implantation, vessels were visible in response to PDGF-BB and/or FGF-2 
at three different concentrations. 
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Figure 2-25: Vessel density, fractal dimension, and lacunarity were quantified. Vessel 
density, fractal dimension, and lacunarity were measured to quantify the vascular response (A-F). 
7 Days after implantation, vessel density, fractal dimension and lacunarity parameter b were 
found to increase as growth factor dose increased (A, C, E). 14 days after implantation, similar 
trends in vessel density, fractal dimension and lacunarity parameter were observed in response to 
the growth factors PDGF-BB and FGF-2 at similar dose concentrations (B, D, F). For this study 
high dose was 640:160ng PDGF-BB: FGF-2, medium was 160:40ng PDGF-BB: FGF-2, low dose 
was 40:10ng PDGF-BB: FGF-2. 
Branching and diameters were quantified and within the PDGF-BB I FGF-2 
combination group, the high, medium and low dose groups were significantly different in 
branching morphology (p<O.O 1) at 7 days, with high dose exhibiting the greatest 
branching (74±5.5) versus medium (56±3.8) and low (17±5.0) dose groups (Figure 2-26 
A). At 14 days similar differences within this treatment group were seen (p<0.05). This 
level of separation between doses with branching was not seen in the FGF-2 and PDGF-
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BB alone groups. Similar trends were observed for vessel diameters, within dose groups 
at 7 days, in that there were differences between high, medium and low dose groups in 
the case ofFGF-2 or PDGF-BB I FGF-2 (p<O.Ol). In the PDGF-BB alone treatment, 
there was only a significant difference between medium and low dose groups (p<0.01) 
(Figure 2-26 C). One important change highlighted by diameter measurements was the 
difference within dose groups and within specific dose levels between 7 and 14 days. In 
each group, with the exception of the PDGF-BB only, high dose group, there was a 
significant decrease in the average vessel diameter from 7 to 14 days (p<0.05). Also at 
14 days, the only group which had no significant difference between high, medium and 
low dose groups was the PDGF-BB I FGF-2 containing group. In contrast, the PDGF-BB 
alone and FGF -2 alone groups showed significant differences between the high and low 
dose groups, and medium and high dose groups (p<0.05). These data indicate that at 
fourteen days, the vessel branches are relatively unchanged, and that the vessel diameters 
are more uniform particularly in the PDGF-BB I FGF-2 combination group. In summary, 
the key findings were that significant differences in the vessel density, fractal dimension, 
and lacunarity were supported by similar differences in branching, that the branching 
differences were only consistently different in the combination treatment, and that the 
only group with relatively equally distributed vessel diameters in all three treatment 
groups was the combination treatment group. 
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Figure 2-26: Branch point and vessel diameter comparisons. Branching was quantified, by 
counting the number of branch points using the LSM image browser software in the three 
dimensional z stacks of the different vessel structures at 7 and 14 days (A, B). Diameters of 
vessels were measured in similar fashion at 7 and 14 days (C, D) and a histogram was plotted 
to elaborate on the differences between vessel diameters (E). Interestingly, there were not 
significant differences between branchlng from 7 to 14 days in all groups except the medium 
dose group in the combination PDGF -BB I FGF -2 treatment group (p<0.05). In the case of 
the vessel diameters, there were significant changes in treatment groups between 7 and 14 
days, however, the differences that were apparent within treatments, between doses at seven 
days (p<0.01) were not seen in the 14 day timepoint in the PDGF-BB I FGF-2 combination 
treatment group. This suggests the combination group induces vessels with relatively stable 
branching and relatively uniform vessel diameter distribution at 14 days, reflected by the 
histogram in (F) which shows an increased fraction of 6-8um diameter vessels. 
The dose ofFGF-2/PDGF-BB was shown to have a significant effect on vessel 
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density, fractal dimension and lacunarity. In fact, a linear relationship exists between the 
dose ofFGF-2/PDGF-BB and the values for these three properties for the day 14 data 
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(Figure 2-27). A fitting function was applied to each set of data at each time point for 
each recorded parameter (vessel density, fractal dimension, lacunarity). The best fits 
were seen for aU measurements in the combination PDGF-BB I FGF-2 group, which had 
r values which were greater than those of the FGF-2 only and PDGF-BB only groups 
(which were no higher than r=O. 77) at both 7 and 14 days. Importantly, the r2 values 
were the highest for the 14 day timepoint in the PDGF-BB I FGF-2 treatment group 
(r=0.94 at 14 days, compared to 0.80 at 7 days). This linear fitting data, in conjunction 
with the observations about branching and diameter appears to support other researchers 
claims about the beneficial effect of using PDGF-BB and FGF-2 in combination (Cao, 
2003). The fractal dimension from each combination PDGF-BB I FGF-2 group at 14 
days was plotted versus the original dose used (Figure 2-27 A). Linear fits were then 
applied to the data in order to interpolate the dose ofPDGF-BB and FGF-2 necessary to 
induce vessels with a known target fractal dimension (Figure 2-27 A). Figure 2-27 shows 
the original data (fractal dimension, vessel density, and lacunarity) from the dose 
escalation using the combination PDGF-BB I FGF-2 treatment group, plotted with the 
linear fit shown and the 95% confidence intervals plotted above and below. This served 
as the rationale for choosing the PDGF-BB I FGF-2 treatment group at a 14 day 
timepoint to tune the vascular response. Fractal dimension alone was used to interpolate 
the dose needed to recapitulate morphology of known tissues, because this parameter had 
previously been measured using similar techniques, and is known to be scale-invariant 
(Gould et al., 2011 ). 
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Figure 2-27: Morphological Parameters Used to Calculate a Linear Fit. Fractal 
dimension (A), vessel density (B) and lacunarity parameter b (C) were plotted against dose 
released. A linear fit was applied to the data, with R2 values over 0.9 in each parameter based 
plot. Linear fit equations were used to back calculate doses necessary to recapitulate vessels 
with given morphological parameters. The doses were based on the linear plot for the fractal 
dimension. The measured values for the induced vessels using the interpolated skin and 
muscle doses are plotted and indicated by the triangle symbols. The 95% confidence intervals 
are noted as small bars above and below each value. The linear fit for the fractal dimension 
(A) had an r2 value of0.92. For vessel density the fit was r2 = 0.96, for lacunarity r =0.92. 
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Next, a determination was made as to whether the vessels induced by the range of 
FGF-2/PDGF-BB doses were similar to vessel beds in endogenous tissues in terms of the 
fractal dimension. Native skin and muscle tissues from Flkl-myr::mCherry transgenic 
mice were imaged prior to this study to identify the fractal dimensions at 1.80 ± 0.03 and 
1.70 ± 0.05(Table 2-l)(Gould et al., 2011). Thus, the fractal dimension of endogenous 
vessels within the skin and the muscle fit within the linear range of concentrations tested 
for FGF-2/PDGF-BB. 
Table 2-1: Vessel Parameters for Induced and Native Vessels. Table 2-1 provides the 
complete set of measured parameters from the induced vessels and the native vessels. 
Since the space-filling properties of vessels within endogenous tissues fit well 
within the linear range of tested growth factor concentrations, a linear relationship was 
used to predict the growth factor concentration that would induce vessel structures with 
space-filling properties that better matched those measured from skin and muscle. 
Growth factor concentrations necessary to reproduce these fractal dimensions were 184 
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ng PDGF-BB and 46 ng FGF-2 for skin, and 89 ng PDGF-BB and 22 ng FGF-2 for thigh 
muscle based on the linear fit of the fractal dimension data. To test whether these doses 
could indeed induce new vessels with similar properties as those found in skin and 
muscle, hydrogels were implanted with the predicted concentrations in mouse cornea. 
The resulting induced vessels are shown in Figure 2-28 (A, C) alongside images of 
normal vessels in the muscle (B) and skin (D) of a Flkl-myr::mCherry mouse. When the 
density, fractal dimension and lacunarity of these vessels was measured, a strong 
correlation existed between the native tissue values and those measured from the vessels 
induced by FGF-2/PDGF-BB (Table 2-1). Interestingly, even though the fractal 
dimension was used to tune the vascular response, the muscle and skin vasculature 
morphological parameters of lacunarity and vessel density also followed a linear fit 
(Figure 2-27). Interestingly, other parameters such as vessel diameter and the number 
of branch points also were statistically indistinguishable between native tissue and 
vessels induced by the optimized dosage of FGF -2/PDGF -BB (vessel diameter (p=0.55 
and 0.48 for skin and muscle) and branch points (p=O.ll and 0.68))(Figure 2-29). Thus, 
these data show the utility in using space filling morphological parameters such as fractal 
dimension to define specific growth factor doses to tune the induced angiogenic response. 
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Figure 2-28: Recapitulation of Native Vessels. Vessels in the native mouse skin and thlgh 
muscle (B and D) are visually similar to vessels formed in response to growth factor release from 
hydrogels (A and C). 
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Figure 2-29: Recapitulation of native tissue branch points and vessel diameter. Analysis of 
vessel diameter and branch points indicates no significant difference between native vessel and 
induced vessel morphological characteristics. 
2.4 Conclusions 
Advantages and Disadvantages of the Corneal Micro pocket Assay 
Due to its external location, immune privilege state, and transparency, the mouse 
cornea micropocket offers an accessible, high-throughput system in which to rapidly test 
a variety oftissue constructs in vivo. Using this assay, 70 hydrogel constructs can be 
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implanted per day based on time to do the surgery. This way, one can quickly screen 
many candidate tissue constructs and assess specific properties, such as host vessel 
ingression, perfusion, donor cell survival and integration, and scaffold degradation. 
Another obvious advantage of the cornea model is that the mouse has two eyes. Thus, one 
eye can be used as an internal control, thereby reducing the number of mice needed for 
characterization of test and control constructs. Finally, because the mouse eye is 
externally localized and the cornea is a transparent tissue, live imaging studies are easily 
performed. There are two main drawbacks of the cornea as a transplantation site. First, 
due to the size of the eye, there is an inherent limitation on the size of the implanted tissue 
construct. Also, the cornea is a highly specialized tissue consisting of a unique 
microenvironment, and one has to take this into consideration when making comparisons 
to other transplantation sites. It is important to note that cornea is not the only mouse 
transplantation site that is amenable to live imaging oftissue constructs. The cranial 
window (Yuan et al., 1994) and dorsal skin fold (Leunig et al., 1992) have been 
successfully employed in live imaging studies. Although these methods are better suited 
for the implantation oflargertissue constructs and constitute more "typical" cellular 
environments as compared to the highly specialized, avascular cornea, the surgical 
procedures are fairly laborious for the researcher and invasive to the animal. This 
combined approach took advantage of the relative ease of the corneal micropocket 
surgery to analyze many candidate tissue construct designs first in the cornea. Once 
constructs with the desired properties are identified, larger versions of these constructs 
can then be generated and validated in other in vivo settings, such as the cranial window 
and dorsal skin fold (Poche et al., 2010). 
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Tunability of Implanted Hydrogels 
This project has provided a tunable system for angiogenesis in vivo in the 
modified mouse corneal pocket. Importantly, as demonstrated by the linear response of 
these vessel parameters to loaded protein; it is possible to tune the delivery of angiogenic 
factors to generate specific vascular structures. This tunable system could provide for 
numerous in vivo studies of vasculature and models of vascular disease or remodeling. 
Beyond the contribution of a tunable system, it has also provided information on the 
range of doses of factors which may be used for angiogenesis in the corneal micropocket 
system, and it has demonstrated the utility of scale invariant space filling measures in 
analysis and design of induced vessel beds for tissue engineering scaffolds. Here, 
statistical measures including vessel density (Penn et al., 1992), fractal dimension 
(Mandelbrot, 1982), and lacunarity parameter (b) (Tolle et al., 2008; Mandelbrot, 1982) 
used in conjugation with vessel diameter and density to examine membrane-labeled 
vessels of the flk1 ::myr-mCherry mouse, helped to quantify microvascular morphology 
and remodeling (Gould et al., 2011). These methods have the potential to aid the 
development of engineered tissues, such as skin, muscle and soft tissue, by providing the 
important vessel parameters needed to permit physiologic metabolic exchange and to 
ensure good incorporation of the scaffold with native tissue. 
This technique may help to design therapeutic strategies for re-vascularization, in 
order to control the resultant morphology of induced vessels. It should be noted however, 
that more complex vessel beds like the 3-5 tufts of capillaries surrounded by Bowman's 
capsule in the glomerulus or the juxtaglomerular apparatus in the kidney may require 
more complex methods to recapitulate the vessel architecture and may not be applicable 
to the methods described here, because of their complex structures involving several 
specialized cell types. 
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The methodology presented in this work has demonstrated utility by informing a 
formulation parameter necessary to synthesize bioactive scaffolds for a particular 
angiogenic application. Here, the effect of growth factor concentration was evaluated 
with respect to influence on the space-filling properties of vessels induced using a 
hydrogel matrix. In the future, this methodology could be used to optimize other factors 
within bioactive scaffolds, and to study other angiogenic compounds in vivo in 
applications within tissue engineering, therapeutic angiogenesis, and other applications in 
regenerative medicine. 
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Chapter 3: Covalently Immobilized Platelet Derived Growth Factor-DB 
Promotes Angiogenesis in Biomimetic Poly( ethylene glycol) Hydrogels 
A significant portion of Chapter 3 is taken from Saik, JE, DJ Gould, EM Watkins, ME 
Dickinson, and JL West (2011). Acta Biomaterialia, 7, 133-43. 
3.1. Introduction 
Engineered tissues are often plagued by the regression of tubule networks. When 
these networks regress, transport of oxygen to the tissue ceases and cells cannot survive. 
To stabilize the engineered vessel networks, platelet-derived growth factor BB (PDGF-
BB) was used in hydrogels for its ability to recruit pericytes and induce anastomosis. To 
prolong the signaling ofPDGF-BB, the protein was covalently immobilized to hydrogels. 
Immobilized PDGF led to endothelial cell tubule formation on 2D modified surfaces and 
an increase in cell migration and matrix metalloproteinase (MMP) activation in 3D. 
Finally, the presence of immobilized PDGF in these bioactive hydrogels significantly 
increased vessel density in the mouse cornea micropocket angiogenesis assay. 
PDGF, originally identified in the 1970s, contains 100 amino acid long A- and B-
chains which exhibit 60% sequence identity with eight conserved cysteine residues (Saik 
et al., 2011). The second and fourth residues form the bond between the two subunits, 
while the rest form intrachain bonds necessary for proper protein folding. A-chain genes 
are located on chromosome 7, with B-chain genes on chromosome 22 (Heldin et al., 
1999). Exon 6 contains the sequence for interaction with the extracellular matrix, as 
PDGF binds collagen, thrombospondin, and heparan sulfate. Therefore, the B-chain 
precursor can be retained in the extracellular matrix (ECM) until cleavage of the retention 
sequence. The three-dimensional structure and amino acid sequence show great 
similarity to VEGF, as well as to nerve growth factor and transforming growth factor 13, 
which have no sequence similarity (Heldin et al., 1999). 
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Two PDGF receptors exist, a- and 13-, both with five extracellular 
immunoglobulin-like domains and intracellular tyrosine kinase domains. Three amino 
acids, Asn-115, Arg-154, and Ile-158, are responsible for PDGF-BB binding both 
receptor types with high affinity as compared to PDGF-AA, which only binds PDGFRa 
(Ostman et al., 1991, 20]). PDGF receptors form non covalent dimers, held together by 
the PDGF ligands (Betsholtz, 2003). Ligand-induced receptor dimerization initiates 
receptor autophosphorylation, which provides SH2 domain docking sites for signal 
transduction molecules. Approximately 10 signaling molecules bind PDGF receptors, 
including phosphatidylinositol3'-kinase (PI3-kinase), Ras, Src, and Phospholipase C1 
(Betsholtz, 2003). The pathway induced by receptor dimerization affects the functional 
response to PDGF. For example, the PI3-kinase pathway induces cell migration and 
apoptosis inhibition. Induction of the MAP kinase pathway via Ras and the transcription 
factor Myc via Src lead to mitogenesis (Heldin et al., 2002). Each receptor type induces 
different signaling responses. For example, the al3 receptor has a more potent mitogenic 
effect. Differences are due to more efficient Ras phosphorylation from the 1313 receptor 
via a GTPase-activating protein (Heldin et al., 2002). 
Each A- and B- chain is synthesized as precursor molecules, which undergo 
proteolytic processing. Based on the presence of all three PDGF isoforms from cell lines, 
PDGF isoforms most probably form by random assembly (Hart et al., 1990). 
Furthermore, biologically reactive recombinant chains assemble into both homo- and 
heterodimers in vitro based on mixing conditions (Hoppe et al., 1990) and all three 
isoforms are seen in cells transfected with both A- and B-chains (Ostman et al., 1988). 
83 
PDGF-B, often involved in angiogenesis, is released in high concentrations by 
endothelial cells at the sprouting tip and mediates pericyte recruitment (Betsholtz et al., 
2005). PDGF-B is also expressed in many connective tissue cell types, including 
fibroblasts, keratinocytes, smooth muscle cells, endothelial cells, neurons, Schwann cells, 
and macrophages. Expression varies, but can be induced via thrombin, hypoxia, and 
growth factors. Endothelial cells also increase PDGF expression in response to shear 
stress via NFKB (Khachigian et al., 1995). Fibroblasts and smooth muscle cells have 
both a- and f3-receptors, but display higher levels of f3-receptors. Platelets and liver 
endothelial cells only express a-receptors, and mouse capillary endothelial cells express 
only f3-receptors (Heldin et al., 1999). Upon dimerization, receptors are internalized into 
endosomes. In the endosome, the receptor complex dissociates so the receptor can be 
recycled to the cell membrane or degraded in the lysosome. This thesis immobilized 
PDGF in order to prevent its degradation. Research involving application to wounds 
showed increased wound healing, increased wound-breaking strength (Pierce et al., 
1988), and an increased rate of reepithelialization due to PDGF (Pierce et al., 1991 ). The 
FDA has approved the use ofPDGF- BB for use in periodontal bone defects and diabetic 
ulcers. 
PDGF has widespread activities throughout the body, especially in the 
development of the kidneys, lungs, CNS, and blood vessels. Specific to the vascular 
system, endothelial cells not only produce PDGF but display PDGF receptors (Bar et al., 
1989). Although PDGF is not involved in initial vessel formation, PDGF-BB is involved 
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in neovessel stabilization and functionalization by inducing functional anastomoses and 
recruiting pericytes. Vessel stabilization has been shown to be dependent on expression 
of~-receptors (Zhang et al., 2009). Mice lacking the PDGF-B chain exhibited defective 
blood vessel development and microaneurysms, likely as a result of the inability of 
neovessels to attract stabilizing pericytes (Lindahl et al., 1997). PDGF stimulates 
pericyte production ofECM proteins, including fibronectin, collagen, and proteoglycans, 
necessary for the basement membrane of capillaries. Furthermore, PDGF stimulates 
fibroblasts to produce and secrete collagenases, which is further investigated in this 
thesis. PDGF also increases expression levels of VEGF in mural cells, which target 
endothelial cells. PDGF can regulate vessel tone by inducing dose-dependent constriction 
of small blood vessels or relaxation of large blood vessel via nitric oxide (Berk et al., 
1986). PDGF maintains tissue interstitial fluid pressure through interactions between the 
ECM and connective tissue cells (Rodt et al., 1996). Mouse embryonic stem cells even 
responded to PDGF by forming capillary-like structures with vascular sprouting as a 
result of Ca2+ induced reactive oxygen species generation (Lange et al., 2009). 
Growth factors with short half lives and widespread effects, such as PDGF-BB, 
have seen relatively few clinical successes despite documented in vitro efficacy (Kuhl et 
al., 1996). This is possibly due to a short circulating half-life (Hollinger et al., 2008) or 
the potential for unintended action due to the ubiquity ofPDGF-BB targets. Covalent 
immobilization enables controlled, spatial presentation of potent growth factors to 
stimulate a desired response and mediate potential drawbacks. Immobilization of 
biomolecules can be accomplished by attaching them to a polymer, such as poly( ethylene 
glycol) (PEG), which is then incorporated into a larger scaffold network. The 
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conjugation of growth factors to PEG has been shown to improve solubility, decrease 
immunogenicity, and increase stability (Veronese et al., 2008; Roberts et al., 2002), while 
at the same time retaining bioactivity of the original molecule. For example, PEG-
conjugated epidermal growth factor (EGF), which does not diffuse or become 
endocytosed, has been shown to be bioactive and capable of inducing DNA synthesis in a 
manner comparable to soluble EGF (Kuhl et al., 1996). In another study, PEG-VEGF 
incorporated into a biodegradable gel not only increased endothelial cell tubulogenesis, 
but also increased endothelial cell motility 14-fold and cell-cell connections 3-fold 
(Leslie-Barbick et al., 2009). 
The work reported in this thesis used bioactive, PEG-based hydrogels modified 
with covalently immobilized PDGF-BB to promote in vitro tubule formation and 
stabilization, as well as in vivo angiogenesis. Bioactive, immobilized PDGF-BB was 
shown to enhance the angiogenic activities of tubule formation on modified surfaces in 
2D and promote cell migration in 3D degradable hydrogels. Since angiogenesis and 
vessel stabilization in vivo require the precise coordination between multiple growth 
factors, the combination ofPDGF-BB with fibroblast growth factor-2 (FGF-2) was also 
investigated. PDGF-BB and FGF-2 had previously been found to induce a synergistic 
vascular response in both the mouse cornea and ischemic hindlimb models (Cao et al., 
2003). In this thesis, the combination of covalently immobilized PDGF-BB and FGF-2 
showed enhanced cell migration in 3D degradable hydrogels (Saik et al., 2011). 
Previous research had shown that a co-culture of human umbilical vein 
endothelial cells (HUVECs) and 10Tl/2 pericyte precursor cells formed long-term stable 
vessels in vivo on a fibronectin-type I collagen matrix (Koike et al., 2004). Additionally, 
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10Tl/2s, when cultured with HUVECS, displayed a smooth muscle cell morphology and 
began expressing pericyte markers, such as a-smooth muscle actin, smooth muscle 
myosin, and calponin via the transforming growth factor ~ 1 (TGF -~ 1) pathway (Hirschi 
et al., 1998). However, FGF-2 has been shown to act as an antagonist ofTGF-~1 
induced smooth muscle cell gene expression in 10Tl/2 cells (Kawai-Kowase et al., 
2004). In this thesis, a co-culture of cells resulted in tubule formation independent of 
surface modifications with covalently immobilized growth factors, and FGF-free media 
enhanced tubule formation. Finally, bioactive hydrogels containing the combination of 
both soluble PDGF-BB to initiate angiogenesis and immobilized PEG-PDGF-BB 
exhibited a significant increase in vessel density when implanted into the mouse cornea 
micropocket angiogenesis assay. These studies reaffirm that PEG-based hydrogels can 
be designed with covalently immobilized growth factors to stimulate a desired cellular 
response. 
3.2 Materials and Methods 
3.2.1 Cell Maintenance 
HUVECs (Lonza, Walkersville, MD) were cultured in endothelial growth 
medium EGM-2 (Lonza), supplemented with ascorbic acid, epidermal growth factor, 
fibroblast growth factor (hFGF-2), heparin, hydrocortisone, insulin-like growth factor, 
GA-1000 (gentamicin, amphotericin-B), 2% fetal bovine serum (Bulletkit, Lonza), 2 mM 
L-glutamine, 1 U/ml penicillin, and 1 flg/ml streptomycin (GPS, Sigma, St. Louis, MO, 
USA). 10Tl/2 cells (American Type Culture Collection, Manassas, VA) were cultured in 
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Dulbecco's modified Eagle's Medium with high glucose (DMEM, Gibco, North 
Andover, MA) supplemented with 10% fetal bovine serum and 2 mM L-glutamine, 1 
U/ml penicillin and 1J.Lg/ml streptomycin (GPS, Sigma). HUVECs were used from 
passages 4 to 6, and 10Tl/2 cells were used from passages 15 to 19. Cells were 
maintained in an incubator at 3 7 °C and 5% C02 with media replenished every two days 
and subculturing as necessary. 
PEGDA, PEG-RODS, and PEG-PQ-PEG were synthesized as described in 
Chapter 2. 
3.2.2 Synthesis and Purification of acryloyl-PEG-succinimidyl carbonate (PEG-
SMC) 
The organic solvents needed to accommodate the short half-life of the 
succinimidyl carboxymethyl reactive group on the PEG-SCM, which was purchased and 
used for conjugation ofpeptides, were not compatible with proteins used in this study. It 
was therefore necessary to synthesize a heterobifunctional acryloyl-PEG-succinimidyl 
carbonate (PEG-SMC) in-house. PEG-SMC is functionally similar to the commercially 
available PEG-SCM, but has a longer reaction half-life and can thus be used under 
aqueous conditions. 
PEG (Fluka/Sigma, MW = 3400 Da ) was reacted with Ag20 (Sigma, St. Louis, 
MO), acryloyl chloride (Sigma, St. Louis, MO), and KI (Sigma, St. Louis, MO) in 
anhydrous dichloromethane (DCM; Sigma, St. Louis, MO) at 4 °C overnight, at molar 
excess ratios of 1.5, 1.1, and 0.3 respectively. Silver was removed by filtering the 
solution through Celite 521 (Spectrum Chemical Mfg Corp, Gardena, CA). A Rotovap 
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was used to dry the solution prior to dissolution in di H20. The pH was adjusted to 3 with 
HCl, and the solution was heated to 35 °C for 1 h. Iodine was removed by adding 
activated charcoal (Fisher, Pittsburg, PA), and the solution was filtered through Celite 
521. NaCl and DCM were added, followed by DCM extraction. Phase separation with 2 
M K2C03 was used to remove acid and chloride ions. Monoacrylated PEG was dried 
with sodium sulfate (Fisher, Pittsburg, PA), and a Rotovap was used to concentrate the 
solution followed byethyl ether precipitation and vacuum filtration. A four molar excess 
of disuccinimidyl carbonate (Sigma) was reacted with the monoacrylated PEG in 
anhydrous acetonitrile (Sigma) and pyridine (Sigma) under argon overnight. The product 
was dried using a Rotovap prior to dissolving in anhydrous DCM. The solution was 
filtered, and PEG-SMC was purified in acetate buffer (0.1 M, pH 4.5, 15% NaCl) via 
phase separation. The purified PEG-SMC was dried with anhydrous MgS04. PEG-SMC 
was precipitated into ethyl ether, filtered, and dried overnight under vacuum. PEG-SMC 
was characterized by proton nuclear magnetic resonance spectroscopy (1H-NMR, A vance 
400Hz; Bruker, Billerica, MA, USA) and matrix-assisted laser desorption/ionisation-
time offlight mass spectrometry (MALDI-TOF; Bruker Daltonics, Dillerica, MA, USA). 
The final PEG-SMC product was stored at -80 °C under argon. 
3.2.3 Synthesis ofPEG-PDGF-BB and PEG-FGF-2 
In-house synthesized acryloyl-PEG-SMC was dissolved in 50 mM sodium 
bicarbonate buffer (pH 8.5) and sterilized via filtration (0.2 Jlm). PDGF-BB (ProSpec 
Bio, Israel) was conjugated to PEG-SMC using a 400:1 PEG-SMC: PDGF-BB molar 
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ratio in 200 mM sodium bicarbonate buffer (pH 8.5) at 4 °C for 4 d (Figure 3-1 ). The 
resulting PEG-PDGF-BB solution was lyophilized under sterile conditions. PEG-PDGF-
BB powder was reconstituted and stored in HEPES Buffered Saline (I 00 mM NaCI, 10 
mM HEPES in deionized water; HBS; pH 7.4) with 0.1% BSA at 4 °C for up to three 
months. A similar procedure was followed for PEG-FGF-2 (ProSpec Bio) at a 100:1 
PEG-SMC: FGF-2 molar ratio. All growth factor conjugations were confirmed via 
Western Blot analysis on a 15% Tris-HCL precast polyacrylamide gel (Biorad, Hercules, 
CA). Primary antibodies included rabbit polyclonal anti-PDGF-B antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) and rabbit polyclonal anti-FGF-basic antibody 
(Millipore, Billerica, MA). Secondary antibody HRP-conjugated goat anti-rabbit IgG 
(Santa Cruz Biotechnology, Santa Cruz, CA) and an ECL TM chemiluminescent western 
blotting analysis system (GE Healthcare, Buckinghamshire, UK) were used. The western 
blot membrane was exposed to film (Kodak, Rochester, NY) for 15 s and developed 
using a Micromax Developer (Hope, Seattle, WA) with T2 developer and T2 fixer (White 
Mountain Imaging, Salisbury, NY). The presence of PEG was confirmed using a PEG 
stain adapted from (Zhang et al., 2006), which allows barium iodine to react with PEG to 
form a yellow color. 
Unconjugated PDGF-BB was quantified using a PDGF-BB ELISA (R&D 
systems, Minneapolis, MN). PEG chains mask antibody binding to PEG-PDGF-BB, so 
the amount ofunconjugated PDGF-BB was quantified after running a sample of the 
reacted solution on an ELISA as compared to a soluble PDGF -BB standard curve. With 
the amount of soluble PDGF-BB quantified, appropriate concentrations ofPEG-PDGF-
BB were calculated. 
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Figure 3-1: Synthesis of conjugated biomolecules. (A) Acryloyl-PEG-succinimidyl carbonate (PEG-
SMC) was synthesized by reacting poly( ethylene glycol) with acryloyl chloride in the presence of 
silver oxide and potassium iodide followed by disuccinimidyl carbonate. (B) acryloyl-PEG-PDGF-BB 
was synthesized by reacting PEG-SMC with the primary amines ofPDGF-BB. 
3.2.4 Formation and Surface Modification ofPEGDA Hydrogels 
Six kDa PEGDA was dissolved in HBS to a 10% polymer weight percentage 
solution. A stock solution of the photoinitiator 2-dimethoxy-2-phenylacetophenone 
(acetophenone, Sigma) was prepared by dissolving 300 mg acetophenone in 1 ml N-
vinylpyrrolidone (NVP) and then added to the polymer solution at a concentration of 10 
flllml. 
The solution was vortexed and sterile filtered. Hydrogels were polymerized 
between two glass slides separated by a 0.75 mm thick poly(tetra fluoroethylene) (PTFE) 
spacer. The glass slides and spacer were secured using clips. Polymer solution was 
exposed to UV light (B-200SP UV lamp, UVP, 365 nm, 10 mW/cm2) for 30 sand stored 
in PBS with 0.1% sodium azide. 
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The effects ofPEGylated proteins in 2D were studied by modifying the surface of 
bulk PEGDA hydrogels as previously described (Moon et al., 2007). Briefly, 5 mm 
diameter circles were punched from the hydrogel slabs prepared above. A solution 
containing 10 ~1/ml acetophenone along with PEG-RGDS and PEGylated growth factors 
was then added in sufficient volume to completely cover the surface of the hydrogel. The 
exact combination and concentrations of each factor are given in the individual 
experiments below. Hydrogels were then exposed to UV light for 2 min followed by 
soaking in sterile PBS to allow for swelling and removal of the photoinitiator solution. A 
schematic representation ofthe surface modification process is shown in Figure 3-2. 
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Figure 3-2: To study tubulogenesis in two dimensions, surface modifications of PEGDA 
hydrogels were performed. PEG-RGDS and PEG-PDGF-BB were covalently immobilized onto 
the surface of bulk PEGDA hydrogels using the photoinitiator acetophenone. 
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Patterned hydrogel surfaces were also made to emphasize the utility of spatial 
control ofPEG-PDGF-BB. Hydrogels were patterned by pipetting a solution containing 
10 J.Lllml acetophenone along with PEGylated growth factors onto the surface of a 5 mm 
diameter punch of a bulk hydrogel. A black transparency was used to block UV light 
from part ofthe gel. Hydrogels were exposed to 2 min ofUV light followed by extensive 
rinsing. PEG-RGDS was then immobilized to the entire surface by adding a solution 
containing 10 J.Lllml acetophenone with PEG-RGDS to completely cover the surface of 
the hydrogel followed by 2 min UV light exposure. 
For all studies, unconjugated PDGF-BB and PEG-SMC were removed via 
diffusion before the hydrogels were used. Alternatively, soluble PDGF -BB could also be 
left in place to act as a diffusible growth factor to encourage cell migration in the 
surrounding tissue for other applications. 
To quantify the surface concentration ofimmobilized PEG-PDGF-BB, hydrogels 
were synthesized as described above and then degraded in 0.1 N sodium hydroxide for 
three days. After complete hydrogel degradation, the protein concentration was read on a 
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). 
3.2.5 Bioactivity of Conjugated PDGF-BB via lOTl/2 Proliferation 
In order to evaluate the bioactivity of covalently attached PEG-PDGF-BB, lOTl/2 
cells (8.5 x 104 cells/cm2) were seeded onto gels modified with 5 mg/ml PEG-RGDS 
alone or in combination with 0.70 nmollml PEG-PDGF-BB. As a positive control, 0.70 
nmol/ml soluble PDGF-BB was added to the media of gels modified with PEG-RGDS 
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alone. Cells were imaged using an Axiovert 135 (Zeiss) inverted fluorescent microscope 
after 48 h of culture. Cell nuclei were visualized via incubation with Hoechst 33342 dye 
(Bis- 119 Benzimide, Sigma) at a concentration of 5 J.lg/ml in DMEM without serum for 
one hour at 37 °C. Four fluorescent images were taken per gel at excitation= 350 nm and 
emission= 460 nm. Cell nuclei were quantified using ImageJ. Cell counts in the 
presence ofPDGF-BB were normalized to counts on surfaces modified with PEG-RGDS 
alone. Data from three separate experiments using gels with PEG-RGDS (n=31), PEG-
PDGF-BB and PEG-RGDS (n=28), and PEG-RGDS and soluble PDGF-BB (n=l8) were 
pooled for statistical analysis as described below. 
3.2.6 Quantification of Tubule Formation 
To investigate the impact of covalently incorporated growth factors on vascular 
tubulogenesis, surface-modified PEGDA hydrogels were used. Bulk hydrogels were 
prepared from 10% 6kDa PEGDA and surfaces were modified as described above. Four 
modified surfaces were investigated: (1) 7.5 J.lffiOl/ml PEG-RGDS, (2) PEG-RGDS and 
0.27 nmol/ml PEG-FGF-2, (3) PEG-RGDS and 0.70 nmol/ml PEG-PDGF-BB and (4) 
PEG-RGDS, PEG-PDGF-BB, and PEG-FGF-2. HUVECs (8.5 x 105 cells/cm2) or a co-
culture ofHUVECs and 10T1/2 cells at a ratio of 4:1 were seeded onto the modified gels 
and cultured in EGM-2 media either with or without FGF-2 and imaged using an 
Axiovert 135 (Zeiss) inverted fluorescent microscope. Hydrogels were observed over a 
30-day period and images of the entire surface of the gels were merged in Adobe 
Photoshop Elements. Tubules and modified surface areas were traced in Adobe 
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Illustrator and quantified using lmageJ. For gels seeded with HUVECs alone, data from 
three separate experiments using gels with PEG-RGDS (n=lO); PEG-FGF-2 and PEG-
RODS (n=3); PEG-PDGF-BB and PEG-RGDS (n=10); and PEG-FGF-2, PEG-PDGF-
BB, and PEG-RGDS (n=4) was pooled. For the co-culture ofHUVEC and 10Tl/2 
hydrogels, data from three separate experiments using gels in media with FGF-2 with 
PEG-RGDS (n=10), PEG-FGF-2 and PEG-RGDS (n=3), PEG-PDGF-BB and PEG-
RODS (n=12), and PEG-FGF-2, PEG-PDGF-BB, and PEG-RGDS (n=12) was pooled. 
Similarly, data from three separate experiments using gels in media without FGF-2 with 
PEG-RGDS (n=7); PEG-FGF-2 and PEG-RGDS (n=6); PEG-PDGF-BB and PEG-RGDS 
(n=8); and PEG-FGF-2, PEG-PDGF-BB, and PEG-RGDS (n=7) was pooled. 
3.2. 7 Immunohistochemistry 
To examine tubule morphology, immunohistochemistry was performed to identify 
endothelial pericyte cell markers. After 30 d in culture, gels were fixed in 4% 
paraformaldehyde for 30 min and washed with phosphate buffered saline (PBS). Cells 
were permeabilized with 0.5% Triton-X for 10 min followed by a second PBS wash. 3% 
normal donkey serum (Sigma) was used as a blocking agent prior to application of the 
primary antibodies. Gels were incubated overnight at 4 °C in a 1 :200 dilution of mouse 
anti-alpha smooth muscle actin (R&D systems, Minneapolis, MN) and a 1: 100 dilution of 
goat anti-PECAM-1 (Santa Cruz Biotechnology) in 3% bovine serum albumin solution in 
PBS. Following incubation, gels were rinsed five times in PBS for 1 h each time. A 
1:400 dilution of Alexafluor 488 donkey anti-goat lgG (Invitrogen) and Alexafluor 555 
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donkey anti-mouse IgG (Invitrogen, Carlsbad, California) was applied overnight at 4 °C 
in order to visualize the primary antibodies. After washing, gels were incubated in a 
DAPI solution (2 J.lM, Invitrogen) for 45 min. Images were taken using a confocal 
microscope (Zeiss5 LIVE, Plan-Apochromat 20x objective with 0.8 numerical aperture 
and Plan-Apochromat oil-immersion 63x with 1.4 numerical aperture, for Alexafluor 
488: excitation= 489 nm, emission BP filter= 500-525 nm; for Alexafluor 555: 
excitation= 532nm, emission BP filter= 560-675 nm, for DAPI: excitation = 405 nm, 
emission BP filter= 415-480 nm). 
3.2.8 Cellular Encapsulation into Hydrogels 
To further understand the effects of covalently immobilized growth factors on 
cells in 3D, HUVECs were encapsulated into MMP-sensitive hydrogels containing 
covalently immobilized growth factors. HUVECs were fluorescently labeled the day 
before encapsulation by incubation with 10 J.lg green CMFDA Cell Tracker® (Invitrogen, 
Eugene, Oregon) in the culture media for 1 h. Following incubation, cells were rinsed 
with PBS and fresh media was added. 
Polymer solution was prepared in HBS (10 mM, pH 7.4) with a final formulation 
of 10% PEG-PQ-PEG, 3.5 J.lmol/ml PEG-RGDS, and 0.3% w/v Irgacure 2959 (Ciba 
Corporations, Based, Switzerland). Four treatment groups were observed, including 
hydrogels containing: (1) PEG-RGDS alone, (2) PEG-RGDS and PEG-FGF, (3) PEG-
RGDS and PEG-PDGF-BB, and (4) PEG-RGDS, PEG-FGF-2, and PEG-PDGF-BB. 0.03 
nmol/L PEG-FGF and 0.08 nmol/L PEG-PDGF-BB were used for both the individual 
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factor groups and the combination of factors. Fluorescently-labeled HUVECs were 
harvested using trypsin-EDT A and counted using a Coulter counter to determine the cell 
concentration. After counting, the cells were pelleted by centrifuging at 2700 RPM for 4 
min and resuspended in polymer solution to a concentration of 30,000 cells/~1. 5 ~I 
droplets of cell-laden polymer were formed and exposed to UV light for 7 min and the 
resulting cell-laden hydrogels were immediately immersed in EGM-2 media for in vitro 
analysis. 
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Figure 3-3: Cellular encapsulation into degradable hydrogels. To study tubulogenesis in three 
dimensions, endothelial cells were encapsulated into MMP-sensitive hydrogels containing 
covalently immobilized cell adhesive peptides and proteins. 
Activity of the cells in the hydrogels was monitored for 60 h using a Zeiss LSM 5 
LIVE confocal microscope. Images were captured every hour and analyzed using Logger 
Pro Software to track cell movement. Data from three separate experiments was pooled 
(n=30) for data analysis. 
3.2.9 Zymography 
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To determine MMP activity, media was collected from gels with encapsulated 
HUVECs 60 h after encapsulation. Standard zymography was performed on a 10% 
precast polyacrylamide gel with gelatin (Biorad, Hercules, CA) following a Millipore 
protocol. Briefly, after running electrophoresis, gels were immersed in a 25% triton-X-
I 00 solution in water with gentle mixing for 30 min. After decanting the solution, a 
developing buffer (50 mM Tris base, 50mM Tris-HCl, 0.2 M NaCI, 5 mM CaCh, 5 mM 
Brij 35) was applied overnight at 37 °C. Gels were then stained with Coomassie Blue 
and destained with Methanol:acetic acid:water (50:10:40). Gel images were obtained 
using a Fujifilm LAS 4000 and analyzed for the presence ofMMP bands. 
3.2.10 Hydrogel Implantation into the Mouse Cornea 
Hydrogels were prepared following the protocol outlined in Poche eta/. (Poche et 
al., 2009). Briefly, the prepolymer solution contained a 10% polymer weight percentage 
(100 mg/ml) ofPEG-PQ-PEG, 3.5 J.llllol/ml PEG-RGDS, 10 Jll/ml acetophenone stock 
solution, and 160 ng soluble PDGF-BB per gel with or without 1.6 ng PEG-PDGF-BB 
per gel (n=8). Hydrogels were prepared by injecting 0.12 Jll polymer solution in between 
the glass slides spaced by a 0.005 in thick PTFE spacer secured with binder clips and 
exposed to UV light for two min. 
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Bioactive hydrogels were implanted into the cornea following a modified mouse 
cornea micropocket angiogenesis assay (Poche et al.). All animals were used under an 
approved protocol of the Institutional Animal Care and Use Committee at Baylor College 
of Medicine. Briefly, mice were anesthetized and a partial thickness incision of 
approximately 50 !Jll1 in depth was made in the eye. A Von Graff knife was used to create 
a micropocket in the cornea stroma into which a hydrogel was implantated immediately 
after crosslinking. The Flkl-myr: :mCherry transgenic mice utilized in this study enabled 
visualization of vessel invasion via endothelial cell specific florescence (Larina et al., 
2009). Fourteen days after implantation, mice were euthanized and corneas were 
collected and fixed in 4% paraformaldehyde. Flatmounts of tissue were made and 
imaged on a Zeiss LSM 510 META confocal microscope using a 40x/1.2NA C-
Apochromat water immersion objective lens with a working distance of0.28 mm and 
corrected for UV vis IR. A 543 nm laser was used to excite the mCherry fluorophore. 
Images ofvessels on the hydrogel were compiled from projections ofz-stacks exactly 22 
flm in thickness, spaced 1.1 !Jll1 apart. 
3.2.11 Statistics 
One-way ANOVA and subsequent Tukey's Least Significant Difference (LSD) 
tests were used to statistically analyze the bioactivity ofPEG-PDGF-BB and HUVEC 
tubulogenesis on surface-modified hydrogels and the movement of cells inside the 
hydrogels. In the tubulogenesis study, a generalized linear model in Minitab was used to 
analyze statistical differences in tubule formation of the co-culture ofHUVEC and 
1 OTl/2 cells. For each analysis, p<0.05 was considered significant. 
3.3 Results 
Immobilized PDGF-BB was used in bioactive hydrogels to induce tubule 
formation. First, the successful conjugation and bioactivity ofPEG-PDGF-BB were 
confirmed followed by the application ofPEG-PDGF-BB for angiogenesis in 2D, 3D, 
and in vivo. 
3.3.1 Polymer Characterization 
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Conjugation ofacryloyl PEG-SMC to the primary amines ofPDGF-BB was 
confirmed using a western blot. Conjugated PDGF-BB was compared to unmodified 
PDGF-BB, with an increase in molecular weight representing conjugation of PEG chains 
to the protein (Figure 3-4). The presence of an intense PEG band in the PEG stain (arrow, 
Figure 3-4B) at the same molecular weight as the conjugated PDGF-BB band on the 
western blot further verified PEG-conjugation (Saik et al., 20 II). 
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Figure 3-4: Successful Conjugation of PEG to PDGF -BB (A) Successfully conjugated PDGF-
BB was confirmed on a western blot by the increase in molecular weight after conjugation. (B) A 
PEG stain confirmed the presence of a PEG band at the same molecular weight (arrow) as PEG-
PDGF-BB in the western blot, further validating PEG-PDGF-BB conjugation. 
3.3.2 PEG-PDGF-BB Bioactivity 
Bioactivity ofthe conjugated PDGF-BB was confirmed by quantifying 10Tl/2 
proliferation on hydrogel surfaces modified with PEG-RGDS and PEG-PDGF-BB as 
compared to those with PEG-RGDS alone. Soluble PDGF-BB was added to the media of 
some gels modified with PEG-RGDS to serve as a positive control. As shown in Figure 
3-SA, 1 OT1/2 proliferation significantly increased in the presence of either soluble or 
bound PDGF-BB at 48 h (ANOVA, p<0.05). There was no significant difference in 
proliferation in the presence of soluble PDGF-BB compared to PEG-PDGF-BB, 
suggesting that bioactivity of this growth factor is not adversely affected by conjugation 
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to PEG. The capability to spatially control immobilized PDGF-BB was demonstrated on 
hydrogels patterned with immobilized PDGF-BB (Figure 3-5 B-C). 1 OTl/2 cells evenly 
adhered to surfaces with and without PEG-PDGF-BB at 4 hours (Figure 3-5B). By 48 
hours, 10Tl/2 cells seeded onto these patterned hydrogels proliferated more on areas with 
immobilized PDGF-BB (Figure 3-5C). 
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Figure 3-5: Bioactivity of PEG-PDGF was confirmed by seeding lOTl/2 cells onto modified 
surfaces. (A) By 48 hr, lOTl/2 proliferation had significantly increased in the presence ofPDGF-
BB (ANOV A,# p<0.05). No significant difference between soluble and bound forms ofPDGF-
BB indicated that covalently-immobilized PEG-PDGF-BB retained its bioactivity. (B-C) 
Hydrogels with patterned regions ofPEG-PDGF-BB demonstrated the utility of spatial control of 
PDGF-BB. lOTl/2 cells seeded onto these patterned gels were evenly dispersed at 4 hours (B) but 
exhibited increased proliferation on regions patterned with PDGF -BB after 48 hours (C). 
102 
3.3.3 Covalently Immobilized PDGF-BB Promotes Tubulogenesis 
Thirty days after seeding HUVECs on surfaces modified with PEG-RGDS and 
PEG-PDGF-BB, endothelial cell tubules and branching networks were visible (Figure 3-
6A). HUVECs on surfaces modified with PEG-RGDS alone exhibited the normal 
cobblestone morphology of the cell type (Figure 3-6B). Early tubulogenesis was 
apparent after 18 d, with robust tubulogenesis at day 30. The presence oftubulogenesis 
after 30 d suggests that the bioactivity of covalently immobilized PEG-PDGF-BB was 
maintained. Statistical analyses indicated significantly higher tubule formation on 
surfaces modified with PEG-RGDS and PEG-PDGF-BB (1122 ~/mm2) as well as 
surfaces modified with the combination ofPEG-RGDS, PEG-PDGF-BB, and PEG-FGF-
2 (983 and 807 ~mm2, respectively) when compared to surfaces modified with PEG-
RGDS alone (384 ~/mm2; ANOVA with Tukey's LSD, p<0.05, Figure 3-6C). 
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Figure 3-6: Modified surfaces significantly enhanced endothelial cell tubule formation. (A) 
HUVECs seeded onto modified surfaces exhibit extensive tubule formation (arrows) as early as 18 
days compared to the cobblestone appearance ofHUVECs seeded on surfaces with only PEG-RODS 
(B). (C) A significant increase in tubule formation on surfaces with covalently immobilized PDGF-
BB (* p<O.Ol) and surfaces with both covalently immobilized PDGF-BB and FGF-2 (# p<0.05) is 
seen as compared to surfaces modified with PEG-RODS alone. 
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3.3.4 Tubule Formation by Co-cultures ofHUVEC and lOTl/2 Cells is Independent 
of Surface Modification 
The co-culture ofHUVEC and 10T1/2 cells in a 4:1 ratio was seeded onto 
PEGDA hydrogels modified with cell adhesive peptides and growth factors. Cells in 
these studies formed tubules within 6 d, with some tubule formation visible by 2 d. 
Tubulogenesis was independent of surface modifications, indicating that covalently-
immobilized FGF-2 and PDGF-BB are not necessary to stimulate tubule formation. 
Additionally, because FGF-2 is known to antagonize the TGF-~1 dependent 
differentiation of 1 OTl/2 into pericytes, cultures were maintained in media both with and 
without this additive. A generalized linear model in Minitab showed a significant 
difference in tubule formation between these two experimental groups (Figure 3-7, 
p<0.0005), with FGF-2 free media resulting in the greatest degree oftubulogenesis. 
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Figure 3-7: Analysis of total tubule length using a generalized linear model confirmed a 
significant difference between cells cultured in media with and without FGF -2 (p<O.OOOS). 
The co-culture ofHUVECs and lOTl/2 cells exhibited robust tubule formation independent of 
surface modifications with covalently immobilized growth factors. 
3.3.5 Endothelial and Smooth Muscle Cell Marker Expression Induced by 
Immobilized PEG-FGF-2 and PEG-PDGF-BB 
Immunohistochemistry confirmed the expression of endothelial and smooth 
muscle cell markers in tubules formed by co-cultures ofHUVEC and 10Tl/2 cells on 
modified surfaces. 1 OT 112 cells were found to express alpha smooth muscle actin, 
suggesting a pericyte phenotype (Figure 3-8). PECAM-1 labeled HUVECs formed 
extensive and branching tubule networks throughout the surface. No visible difference in 
tubule formation was observed between cells seeded on surfaces modified with PEG-
RGDS alone or with the cell adhesive peptide in combination with PEG-PDGF-BB 
and/or PEG-FGF-2. This suggests that tubule formation in the co-culture ofHUVECs 
and 1 OTl/2 cells is independent of surface modification (Figure 3-8A and B). 
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Upon closer examination, single 10Tl/2 cells were found to associate with 
multiple HUVECs in a typical pericyte "umbrella-like" morphology (Figure 3-8C). In 
addition, the appearance oflarge vacuoles within HUVECs in these networks (arrows, 
Figure 3-8D) is suggestive of the early stages of capillary lumen formation. Both of these 
features confirm the successful formation of stable and functional tubule networks. The 
presence of pericytes is necessary to prevent tubule regression, and lumen formation is 
required for red blood cell perfusion. 
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Figure 3-8: Immunofluorescent staining showing tubule morphology. Staining showing 
PECAM-1 (green), alpha smooth muscle actin (red) and cell nuclei (blue). No significant 
difference in tubule formation was visible between surfaces modified with RGDS (A) and 
surfaces modified with covalently immobilized PDGF-BB (B). lOTl/2 cells exhibiting a pericyte 
morphology can be seen encompassing an endothelial cell and associating with multiple 
endothelial cells on surfaces modified with RGDS (C). Vacuole formation (arrow) is visible as an 
early step toward lumen formation on surfaces modified with covalently immobilized PDGF -BB 
(D). 
3.3.6 Covalently Immobilized PEG-PDGF-BB Promotes Cell Migration in 3D 
Degradable Hydrogels 
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Timelapse confocal microscopy offluorescently-labeled HUVECs encapsulated 
in 3D degradable hydrogels exhibited a significant increase in migration distance per 
hour in the presence of covalently immobilized growth factors. Single images at 0, 10, 
20, and 30 hours are provided to illustrate the cell locations (Figure 3-9). At the starting 
time, cells are evenly dispersed throughout the hydrogels. By 20 hours, cell movement is 
visible in the presence ofPEG-PDGF-BB. Significant cell clumping is visualized by 30 
hours, especially as the gel containing both PEG-PDGF-BB and PEG-FGF-2 collapsed. 
Cell movement was quantified for the first 14 h, after which time extensive cell clumping 
and eventual gel collapse hindered measurement. Endothelial cells encapsulated in 3D 
degradable hydrogels exhibited significantly higher migration in the presence of 
covalently immobilized PEG-PDGF-BB and PEG-FGF-2 compared to hydrogels 
containing only PEG-RGDS (Figure 3-10A, *p<O.Ol). Also, PEG-FGF-2 significantly 
increased migration relative to PEG-PDGF-BB (Figure 3-lOA, #p<0.05), most likely due 
to FGF-2's role as a chemoattractant (Bikfalvi et al., 1997). The combination of 
covalently immobilized PEG-PDGF-BB and PEG-FGF-2 was found to significantly 
increase migration (Figure 3-lOA, *p<O.Ol) and decrease the time to gel collapse (Figure 
3-lOB, *p<0.01) as compared to the presentation of either ofthe factors alone. 
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Figure 3-9: Images from timelapse confocal microscopy illustrating cell movement. 
Fluorescently labeled HUVECs are evenly dispersed at the beginning of the experiment. In the 
presence of PEG-PDGF -BB, cells begin to move by 20 hours and significant cell clumping is 
visualized at 30 hours. 
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Figure 3-10: Endothelial cells exhibit angiogenic characteristics in 3D. (A) HlNECs encapsulated 
into 3D degradable hydrogels exhibited greater cell movement in gels containing covalently 
immobilized growth factors (* p<O.O 1 ). PEG-FGF -2 significantly increased migration as compared to 
PDGF -BB (# p<0.05), and the combination of PEG-PDGF -BB and PEG-FGF -2 induced significantly 
increased cell migration as compared to PDGF-BB and FGF-2 alone(* p<O.Ol). (B) Hydrogels 
containing covalently immobilized growth factors collapsed after 20-40 hr. The combination of 
PDGF -BB and FGF -2 lead to earlier gel collapse as compared to each growth factor alone (* p<O.O 1 ). 
3.3. 7 MMP Activation in Response to Covalently Immobilized Growth Factors 
Gelatin zymography was performed to analyze the presence of matrix 
metalloproteinase-2 (MMP-2) in hydrogels containing encapsulated HUVECs with 
covalently immobilized growth factors (Figure 3-11). Interestingly, the 72 kDa pro-form 
ofMMP-2 was present in all samples, but only samples with covalently immobilized 
PEG-PDGF-BB and/or PEG-FGF-2 contained active MMP-2 (68 kDa), a finding which 
corroborates the increase in cell movement in the same materials. 
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Figure 3-11: Immobilized growth factors induce MMP cleavage. Gelatin zymography 
confirmed the presence of pro-MMP-2 (MW 72 kDa) in all samples, but active MMP-2 (MW 68 
kDa, arrow) was seen only in the presence of covalently immobilized growth factors . 
3.3.8 PEG-PDGF-BB Enhances In Vivo Vascular Response 
To confirm the bioactivity ofPEG-PDGF-BB during angiogenesis in vivo, 
hydro gels containing PEG-PDGF -BB were implanted into the mouse cornea, a well 
defined method to assess angiogenesis (Kenyon et al., 1996). Hydrogels containing 
soluble PDGF-BB initiated an angiogenic response by stimulating vessels from the 
surrounding limbus to invade into the normally avascular cornea. Once vessels reached 
the bioactive hydrogel, the immobilized PEG-PDGF-BB (Figure 3-12B) induced a more 
robust vascular response than hydrogels with soluble PDGF-BB alone (Figure 3-12A), 
including an increase in quantified morphological parameters (Figure 3-12 C-F). 
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Figure 3-12: Immobilized PDGF-BB enhances the in vivo vascular response. Bioactive 
hydrogels incorporating both releasable and covalently immobilized PDGF-BB (B) were implanted 
into the mouse cornea micropocket and resulted in a more robust vascular response than hydrogels 
with releasable PDGF -BB alone (A). Statistical analysis highlights a significant increase in the 
vessel density, fractal dimension, and vessel diameter (D-F) with the addition of immobilized PDGF-
BB (p<0.05). 
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3.4 Discussion 
Controlled delivery of PDGF, such as the work in this thesis, has been 
investigated in several forms. Primarily, biomaterials have been employed as slow 
release delivery mechanisms (De Ia Riva et al., 2009). Rather than relying on growth 
factor release, fibrin matrices using heparin-binding to mimic the body's delivery system 
have also been designed to deliver PDGF-BB and FGF-2, a delivery system which 
increased fibroblast proliferation in tendon tissue (Thomopoulos et al., 2009). However, 
heparin binding does not provide as controlled an environment as the immobilization 
technique used in this thesis because other proteins can bind to heparin, and proteins can 
release and rebind. Recently, two groups have immobilized PDGF, enabling more 
prolonged delivery than that achieved with soluble release only. Aizawa et al. 
immobilized PDGF-AA, which induces PDGF receptor aa homodimers, as opposed to 
PDGF-BB which binds all three dim eric combinations of a- and 13- receptors. Maleimide 
functionalized PDGF-AA was immobilized to a natural material, agarose, containing 
sulfhydryl groups and used for PDGF-AA's known effect in regulating the differentiation 
of neural stem cells (Aizawa et al., 2008). Chen et al. introduced sulfhydryl groups into 
collagen scaffolds and used them to immobilize PDGF-BB, which stimulated fibroblast 
proliferation and increased blood vessel density after subcutaneous implantation (Chen et 
al., 2009). 
As opposed to previous work, this thesis focused on PDGF-BB for its 
involvement in inducing stable and functional neovessel formation. PDGF-BB was 
conjugated to PEG and immobilized in synthetic PEG-based scaffolds, which allow 
precise control over incorporated biological molecules, as well as mechanical properties 
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(Saik et al., 2011). PEG-PDGF-BB was shown in a cell proliferation assay to maintain 
bioactivity. In addition, PEG-PDGF-BB and PEG-FGF-2 stimulated angiogenesis in 
engineered PEG-based hydrogels. 
To form stable and functional vessels, angiogenesis requires the precise 
coordination of various signaling molecules. While combinations of growth factors have 
been used in releasable form, they have never been presented in an immobilized form. 
This work demonstrates the feasibility using immobilized PDGF-BB with FGF-2, a 
previously established synergistic combination (Cao et al., 2003), to promote endothelial 
migration in 3D. HUVECs seeded onto hydrogels exhibited significantly higher tubule 
formation on surfaces modified with PEG-RGDS and PEG-PDGF-BB and the 
combination ofPEG-RGDS, PEG-PDGF-BB, and PEG-FGF-2 as compared to surfaces 
modified with PEG-RGDS alone. The work presented in this thesis confirms that growth 
factors can assist endothelial cells in forming tubes, with robust tubule formation for 30 
days. 
In addition to the necessary growth factors, capillary formation requires two cell 
types where stabilizing pericytes promote endothelial cell survival (Reinmuth et al., 
2001) and form the basement membrane required for vessel stabilization and function 
(Diaz-Flores et al., 2009). In order to more rapidly form stable tubule networks, this 
work made use of a co-culture ofHUVEC and 10Tl/2 cells, which has previously been 
shown to form stable vessels in vivo (Koike et al., 2004). Mouse pericyte precursor 
10T1/2 cells are known to differentiate into pericytes in the presence ofHUVECs via the 
TGF -P 1 pathway (Hirschi et al., 1998). The co-culture of HUVEC and 1 OT 112 cells 
confirmed the role of stabilizing pericytes as the presence of 1 OTI /2 cells was sufficient 
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to induce tubule formation independent of surface modification as early as two days after 
cell seeding. Pericytes, first described in 1873 (Edelman et al., 2006), function to 
contract in order to regulate blood flow but also to regulate permeability. With less than 
20 nm between pericytes and endothelial cells, each pericyte covers several endothelial 
cells in an ''umbrella-like" manner (Edelman et al., 2006). Furthermore, vessels lacking 
pericytes exhibit abnormal features, such as leakage and impaired perfusion due to 
abnormal endothelial junctions, endothelial hyperplasia, and hypervariable diameter 
(Betsholtz et al., 2005). 
Direct contact with HUVECs induces 1 OTl/2 cell differentiation into stabilizing 
pericytes. However, FGF-2 is a known antagonist ofthe TGF-Pl dependent 
differentiation of 1 OTl/2 cells into pericytes, and thereby an important factor in the 
stabilization of new vessels. In this work, the removal ofFGF-2 from culture media 
resulted in increased tubule formation by HUVECs and lOTl/2 cells seeded on modified 
surfaces, suggesting that the critical pericyte differentiation had occurred. Confirmation 
of the presence of endothelial pericyte markers via immunohistochemistry further 
supports this reasoning. As demonstrated, tubule-like networks were visible on all 
surfaces, with alpha smooth muscle actin-positive cells seen extending over several 
endothelial cells in a pericyte-like fashion. Furthermore, the presence of multiple, large 
vacuoles within endothelial cells suggests lumen formation and capillary development 
(Kamei et al., 2006) on these functionalized hydrogels. 
Reduced tubule formation in the presence ofFGF-2 in vitro may affect the design 
of the hydrogels for in vivo use. Koike et al. have shown that a co-culture ofHUVEC 
and lOTl/2 cells is capable offorming functional tubule networks in vivo, which is 
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supported by the tubule formation seen in this in vitro work (Koike et al., 2004). 
However, to enhance tubule formation, local FGF-2 may need to be reduced, possibly 
through design ofhydrogels with FGF-2 antibodies. As an alternative, hydrogels could 
be designed with only HUVECs with the addition of immobilized PDGF-BB as the 
immobilized PDGF-BB induces HUVEC tubule formation. 
Based on the success ofPEG-PDGF-BB in 2D, its effects were also studied in 3D. 
It has been well established that growth factors, and in particular FGF-2 and PDGF-BB, 
effectively increase the migratory behavior of cultured endothelial cells. Soluble factors 
have been shown to induce a migratory phenotype, characterized by cytoskeletal 
rearrangement and pseudopodia formation, and to increase random movement in wound 
healing models of endothelial cells cultured in monolayer (Lee et al., 2006; Zhang et al.). 
In the presented thesis work, a similar effect was observed in degradable hydrogels 
containing immobilized PEG-FGF-2 and PEG-PDFG-BB. HUVECs encapsulated in 
these MMP-sensitive hydrogels exhibited a significant increase in random migration 
distance per hour as compared to materials without the growth factors. In addition, the 
combination ofPEG-FGF-2 and PEG-PDGF-BB resulted in a decreased time to gel 
collapse (33 hours as opposed to 52 and 43 hours, respectively), likely due to FGF-2 
induced PDGF receptor expression in vascular endothelial cells (Cao et al., 2008). Also, 
PDGF-BB is capable of inducing a positive feedback signal to amplify FGF-2 expression 
in vascular mural cells, which in turn enhances mural PDGF receptor P expression (Kana 
et al., 2005; Cao et al., 2008). 
In addition to stimulating migration, growth factors such as PDGF -BB stimulate 
the release ofMMP-2 and MMP-9. The degradable hydrogels used in this work 
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comprised crosslinked polymer chains that contain a protease-sensitive, PQ peptide 
segment. As such, when MMPs are secreted near or within the hydrogel material, the PQ 
peptide is degraded, causing the polymer backbone to fragment. As more peptides are 
cleaved, polymer fragments are released to solution and the hydrogel loses its integrity. 
In the current study, the increase in cell motility in the presence of growth factors appears 
to have hastened the collapse of the collagenase-sensitive hydrogel, presumably due to 
the secretion ofMMPs by migrating cells. This reasoning is supported by results from 
gelatin zymography, which confirmed the presence ofMMP-2 in hydrogels containing 
encapsulated HUVECs. MMPs play an active role in angiogenesis, particularly MMP-2, 
by enabling sprouting endothelial cells to migrate and by regulating growth factor release 
and activation (Stamenkovic, 2003). In addition, MMP activity is often controlled by 
proteolytic cleavage, in which a propeptide is cleaved to generate an active form of the 
enzyme. Interestingly, only samples with covalently immobilized growth factors 
contained active MMP-2 (68 kDa), corroborating the increase in cell movement and 
earlier hydrogel collapse in the same materials. 
Controlled delivery ofPDGF-BB is particularly useful for in vivo applications. 
Soluble PDGF-BB was necessary to stimulate the initial angiogenic response of the 
surrounding limbic vessels into the cornea. Since soluble PDGF-BB degrades very 
rapidly in vivo, the presence ofPEG-PDGF-BB enables prolonged angiogenic signaling 
on the hydrogel, leading to an increase in vessel density and diameter. This manuscript 
presents the first work with a PEGylated growth factor in vivo. 
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3.5 Conclusion 
Biomimetic hydrogels can be designed to incorporate cell adhesive sequences and 
covalently immobilized growth factors to stimulate a desired cellular response in tissue 
engineered constructs. This thesis work demonstrates that PEG-PDGF-BB is bioactive 
and can be successfully incorporated into PEG-based hydrogels alone and in combination 
with PEG-FGF-2. HUVECs seeded onto hydrogel surfaces modified with covalently 
immobilized growth factors formed extensive and branching networks of tubules. 
Additionally, a co-culture ofHUVEC and mouse pericyte precursor IOTl/2 cells seeded 
onto modified surfaces induced tubule formation independent of growth factor 
modification as early as two days after cell seeding. Endothelial cells encapsulated in 
MMP-sensitive hydrogels with covalently immobilized growth factors exhibited key 
steps in angiogenesis, such as a significantly higher migration rate and MMP-2 
activation. Finally, bioactive hydrogels containing both soluble PDGF-BB and 
immobilized PEG-PDGF-BB led to a significant increase in vessel density when 
implanted into the mouse cornea as compared to hydrogels with soluble PDGF-BB alone. 
Further work is necessary to determine optimal combinations of cell types as well as both 
bound and soluble growth factors to form stable and functional vascular networks. The 
results presented here demonstrate the potential ofbiomimetic, PEG-based hydrogels 
containing immobilized growth factors as a promising methodology to engineer a 
microvascular system within tissue engineered constructs for regenerative medicine 
applications. 
Chapter 4: Biomimetic Hydrogels with Immobilized EphrinAl for 
Therapeutic Angiogenesis 
A significant portion of this chapter is from Saik, JE, DJ Gould, AK Keswani, ME 
Dickinson, and JL West. Biomacromolecules. In press 2011. 
4.1 Intoduction 
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The formation of a microvascular system requires precise coordination between 
cells and their environment. In order to influence cell-cell interactions during 
microvascular formation, the receptor tyrosine kinases family of Eph receptors and their 
ephrin ligands were utilized for their involvement in growth, differentiation, and 
patterning of tissues. Most commonly expressed on neuron and endothelial cells, 
ephrinAl is notably involved in the formation ofthe neuronal system as well as 
organization of the vasculature (Pasquale, 2008). Unlike other receptor tyrosine kinases, 
Eph receptors bind to membrane bound ephrin ligands. Ephrin ligands are categorized as 
type A for having a Glycosylphosphatidylinositol-anchor or type B for having a 
transmembrane domain. Eph receptors of the A class usually interact with ephrin ligands 
of the A class. Signaling can occur in a forward manner by ephrin ligands activating Eph 
receptors or in reverse by Eph receptors activating ephrin ligands (Heroult et al., 2006). 
The Eph receptors, the largest family of receptor tyrosine kinases, were first 
identified in 1987 as organ receptors with no known ligands. Several years later, ephrins 
were identified. The extracellular structure for the Eph receptor includes a NH2-terminal 
ephrin-binding domain with a cysteine-rich domain and two fibronectin-type III repeats 
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(Wykosky et al., 2008). The receptor then passes through the cell membrane and the 
intracellular structure contains two tyrosines, enabling autophosphorylation, and a 
tyrosine kinase domain. The COOH terminal end of the receptor provides a docking site 
for downstream signaling proteins (Wykosky et al., 2008). Reverse signaling via the 
ephrinA ligand may involve protein interactions, including the Src family, with the GPI 
linker (Wykosky et al., 2008). Signaling requires clustering of receptors, naturally done 
via membrane linkage. This thesis will use an Fc-conjugated ephrinA1 to enable 
clustering. The specific interaction between EphA2 and eprhinA 1 likely occurs between 
the serine or alanine at the 1 09th position on ephrinA 1 with the glutamine or methionine 
at the 38th position on EphA2. EphA2 is a 130 kDa, 976 amino acid receptor expressed 
on chromosome 1 p36. ephrinA 1 is a 22 kDa, 205 amino acid ligand from chromosome 
lq21-2. Tumor necrosis factor a is capable of inducing ephrinAl-mediated endothelial 
cell migration (Ogawa et al., 2000). 
Since both Ephs and ephrins are membrane bound and involve cell-cell contacts, 
signaling occurs in both a forward and reverse manner. Forward signaling generally 
repels two cells apart while reverse signaling generally adheres cells (Himanen et al., 
2007). The interaction between ephrinB2 and EphB4 is widely known to pattern arterial 
versus venous endothelial cells, respectively. Similar to PDGF, stabilization of vessels 
may also be due to recruitment of pericytes. Only ephrinB2 has been specifically shown 
to recruit pericytes, but ephrinAl may also be involved. Furthermore, ephrinAl is known 
to induce formation of actin stress fibers for smooth muscle cell contractility in regulating 
blood pressure (Kuijper et al., 2007). Interestingly, as Ephs and ephrins are known to be 
involved in both axonal guidance and angiogenesis, similarities between endothelial tip 
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cells and axon growth cones have recently been made. For example, peripheral nerves 
guide artery pattern formation and arteries will continue to form along disrupted nerves 
(Mukouyama et al., 2002). Therefore, the endothelial tip cells resemble axon growth 
cones by displaying a similar morphology, responding to similar growth factors including 
ephrins, and comprising a necessary component to form new cell-cell connections 
(Adams et al., 201 0). 
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Figure 4-1:. E~hrins ~nd their Eph receptors involved in vascular development. Membrane 
?ound ~~hrm hga?ds mteract with membrane bound Eph receptors. In this thesis, a covalently 
u?mobihzed ephrmA 1 (red box) was used to induce tubule formation in PEG-based hydro gels 
Figure adapted from (Gale et al., 1999) · 
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Although initially discovered in 1990 for involvement in the nervous system, the 
interaction between ephrinAl and its EphA2 receptor first elicited the role of ephrins and 
their Eph receptors in angiogenesis (Pandey et al., 1995). Activation ofephrin-A1 and its 
EphA2 receptor has been shown to initiate endothelial cell migration and capillary 
invasion by regulating vascular cell shape, migration, adhesion, and proliferation 
(Brantley et al., 2002). Expression of ephrinAl is induced by tumor necrosis factor-a, 
interleukin-1 beta, and vascular endothelial growth factor (Cheng, Brantley, and Chen, 
2002). Soluble ephrin-A1 has been shown to induce human umbilical vein endothelial 
cells (HUVECs) to form capillary-like structures (Daniel et al., 1996). Furthermore, a 
dominant-negative form ofEphA2 inhibited HUVECs from forming capillary-like 
structures (Ogawa et al., 2000). Soluble ephrinAl has also induced endothelial cell 
migration (Brantley et al., 2002) and capillary sprouting (Cheng, Brantley, Liu et al., 
2002) and in vivo angiogenesis in a variety of assays, including the cornea micropocket 
(Cheng, Brantley, Liu et al., 2002) and subcutaneous implantation ofephrinAl soaked 
sponges (Brantley-Sieders et al., 2004). Alternatively, an immobilized ephrinA1 may be 
used to induce the formation of a microvascular system in tissue engineering constructs 
(Moon et al., 2007), specifically PEG-based hydrogels. 
Immobilized growth factors and signaling peptides have been used to induce 
precise local effects. Previously, basic fibroblast growth factor was immobilized onto 
PEGDA hydrogels and induced vascular smooth muscle cell proliferation and migration 
(DeLong et al., 2005). Immobilized ephrinA1lead to dose-dependent endothelial cell 
adhesion to PEGDA hydrogels via av~3 integrins as well as tubule formation with lumen 
formation (Moon et al., 2007). In this work, the role of immobilized ephrinAl was 
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highlighted in microvascular formation via 2D tubule formation ofHUVECs on 
hydrogels modified with PEG-ephrinAl and in three dimensional degradable matrices. 
Extensive tubule formation was visualized as early at 24 hours and up to 7 days. Tubule 
deposition of collagen IV was found to be dependent upon immobilized ephrinAl 
concentration, and laminin deposition was dependent upon immobilized ephrinA 1 
concentration and time. To confirm the role of the EphA2-ephrinA1 interaction in tubule 
formation, soluble EphA2 reduced tubule formation in a co-culture ofHUVEC and 
human brain vascular pericytes on modified hydrogels. Finally, hydrogels incorporating 
immobilized ephrinAI in a mouse cornea micropocket exhibited a significant increase in 
vessel density and the number of branch points as well as space filling parameters of 
fractal dimension and lacunarity. Based on these findings, immobilized ephrinAl 
represents a promising molecule to regulate cell adhesion and migration for the formation 
of a microvasculature in tissue engineered constructs. 
4.2 Materials and Methods 
4.2.1 Cell Maintenance 
Human Umbilical Vein Endothelial Cells (HUVEC, Lonza, Walkersville, MD) 
were cultured in endothelial growth medium EGM-2 (Lonza), supplemented with the 
EGM-2 bullet kit containing ascorbic acid, epidermal growth factor, fibroblast growth 
factor (hFGF-2), heparin, hydrocortisone, insulin-like growth factor, GA-1000 
(gentamicin, amphotericin-B), and 2% fetal bovine serum (Bulletkit, Lonza). Human 
brain vascular pericytes (HBVP, ScienCell, Carlsbad, CA) were cultured in pericyte 
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medium (ScienCell) on poly-L-lysine coated flasks (2 J..Lg/cm2). HUVECs were used from 
passages 4 to 6, and HBVP cells were used from passages 4 to 9. Cells were incubated at 
37 °C and 5% C02 with media replenishment and subculturing as necessary. 
Immunohistochemistry was performed to confirm ephrinA 1 expression on HBVP and 
EphA2 expression on HUVECs (Figure 4-2). 
EphA2 DAPI ephrinAl merge 
Figure 4-2: HBVP positively label for expression ofEphA2 (green) and ephrinAl (red) while 
HUVECs only express EphA2. 
4.2.2 Seeding Cells on Modified Hydrogel Surfaces with Soluble EphA2 
Hydrogel surfaces were modified as described in Chapter 2 with 50 mg/ml PEG-
RGDS. 8.5 x 105 cells/cm2 HUVEC and HBVP cells were seeded onto the modified 
surfaces at a ratio of 4:1 HUVEC:HBVP. Cells were seeded in media with 0, 500 ng/ml, 
1500 ng/ml, or 5000 ng/ml soluble EphA2 (R&D Systems) based upon previously 
established effective levels ofEphA2 (Dobrzanski et al., 2004). Six days after cell 
seeding, hydrogels were imaged using an Axiovert (Zeiss) inverted fluorescence 
microscope. Hydrogel area and tubule length were quantified as described above. 
4.2.3 PEG-ephrinAl Synthesis 
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Acryloyl-PEG-succinimidyl carbonate (PEG-SMC) was synthesized in house in 
order to formulate a product that was capable of reacting in aqueous conditions, amenable 
for protein conjugations. Synthesis followed procedures previously outlined. (Leslie-
Barbick et al., 2009) 
EphrinA1 was obtained from R&D Systems (Minneapolis, MN) as a recombinant 
fusion protein containing the extracellular binding portion of ephrinA 1 and the Fe 
fragment ofhuman IgG. This protein, now referred to as ephrinA1, was reacted with in-
house synthesized acryloyl-PEG-SMC to form PEG-ephrinAl (Figure 4-2 A and B). 200 
mM sodium bicarbonate buffer (pH 8.5) was used to dissolve synthesized acryloyl-PEG-
SMC. The solution was sterile filtered (0.2 ~-tm) and combined with ephrinA1 at a 1:100 
molar ratio of ephrinA 1 :PEG-SMC. The reaction was placed on a rocker for four days at 
4°C before lyophilization under sterile conditions. The PEG-ephrinA1 powder was 
reconstituted and stored in HEPES Buffered Saline (100 mM NaCl, 10 mM HEPES in 
deionized water; HBS; pH 7.4) for up to three months at 4°C. A western blot was used to 
confirm successful conjugation on a 4-15% Tris-HCL precast polyacrylamide gel 
(Biorad, Hercules, CA). The primary antibody used was anti-ephrinAl produced in goat 
(Sigma, St. Louis, MO) with secondary antibody HRP-conjugated rabbit anti-goat IgG 
(Sigma). Using an ECL TM chemiluminescent western blotting analysis system (GE 
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Healthcare, Buckinghamshire, UK) images were taken on an LAS 4000 (FujiFilm, Little 
Rock, AK). 
4.2.4 Surface Modification of Hydrogels with PEG-ephrinAl 
6 kDa PEGDA hydrogels were synthesized by dissolving polymer (1 0% w/v) in 
HBS with 10 ~-tl/ml acetophenone stock solution (300 mg acetophenone in 1 ml n-vinyl 
pyrrolidone (NVP)). Prepolymer solution was injected between glass slides separated by a 
0.75 mm polytetrafluoroethylene spacer secured by binder clips. Hydrogels were 
crosslinked via exposure to UV light for 30 s and allowed to swell by soaking in HBS 
with 0.1% sodium azide. 
Circular disks of diameter 5 mm were punched from the bulk hydrogels using a 
#2 biopsy punch. A solution containing 50 mg/ml PEG-RGDS and 10 J..Ll/ml 
acetophenone stock solution with 0, 0.0392, 0.216, 0.392 J..Lg PEG-ephrinA1 was added to 
the gel surface and exposed to UV light for 2 minutes to achieve conjugation. Hydrogels 
were soaked in sterile HBS before use. HUVECs (8.5 x I 05 cells/cm2) were seeded onto 
the modified surfaces and imaged using an Axiovert (Zeiss) inverted fluorescence 
microscope 2, 3, and 4 weeks after cell seeding. Images of the hydrogels were merged 
using Adobe Photoshop Elements, and modified surface area and tubule lengths were 
traced using Adobe Illustrator. Modified surface are and tubule lengths were quantified 
using ImageJ. 
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4.2.5 Endothelial Cell Encapsulation into Degradable Hydrogels 
To delineate the effects ofPEG-ephrinA1 on endothelial cells in 3D, HUVECs 
were encapsulated into MMP-sensitive hydrogels containing PEG-ephrinA1. Polymer 
solution was prepared with a final formulation of 10% PEG-PQ-PEG, 3.5 J.Unol/ml PEG-
RGDS, 1.5% triethanolamine (v/v), 10 Jlllm1 eosin Y stock solution (10 mM Eosin Yin 
MilliQ H20), and 3.95 Jlllml NVP in 10 mM HBS. Three concentrations ofPEG-
ephrinA1 were used in combination with PEG-RGDS, including 0.25 ng!ml, 2.5 ng!ml, 
and 25 ng!ml. Hydrogels containing PEG-RGDS alone were used as a control group. 
Cells were harvested using trypsin-EDT A and counted using a Coulter counter. After 
counting, the cells were pelleted by centrifuging at 2700 RPM for 4 min and resuspended 
in polymer solution to a concentration of 10,000 cells/ J.d. Five J.l.l droplets of cell-laden 
polymer were formed between a Sigmacoted (Sigma) glass slide and an acrylated 
coverglass spaced by a 380 nm strip ofpolydimethylsiloxane and exposed them to white 
light for 30 second. Hydrogels were immediately immersed in EGM-2 media. 
4.2.6 Immunohistochemistry for Extracellular Matrix Proteins 
To examine tubule morphology, immunohistochemistry was performed to identify 
tubule structure and extracellular matrix production. Gels were fixed in 4% 
paraformaldehyde for 20 min and washed with phosphate buffered saline (PBS). 0.5% 
Triton-X was used to permeabilized cells for 10 min followed by a second PBS wash. 
Hydrogels were blocked with 3% bovine serum albumin (BSA). Gels were incubated 
with a 1:100 dilution of rhodamine phalloidin (Invitrogen) with 2 J.1.M DAPI in 1% BSA 
for 2 hrs. Images were obtained on a confocal microscope (Zeiss5 LIVE, Plan-
Apochromat 20x objective with 0.8 numerical aperture). To quantifY resulting tubule 
formation using phalloidin stainin, Farsight was used to calculate the percent of each 
cell's borders that were shared with other cells (Roysam et al., 2008; Bjomsson et al., 
2008). 
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To identifY collagen IV and laminin production, 3% normal donkey serum 
(Sigma) was used as a blocking agent. Primary antibodies were diluted in 3% BSA in 
PBS and incubated over night at 4 °C on a rocker table. Primary antibodies included anti-
collagen IV produced in rabbit (Abeam, Cambridge, MA) and anti-laminin produced in 
chicken (Sigma). Gels were rinsed five times in PBS for 1 h each time. Gels were 
incubated with a 1 :500 dilution of Alexafluor 488 donkey anti-rabbit IgG (Invitrogen) or 
Alexafluor 488 goat anti-chicken IgG (Invitrogen) overnight at 4 °C in order to visualize 
the primary antibodies. PBS washing was repeated and gels were imaged using a 
confocal microscope. Alexafluor 488 pixel intensity in 3D projections of20 ~in 
thickness with 1 ~ in between slices were quantified in ImageJ and normalized to cell 
number using DAPI pixel intensity. 
4.2.7 Hydrogel Implantation into the Mouse Cornea Angiogenesis Assay 
Hydrogel preparation and implantation followed the protocol outlined in Poche et 
al. (Poche et al., 2009). Briefly, hydrogels were prepared to a 10% polymer weight 
percentage of degradable PEG-PQ-PEG, 3.5 J.lffiOl/ml PEG-RGDS, 10 J.tl/ml 
acetophenone stock solution, and 160 ng soluble platelet derived growth factor BB per 
gel with or without 1.6 ng PEG-ephrinA1 per gel (n=5 and 6, respectively). Images of 
vessels on the hydrogel were compiled from projections of z-stacks exactly 22 f.IJil in 
thickness, spaced 1.1 f.IJil apart. 
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Confocal z-stacks were used to quantify vessel parameters. Vessel branch points 
and diameters were quantified using the image browser in the LSM software. Fractal 
dimension, lacunarity, and vessel density were quantified as previously described (Gould 
et al., 2011). The fractal dimension was quantified to describe the complexity of the 
vessel network and lacunarity to examine nonuniformity of cell distribution in a scale-
invariant manner (Mandelbrot, 1982; Lopes et al., 2009). 
4.2.8 Statistics 
Two-way ANOVA and subsequent Tukey's Least Significant Difference (LSD) 
tests were used to statistically analyze vessel formation and extracellular matrix 
production. For each analysis, p<0.05 was considered significant. 
4.3 Results 
4.3.1 Soluble EphA2 Downregulates PEG-ephrinAl-induced Tubule Formation 
To investigate the role of the EphA2-ephrinA1 interaction in tubule formation, 
soluble EphA2 was used to inhibit PEG-ephrinA1 induced tubule formation. A co-
culture ofHUVEC and HBVP was used since it has previously been shown to form 
tubule networks (Stratman et al., 2010). Six days after cell seeding, the co-culture of 
HUVEC and HBVP exhibited a reduction in tubule formation dependent upon dose of 
soluble EphA2 (Figure 4-3; p<0.05), confirming the importance of the EphA2-ephrinA1 
interaction in tubule formation. 
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Figure 4-3: Soluble EphA2 confirms the role of EphA2-ephrinA1 in tubule formation. 
CD31-labeled vessels (green) are visible only in the lowest dose of 500 nglml EphA2 (B) while 
no vessels are visible in the highest dose of 5000 nglml EphA2 (A; nuclei=blue, a- smooth 
muscle actin=red; scale bar= 50 Jlm). Disruption of the EphA2-ephrinA 1 interaction between the 
cells via soluble EphA2 in the media induced a dose dependent decrease in tubule formation 
between HBVP and HUVECs (C). All dose pairings exhibit statistical significance except 1500 
and 500 ng/ml (p<0.05). 
4.3.2 Polymer Characterization 
PEG-ephrinAl was synthesized by reacting acrylol-PEG-succinimidyl carbonate 
(Figure 4-4 A) with the primary amines of ephrinA 1 to form a conjugated biomolecule 
(Figure 4-4 B). Successful conjugation of acrylyl-PEG-SCM to ephrinA 1 was confirmed 
using a western blot where the increase in molecular weight confirms conjugations of 
PEG chains to ephrinAl (Figure 4-4 C). 
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Figure 4-4: Successful conjugation of ephrinAl. Immobilized ephrinAl was synthesized by reacting 
acrylol-PEG-succinimidyl carbonate (A) with primary amines on ephrinA 1 (B). Successful conjugation of 
PEG to ephrinA 1 was confirmed with a western blot where an increase in molecular weight is visualized 
via the addition of PEG chains to the protein (C). 
4.3.3 HUVEC Tubule Formation on Hydrogel Surfaces Modified with PEG-
ephrinAl 
HUVECs seeded onto surfaces modified with three concentrations of PEG-
ephrinA1 exhibited robust tubule formation with branching networks. Using a two way 
ANOVA and Bonferroni post hoc analysis, a significant effect of the PEG-ephrinA1 
concentration was observed (Figure 4-5, p<<0.001). As early as 14 days, a direct 
relationship existed between the concentration of PEG-ephrinA 1 and tubule formation 
with a significant difference between the highest concentration of 0.392 11g and both 0 
and 0.039 jlg (p<0.05). Prolonged ephrinA 1 signaling via immobilization onto the surface 
maintained tubule formation, especially for the highest concentration ofPEG-ephrinAl. 
A significant difference between the control group and both 0.216 and 0.392 J.lg PEG-
ephrinA 1 groups confirms the concentration affect (p<0.05). 
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Figure 4-5: HUVECs seeded onto surfaces modified with PEG-ephrinAl exhibited robust 
tubule formation where PEG-ephrinA1 concentration had a significant effect (p<<0.05). As 
early as 14 days, the 0.392 Jlg PEG-ephrinA 1 induces significantly more tubule formation when 
compared to 0 and 0.039 Jlg (#, p<0.05). By 28 days, the presence ofPEG-ephrinA1 maintains 
tubule formation, and a significant difference is visible between the control and both 0.216 and 
0.392 Jlg PEG-ephrinA 1 (* , p<0.05). 
4.3.4 Encapsulated HUVECs with PEG-ephrinAl form tubule networks 
HUVECs encapsulated in degradable hydrogels with PEG-ephrinAl formed 
tubule networks, visualized from 6 hours to 7 days via staining for actin and nuclei. Three 
different concentrations ofPEG-ephrinAl were used, including 0.25, 2.5 , and 25 ng/ml 
and compared to the presence of no PEG-ephrinA 1 (Figure 4-6). At early timepoints 
including 24 and 48 hours, the low concentration of 0.25 ng/ml PEG-ephrinA 1 induced 
the most tubule formation. However, by 5 and 7 days, the highest concentration of25 
133 
ng/ml PEG-ephrinAl induced robust tubule formation. In order to quantify tubule 
formation, the percentage of shared borders was calculated for all cells. Using a two way 
ANOV A, the concentration of PEG-ephrinAI, the time elapsed, and the interaction 
between the concentration and time were found to affect HUVEC tubule formation. 
Using a Bonferroni post hoc test, individual comparisons were made. For example, the 
low concentration of0.25 ng/ml PEG-ephrinAl was significantly different from all other 
treatments at 24 hours (p<0.05). This finding corresponds to the images, which clearly 
show tubule formation only in the low concentration. By 7 days, the control with no 
PEG-ephrinA I was statistically significant from all concentrations of PEG-ephrinA 1. 
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Figure 4-6: PEG-ephrinAl enhances 3D tubule formation. HUVEC tubule formation in 3D 
degradable hydrogels with 0, 0.25, 2.5, or 25 ng/ml PEG-ephrinA 1 was visualized with staining 
for nuclei (blue) and actin filaments (red; scale bar= 50 ).!m; 3D projects of 20 ).!ill with 1 J.tm in 
between slices). Robust tubule formation was seen as early as 24 hours with 0.25 ng/ml PEG-
ephrinA 1; however, tubule formation at this lower concentration of PEG-ephrinA 1 regressed by 5 
days. More robust long term tubule formation was visualized with 25 ng/ml PEG-ephrinA 1, seen 
at 2 and 5 days. In order to quantify the resulting tubule formation, the parameter percent shared 
borders was calculated to examine the percentage of each cell 's edges that were interacting with 
other cells to form tubule networks. As the graph corresponds to the images, robust tubule 
formation was seen at early timepoints using low PEG-ephrinA 1 concentrations and at late 
timepoints using higher PEG-ephrinA 1 concentrations. A two-way ANOV A shows a significant 
effect of PEG-ephrinA 1 concentration and time. Additional images are available in the 
supplemental material. 
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4.3.5 Collagen IV and Laminin Expression by Tubule Networks 
Immunohistochemistry was performed to investigate the role of extracellular 
matrix production, specifically collagen IV and laminin, production in tubule formation 
and stabilization. In order to allow time for collagen IV and laminin synthesis and 
deposition, staining began with the 2 day timepoint. The peak fluorescence intensities of 
the collagen IV graph were found to correspond to visually identified areas ofhigh tubule 
formation (Figure 4-7). Specifically, 0.25 ng/ml PEG-ephrinAl at 2 days and 25 ng/ml 
PEG-ephrinAl at 7 days showed the highest expression (Figure 4-7). Laminin deposition 
was found to be dependent upon PEG-ephrinAl concentration and time (p<0.05) with 
laminin deposition increasing over time (Figure 4-8). For example, laminin expression 
increased as more PEG-ephrinAl was included at both 5 and 7 days, confirming the 
dependence upon PEG-ephrinAl concentration (Figure 4-8). Looking specifically at 
images of 0.25 and 2.5 ng/ml, the increase in pixel intensity :from 5 to 7 days is also 
clearly visible, highlighting the dependence upon time. 
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Figure 4-7: Collagen IV deposition is affected by PEG-
ephrinAl concentration. Collagen IV deposition (green) in 
addition to nuclei (blue) illustrated the effect ofPEG-
ephrinA 1 concentration of collagen IV deposition, where 
areas of high tubule formation correspond to areas of high 
collagen IV deposition. This effects is noticeable at 2 days 
using the 0.25 ng/ml PEG-ephrinA 1 concentration as well as 
the 7 days 25 ng/ml PEG-ephrinA 1 concentration (Scale bar 
= 100 jlffi). 
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Figure 4-8: Laminin deposition is dependent 
upon PEG-ephrinAl concentration. Laminin 
deposition (green) in addition to nuclei (blue) was 
shown to be dependent upon both PEG-ephrinA 1 
concentration and time (scale bar= 100 J..lm) (B). For 
example, at 5 days, 25 ng/ml PEG-ephrinA1 
expresses the most laminin and laminin deposition 
decreases with PEG-ephrinA 1 dose (A). The effects 
of time are visible in 2.5 ng/ml PEG-ephrinA1 
where there is a notable increase in laminin 
deposition. 
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4.3.6 PEG-ephrinAl Enhances the In vivo Vascular Response 
Hydrogels were implanted into the mouse cornea micropocket to investigate the 
impact ofPEG-ephrinA1 in vivo. The mouse cornea micropocket facilitates image 
analysis of angiogenesis, using an established and reproducible assay. Using the Flkl-
myr::mCherry transgenic mouse, soluble PDGF was used to stimulate fluorescently 
labeled angiogenic processes to grow onto the gel from the surrounding limbus. The 
addition of immobilized ephrinA1 allowed prolonged signaling once the vessels had 
reached the hydrogel, resulting in a very different vascular morphology in response to 
PEG-ephrinA1 (Figure 4-9B) as compared to no PEG-ephrinA1 (Figure 4-9A). Fourteen 
days after implantation, this vascular morphology was quantified, resulting in a 
significant increase {p<0.05) in vessel density (Figure 4-9C) and vessel branch points 
(Figure 4-9D) with the addition ofPEG-ephrinA1. Additionally, space filling parameters 
were also used to quantify vessel morphology (Gould et al., 2011). The addition ofPEG-
ephrinA1 significantly increased both (p<0.05) fractal dimension (E) and lacunarity (F), 
indicating a greater complexity among the vessel networks where immobilized PEG-
ephrinA1 was included. Interestingly, PEG-ephrinA1 induced smaller diameter vessels. 
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Figure 4-9: Immobilized ephrinAl enhances the in vivo vascular response. Bioactive hydrogels 
incorporating releasable PDGF and PEG-ephrinA 1 (B) showed a more robust vascular response than 
hydrogels with releasable PDGF alone (A) when implanted into the mouse cornea. The presence ofPEG-
ephrinA 1 induced a significant increase in vessel density (C), branch points (D) fractal dimension (E), 
and lacunarity (F). PEG-ephrinA 1 also stimulated a significant decrease in vessel diameter. 
4.4 Discussion 
Rapid vessel formation and perfusion is key to the survival of implanted cells 
(Hegen et al. , 201 0; Laschke et al. , 2006). While stable vessels have been formed in 
engineered constructs using multiple cell types (Chen et al. , 2008; Koike et al. , 2004), the 
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use ofPEG-ephrinAl removes the necessity for a supportive cell type. Exploiting the 
cell-cell interactions for vessel development offers an alternative approach for forming 
long-lasting stable tubule structures in engineered constructs (Jain et al., 2005; Francis et 
al., 2008). Specifically, an immobilized ephrinA1 has been used to induce tubule 
formation for its ability to influence endothelial cell migration and invasion. In 2D, 
immobilized ephrinAl lead to prolonged tubule formation and branching networks for 4 
weeks after cell seeding. In 3D degradable scaffolds, PEG-ephrinAl induced HUVEC 
tubule formation as early as 24 hours with persistent tubules up to 7 days. The dose of 
PEG-ephrinA1 incorporated into the scaffold can also be tailored based on the specific 
application. 
The mechanism by which ephrinAl stabilizes tubule formation may be basement 
membrane production, including laminin and collagen IV, as the basement membrane 
connects cells to the interstitial matrix and is necessary for tissue development and vessel 
stabilization (Kruegel et al., 2010). Samples were stained for the deposition oflaminin 
and collagen IV to determine vessel stabilization via basement membrane formation, and 
laminin deposition was found to be statistically dependent upon PEG-ephrinAl 
concentration and time while collagen IV deposition was found to be dependent upon 
PEG-ephrinA1 concentration. While laminin deposition indicates vessel maturation 
(Risau et al., 1988), collagen IV is largely responsible for the mechanical properties of 
the basement membrane (Kruegel et al., 2010). Laminins are critical in regulating cell 
adhesion, migration, and matrix-mediated signaling (Hamill et al., 2009) via interacting 
with their integrin receptors. Similarly, endothelial cell binding to collagen IV is 
mediated by integrins, and is necessary for cell adhesion, migration, and proliferation 
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(Khoshnoodi et al., 2008). Interestingly, cell binding to both laminin and collagen IV is 
regulated by avrh integrins, which is the same integrin that was shown induce endothelial 
cell adhesion in response to immobilized ephrinAl (Durbeej, 2010; Moon et al., 2007). 
The link between ephrinAl and laminin production has been previously established in 
tumor formation as ephrinA1 and EphA2 play a role in tumor neovascularization, 
enabling tumor growth (Ogawa et al., 2000). Heptocellular carcinoma cell lines that 
overexpressed ephrinA1 also increased expression oflaminin (Iida et al., 2005), and 
aggressive melanoma cells have also been found to overexpress EphA2 and laminin 
(Hendrix et al., 2003). 
To confirm the role ofthe EphA2-ephrinA1 interaction in tubule formation, 
soluble EphA2-Fc was used to prevent EphA2-ephrinA1 interaction between HUVECs 
and HBVP cells (Figure 4-3). Soluble EphA2-Fc was found to decrease tubule formation 
on modified hydrogel surfaces in a dose dependent manner. Similar findings have been 
illustrated when soluble EphA2-Fc inhibited vessel formation in two in vitro assays in a 
dose dependent manner (Dobrzanski et al., 2004). Soluble EphA2 has also been targeted 
in cancer therapy, where delivery of soluble EphA2 receptors inhibited tumor 
angiogenesis and disease progression (Cheng et al., 2003). 
The presence ofPEG-ephrinA1 in in vivo hydrogel implants in the mouse cornea 
induced vessel coverage ofthe hydrogel with an increase in vessel density and branch 
points but a decrease in vessel diameter. This phenomenon has been illustrated previously 
when Lee et al. generated an MMP-resistant form of vascular endothelial growth factor 
and these MMP-resistant VEGF tumors displayed an increase in branch points but 
decrease in diameter (Lee et al., 2005). Vessel remodeling involves alterations to 
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cytoskeletal organization, extracellular matrix composition, and cell-cell connections to 
stabilize vessels. Inhibition of av~3 integrins has been shown to prevent remodeling, and 
av~3 integrin binding is likely involved in determining vascular diameter (Martinez-
Lemus et al., 2009; Iruela-Arispe et al., 2009). Smooth muscle cell recruitment during 
vessel stabilization has also been linked to the av~3 integrin receptor, and may be an area 
for future investigation (Bendeck et al., 2000). Interestingly, embroid bodies lacking 
laminin y1 displayed an increase in lumen size, consistent with findings in laminin a4 
deficient mice (Jakobsson et al., 2008). The increase in lumen is possibly due to a 
weakening of the vessel wall or because laminin-rich basement membrane is important in 
polarization of endothelial cells, which is required for lumen formation. 
4.5 Conclusion 
The formation of a microvascular system is highly regulated by cell-cell 
interactions for capillary sprouting and remodeling. An immobilized ephrinAl was used 
to exploit the cell signaling interaction ofEphA2 and ephrinA1 seen in angiogenesis. 
PEG-ephrinA 1 was then shown to induce HUVEC tubule formation on surfaces modified 
with PEG-ephrinA1 as well as in 3D degradable hydrogels in a dose dependent manner. 
Collagen IV and laminin, extracellular matrix proteins involved in vessel stabilization, 
production was also found to be dependent upon PEG-ephrinA1 concentration. The 
presence of soluble EphA2 prevented EphA2-ephrinAl interactions between HUVEC 
and HBVP cells, reducing tubule formation in a dose dependent manner while confirming 
the importance of ephrinA1 in tubule formation. Finally, hydrogels incorporating PEG-
ephrinAl in vivo resulted in vessels with a statistically significant increase in vessel 
density, branch points, lacunarity, and fractal dimension. The results presented 
demonstrate the utility of an immobilized cell adhesion and patterning molecule 
ephrinAl in inducing microvascular network formation for use in tissue engineered 
constructs for applications in regenerative medicine. 
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Chapter 5: Encapsulated Cells Anastomose to Host Vasculature 
A significant portion of this chapter is from JE Saik and DJ Gould, ME Dickinson and JL 
West. "Building Vascular Bridges: Advances in Tissue Engineering." Nature 
Biotechnology. Submitted 2011 
5.1 Introduction 
The formation of stable and functional vessels in replacement tissues remains a 
tremendous challenge, and a deeper understanding of functional vessels is necessary to 
further tissue engineering, vessel biology, and cancer. Vascularized tissue constructs have 
a wide variety of applications in the replacement of damaged or diseased tissues 
including peripheral limb ischemia and chronic diabetic wounds. While many 
approaches utilize potent growth factors to induce angiogensis, an alternative employs 
cells themselves to recruit vessels via naturally secreted chemokines. Cell-based 
approaches eliminate the time-delay inherent in recruiting host vessels into the 
biomaterial and reduce the necessary concentration of potent growth factors. 
For example, Chen et al. allowed a co-culture of human umbilical vein endothelial cells 
(HUVECs) and fibroblasts to form tubes in vitro for seven days before in vivo 
implantation. Scaffolds containing pre-formed tubes led to anastamosis with the host 
vasculature within 5 days as compared to 14 days for scaffolds without pre-formed tubes. 
Additionally, the number and area of perfused lumens was significantly higher in 
prevascularized scaffolds (Chen et al., 2008). Koike et al. formed long-term stable 
vessels when HUVECs were used alone and in combination with pericyte precursor cells 
(lOTl/2) on a fibronectin-type I collagen matrix (Koike et al., 2004). HUVECs alone 
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formed vessels with minimal perfusion, but HUVECs and 10T1/2 cells formed a 
functional vascular network capable of anatosmosing with host circulatory system up to 
one year later (Au et al., 2007). When HUVECs were cocultured with 10Tl/2 cells, 
1 OTl/2 cells displayed a smooth muscle cell morphology and began expressing pericyte 
markers, such as a-smooth muscle actin, smooth muscle myosin, and calponin (Hirschi et 
al., 1998). 
Cellular response has been enhanced with the addition of growth factors. Lower 
doses of growth factors than currently used in clinical trials can be used to act upon the 
transplanted vessel-forming cells, promoting survival, proliferation, and differentiation. 
Peters et al. showed that functional vessels were formed after seven days when human 
microvascular endothelial cells were seeded with VEGF in PLG (Peters et al., 2002). 
The combination of dermal fibroblasts and HUVECs showed significantly more capillary 
formation in response to FGF-2 and VEGF (Hudon et al., 2003). Frerich et al. enhanced 
capillary formation by combining two cell types, HUVECs and stromal cells from 
adipose tissue, along with two growth factors, VEGF to stimulate angiogenesis and 
insulin-like growth factor (IGF)-1, to stabilize the capillary structures (Frerich et al., 
2001). 
In the thesis research, cell-laden hydrogels were evaluated using a mouse cornea 
micropocket angiogenesis assay (Poche et al., 2010; Moon, Saik, Poche et al., 2010), a 
reproducible and quantifiable assay in a normally avascular tissue (Kenyon et al., 1996). 
Flk1-myr::mCherrytransgenic mice were utilized, which display endothelial specific 
fluorescence to enable imaging of capillary invasion (Poche et al., 2009). This thesis 
research improved upon existing research by reducing the in vitro incubation time before 
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in vivo implantation, making the research more clinically applicable. Additionally, sites 
of anastomosis were identified as early as 24 hours after implantation, earlier than any 
other reports in the literature. Finally, most ofthe cell form tubes contained red blood 
cells, confirming their connection to the host vasculature. This system can be used to 
further probe the process of anastomosis to identify precise locations and timepoints. 
5.2 Materials and Methods 
5.2.1 Cellular Encapsulation 
To confirm that a co-culture of encapsulated cells forms tubules networks in 
response to growth factors, HUVEC and 10T1/2 cells at a 4:1 ratio were incorporated 
into hydrogels at a concentration of30,000 cells/J..Ll. Cells were centrifuged at 2700 RPM 
for 4 min and resuspended in polymer solution containing 10% PEG-PQ-PEG, 3.5 
J..lffiOl/ml PEG-RGDS, 10 J..Lmol eosin Y, and 3.5 J..Ll/ml NVP. Hydrogels were exposed to 
white light for 30 sec and immediately immersed in EGM-2 media. Four days later, cells 
were fixed with 4% formaldehyde, permeabilized with 0.5% Triton X-100, and blocked 
with 1% bovine serum albumin. Cells were then incubated with a 1 :20 dilution of 
rhodamine phalloidin (Invitrogen) in 300 nM DAPI for 2 h. Hydrogels were imaged on a 
confocal microscope (Zeiss5 LIVE, Plan-Apochromat 20x objective with 0.8 numerical 
aperture, for rhodamine: excitation= 532nm, emission BP filter= 560-675 nm, for DAPI: 
excitation = 405 nm, emission BP filter = 415-480 nm). 
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5.2.2 Encapsulated Cell Implantation into the Mouse Cornea 
Poly(ethylene glycol) (PEG) based hydrogels comprised of a biocompatible 
polymer with tunable mechanical properties (Hahn et al., 2007) were used to encapsulate 
a co-culture ofbEnd.3 endothelial cells and lOTl/2 pericyte precursors under mild 
photocrosslinking conditions. Gels with individual cell types were also crosslinked as 
controls. PEG-based hydrogels, normally resistant to protein adsorption and cellular 
adhesion, were cross-linked with immobilized fibronectin-derived peptide RGDS to 
enable cell adhesion. Hydrogels were rendered biodegradable by incorporating a matrix 
metalloproteinase-sensitive peptide into the polymer backbone (West et al., 1999). 
Encapsulated cells were allowed to culture for 48 hours before implantation. Prior to 
implanting the tubule containing constructs, mouse corneas were prevascularized by 
implanting hydro gels containing 320 ng of soluble platelet-derived growth factor-BB and 
80 ng fibroblast growth factor-2 which induced robust angiogenesis toward the hydrogel. 
Two weeks later, the growth factor implants were surgically excised (Figure 5-1). Cell-
laden implants were soaked in media containing 12 mollml PDGF for 2 hours before 
being implanted into the pre-vascularized cornea. Corneas were examined for 
anastomosis and perfusion one day and three days after implantation using confocal 
microscopy. 
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Figure 5-1: Protocol for Implanting Encapsulated Cells. A hydrogel containing soluble 
growth factors was implanted in a mouse cornea micropocket. 14 days after implantation, the 
angiogenic hydrogel was excised and replaced with a cell-laden hydrogel. 1-3 days after 
implantation, the hydrogel was examined for anastomosis between cell formed tubules and host 
vasculature and the presence of red blood cells in tubule networks. 
5.2.3 Viability Staining and Tubule Formation of Encapsulated Cells 
At the time of implantation, some gels were stained to determine cell viability and 
tubule formation. Cell viability was assessed using a LIVE/DEAD Viability/Cytotox icity 
kit for mammalian cells (Invitrogen, Carlsbad, California). Media was removed from 
cells and replaced with phosphate buffered saline (PBS, Sigma) solution containing 2 J.lM 
calcein AM (ex/em: 495 nm/515 run) and 4 J.lM ethidium homodimer (ex/em: 495 
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nm/635 nm). Cells with LIVE/DEAD solution were incubated at 37°C and 5% C02 for 
30 minutes before imaging with a 5LIVE confocal microscope. 
Tubule structures were visualized by staining nuclei with DAPI and actin with 
phalloidin. Hydrogels were incubated in 4% formaldehyde for 20 minutes and rinsed 
with PBS three times. Gels were incubated with a 0.5% Triton X solution for 30 minutes 
and rinsed three times again. A 1% bovine serum albumin (BSA) solution was placed on 
the gels for 40 minutes followed by a rinsing step. A 1: 100 dilution of rhodamine-
phalloidin was incubated on the gel overnight. After rinsing, a 1: 100 dilution of DAPI 
was incubated on the gels for one hour followed by rinsing and visualization under 
fluorescence microscopy. 
5.3 Results 
5.3.1 Encapsulated Cells form Tubule Networks 
Hydrogels containing encapsulated endothelial cells and mouse pericyte precursor 
cells demonstrate the bioactive efficacy of these releasable angiogenic growth factors. 
Hydrogels containing either VEGF, PDGF, or FGF induced encapsulated cells to initiate 
tubule formation as early four days after encapsulation; whereas, hydrogels without 
growth factors did not exhibit this response (Figure 5-2). This finding is supported by 
previous work, which exhibited the effects of angiogenic factor release and further 
supports the development of a tunable system for delivery. For example, VEGF release 
from PLGA/PEG microspheres increased HUVEC proliferation (King et al., 2000), FGF 
release from poly( ester urethane) urea scaffolds induced more smooth muscle cell 
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mitogenicity (Guan et al., 2007), and PDGF release from PLGA microspheres resulted in 
increased blood vessel number in an in vivo soft tissue wound repair model (Jin et al., 
2008). 
Figure 5-2: Encapsulated cells form tubule networks. Endothelial cells and pericyte precursor 
cells were encapsulated into degradable hydrogels with VEGF (A) PDGF (B), FGF (C), and no 
growth factor (D). In the presence of growth factors, tubules are visible after four days in culture, 
suggesting the utility of releasable growth factors in PEG hydrogels to initiate a desired biological 
response. 
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5.3.2 Encapsulated Cells Exhibit High Viability 
Using the co-culture ofbEnd.3 and 10Tl/2 cells, staining confirmed high viability 
of 82% ± 1.5%. Extensive tubule formation with branching, cell-cell interconnections, 
and network formation was visualized via actin staining (Figure 5-3). 
Figure 5-3: Encapsulated cells display high viability and robust tubule formation in vitro. A co-
culture ofbEnd.3 and 10T1/2 cells at a 4:1 ratio in matrix metalloproteinase-sensitive PEG-based 
hydrogels demonstrate 82% ± 1.5% viability (A, green= live; red= dead) after culturing for 48 hours. 
B) Cells also form robust tubules (arrow) as visualized via actin (red) and nuclei (blue) staining. The 
white arrow highlights an example of a tubule with interconnecting cells. Scale bar = 50 J.lffi. 
Additionally, each cell type was encapsulated individually to look for differences in cell 
viability. High cell viability was equally maintained for both cell types. Individual cell types 
were also examined for their ability to form tubule networks. 1 OT1/2 cells alone remained balled 
without elongating or forming networks. bEnd.3 cells elongated and formed cell-cell connections, 
but did not form robust tubule networks as seen in the co-culture of cells. 
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Figure 5-4: Individual cell types confirm cell viability and do not form tubule networks. 
5.3.3 Anastomosis Between Cell-formed Tubules and Host Vasculature 
mCherry-labeled capillaries sprouting from red blood cell-filled arterioles were 
seen connecting to tubules comprised of donor bEnd.3 cells (Figure 5-5 A-C). The 
presence of the originally seeded bEnd.3 cells in the tubules was confirmed using 
immunohistochemistry to stain for the middle T antigen, which was used to immortalize 
the bEnd.3 cells (Figure 5-5 D) (Rothermel et al., 2005). A cartoon rendering of cherry-
153 
labeled vessels and cell-formed tubules highlights the site of anastomosis and presence of 
red blood cells in the cell-formed tubules (Figure 5-5 E-F). 
Figure 5-S: Anastomosis between cell-formed tubules and host vasculature. Transgenic mice with 
fluorescently-tagged endothelial cells (red) enable visualization of smaller vessels (A, red arrow) 
branching from red blood cell filled arterioles 12 Jlm into the hydrogel. B) cherry-labeled capillaries (red 
arrow) connect to unlabeled cell-formed tubules containing red blood cells (yellow arrow) 32 Jlm into the 
hydrogel. C) Cells are seen spreading (yellow arrow) and forming tubules as deep as 58 Jlm into the 
hydrogel. D-F) To confirm the connection between implanted cells and host vasculature, bEnd.3 cells 
were stained for expression of the middle T antigen (green). D) Cherry labeled vessels anastomose to 
middle t antigen-positive bEnd.3 cells in a 3D rendering. E) A three dimensional rendering of red labeled 
host vasculature connecting to green labeled bEnd.3 cells confirms the presence of red blood cells (dark 
blue) in the cell-formed tubule. F) Upon closer examination, the precise location of anastomosis (red 
arrow) and presence of red blood cells (yellow arrow) is visible. 
These functional tubules had an average diameter of 8.2 Jlill ± 2.3 11m while 
nonfunctional tubules had an average diameter of 4.5 ± 0.9 11m 11m (Figure 5-6). The 
diameter of cell-formed tubules enlargened from 6.9 11m± 2.2 11m before implantation to 
8.2 11m± 2.3 11m upon perfusion. Furthermore, no statistical difference existed between 
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host vessels of diameter 9.5 ± 3.3 ~m and cell-formed tubules (Figure 5-6). 
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Figure 5-6: Tubule Diameter. The tubule diameter confirms that larger diameter tubules (8 Jlm) are 
similar in size to host vasculature and contain red blood cells while smaller diameter tubules ( 4 Jlm) 
remain nonfunctional. Furthermore, in vitro tubules enlarged upon red blood cell perfusion. 
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Figure 5-7: High perfusion of implanted 
tubules. 72% of cell-formed tubules contain 
red blood cells. 
Notably, 72% ofthe cell-formed tubules 
contained red blood cells, confirming their 
functionality (Figure 5-7). 
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5.4 Discussion 
This work presents the first precise visualization and confirmation of anastomosis 
between tubules formed by self-assembling cells in vitro and the host vasculature only 24 
hours after implantation in a synthetic material. Additionally, the time of in vitro 
incubation was shortened to only 48 hours, and networks formed by encapsulated bEnd.3 
and lOTl/2 cells were maintained once implanted in vivo. PDGF has previously been 
shown to induce an angiogenic response in the mouse cornea model (Saik et al., 2011). 
Previous studies had demonstrated the importance of in vitro incubation before 
implantation but required at least seven days incubation time and 5 days prior to 
anastomosis (Chen et al., 2008). For ultimate translation into clinical applications with 
cells derived from human patients, this work reduces the time of incubation before 
implantation and shortens the time to anastomosis to 24 hours and suggests that pre-
vascularization may help facilitate anastomosis. Furthermore, while long term stable 
vessels were formed in natural matrices(Koike et al., 2004), a synthetic PEG-based 
polymer can be used as a more advanced platform for testing and identifying key 
processes in vessel development and anastomosis. This system is widely applicable to 
vessel development and disease, including ischemia and organ transplant, and will likely 
shed insight on mechanisms and therapies. Future studies of this in vivo assay will 
pinpoint the exact moment of anastomosis and the required factors. Furthermore, this 
technological feat will allow for greater development in complexity and scale, including 
expansion of incorporated cell types and implant locations. 
5.5 Conclusion 
The formation of stable and functional vessels remains a tremendous challenge 
for replacement of damaged or diseased tissues. 48 hours after encapsulation, tubule 
networks consisting of endothelial cells and pericytes in poly( ethylene glycol) based 
hydrogels were implanted into a prevascularized mouse cornea micropocket. Cell-
formed tubules anastomosed to host vasculature within 24 hours, with 72% containing 
red blood cells, a major advance for design of perfused tissues. 
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Chapter 6: Conclusions and Future Directions 
6.1 Thesis Summary 
Currently, successfully engineered tissues are thin and avascular. In order to 
engineer more complex tissues for the hundreds ofthousands of people awaiting an organ 
transplant in the US alone, engineering constructs need a microvasculature. The 
microvasculature is essential to provide oxygen for cell survival, as well as transport of 
nutrients and waste. This thesis presents rationally designed materials and cell culture 
techniques capable of supporting functional tubule formation and stabilization. 
Combining a synthetic scaffold material with cells and their cell-secreted signals 
instigated tubule formation throughout the scaffold. Poly( ethylene glycol) (PEG) based 
hydrogels were modified to induce desired cell characteristics. In order to mimic the 
body's natural process of new capillary formation, endothelial cells and pericytes were 
used in these constructs. Human umbilical vein endothelial cells were used as a 
reproducible and readily available cell type with mouse pericyte precursor 1 OTl/2 cells. 
First, this thesis research showed the importance of testing angiogenic hydrogels in vivo 
in a mouse cornea micropocket angiogenesis assay, a naturally avascular tissue for easy 
imaging in a reproducible and quantifiable assay. Second, platelet derived growth factor-
DB (PDGF-BB), known for stabilizing newly formed tubule networks, was covalently 
immobilized via conjugation to PEG to enable prolonged bioactive signaling and 
controlled local delivery. Immobilized PDGF-BB led to tubule formation in two 
dimensions and three dimensions as well as angiogenesis in vivo. Similarly, immobilized 
ephrinA 1, a receptor tyrosine kinase also known for tubule stabilization also induce 
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tubule formation and extracellular matrix production. Finally, a co-culture of endothelial 
and pericyte cells encapsulated into hydrogels formed tubules that anastomosed to the 
host vasculature and contained red blood cells. PEG-based hydrogels represent a 
promising technique to induce microvascular formation in engineered constructs, leading 
to stable and functional vessel formation using covalently immobilized growth factors 
and encapsulated cells. These materials can be used for replacement of damaged or 
diseased tissues as the current supply of cadaveric donations cannot meet the demand of 
tissues for the 110,000 people awaiting an organ in the US. 
6.2 Conclusions 
This thesis research presents the first in vivo application of angiogenic PEG-based 
hydrogels. In order to move this translational research ever closer to clinical 
applications, an in vivo assay was necessary. PEG-based hydrogels were shown to 
induce functional vessel formation, which could be adjusted based on hydrogel design. 
Using rational design of these materials, the resulting vascular response was adjusted. 
This thesis presents the first work to covalently conjugate PEG to PDGF-BB, 
enabling precise control and local delivery to promote angiogenic activity in vitro and in 
vivo. Previous work showed that PDGF -BB signaled via endocytosis. However, the 
immobilized PDGF-BB confirms that PDGF-BB does not need to be internalized in order 
to signal. Additionally, PDGF-BB does not need to be cleaved from a matrix to promote 
angiogenic activity. One remaining hurdle is the stabilization of tubule formation. For 
example, tubules forming on 2D modified surfaces regressed. This phenomena was 
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visible for endothelial cells alone and for the co-culture of endothelial cells and pericyte 
precursor cells. In order for the tubule networks to be clinically relevant, tubules will 
need to remain functional until the material is replaced by host tissue. PDGF-BB does 
seem to prolong tubule formation but ultimate regression still occurred. 
Similar to PEG-PDGF, ephrinAI was immobilized to PEG and used to enhance 
angiogenic activity in 3D in vitro hydrogels and in vivo. PEG-ephrinAI induced collagen 
IV and laminin production. Still, the precise mechanism of ephrinA 1 angiogenesis 
activity still remains unknown. EphrinAl has not been as widely studied in angiogenesis 
applications, and its effects on signaling pathways remains to be explored. 
For ultimate clinical application, this thesis work implanted encapsulated cells 
into the mouse cornea and identified precise areas of anastomosis and tubule perfusion 
with red blood cells. Areas of anastomosis were identified by 24 hours, the earliest in all 
the literature. Furthermore, encapsulated cells were cultured in vitro for only 48 hours, 
which is the shortest incubation time for clinical applicability. In order to further verify 
this approach, the immune response to the implanted cells will need to be further 
investigated. For example, only mouse cells were used for implantation. Do suitable 
human cell lines exist or can the patient's own cells be used? 
6.3 Future Directions 
In order to advance this translational research, additional in vivo models will need 
to be developed. Several common in vivo angiogenic assays were discussed in chapter 2, 
including the mouse backpack chamber and CAM assay. Larger animal models will also 
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be necessary before clinical applications. Different in vivo models enable precise tuning 
of growth factor doses necessary for different species as well as different locations 
throughout the body. While the cornea provides an ideal place to determine the 
capabilities to induce angiogenesis, the cornea is mostly collagen I with low levels of 
oxygen, unlike the rest ofthe body. The presence of immune suppressant molecules and 
soluble VEGF receptors is unlike any other tissue. 
Since the cornea has a reduced immune response, the role of immune cells on 
angiogenesis will need to be examined. The role of macro phages on vessel development 
has recently been investigated using transgenic mouse models. For example, in chapter 2 
PDGF-BB and FGF-2 induced more organized branching networks than PDGF-BB, 
FGF-2, or VEGF alone. Interestingly, it was found that hydrogels releasing a 
combination ofPDGF-BB and FGF-2 induced a synergistic macrophage response (Figure 
6-1 ). While many bioengineers attempt to reduce the immune response to implanted 
hydrogels, this finding may suggest that a macrophage response is necessary and actually 
enhances the angiogenic response. These macrophages may be capable of acting as 
pericytes to support the newly formed capillaries (Figure 6-2). 
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Figure 6-1: Macrophage response to growth factor releasing hydrogels. Using a transgenic 
mouse line where macrophages fluoresce green, the macrophage response was quantified at 3 days 
post implantation. Normal corneas and hydrogels with no growth factor do not stimulate and 
angiogenic response. Hydrogels with VEGF, FGF-2, or PDGF-BB alone induce a mild 
macrophage response. However, hydrogels with both PDGF -BB and FGF -2 induce a synergistic 
macrophage response. 
Figure 6-2: Macrophages acting as pericytes. A high magnification image of the PDGF-
BB and FGF -2 releasing gels shows vessels (red) are tightly surrounded by macrophages 
(green). Macrophages have a typical pericyte morphology in wrapping around the capillary 
over multiple endothelial cells. 
As the formation of new capillaries is better understood, the knowledge can be 
applied to therapies for cancer. As tumors growth larger than 1 mm in diameter, the 
tumor must form its own blood supply. Tumors are rapidly growing and often induce 
leaky vessel formation. The knowledge gained through inducing angiogenesis in 
biomaterials can be applied to better understanding tumor vessel formation in order to 
162 
develop more targeted therapies. For example, previous work has shown that endothelial 
cells form tubule networks on soft matrices, but the tubule formation decreases with 
increasing stiffuess (Ingber et al., 1989; Deroanne et al., 2001). Using this information, 
tumor stiffuess could be examined in order to identify soft tumors with rapidly growing 
vessels. Furthermore, PEG hydro gels represent an optimal system to study individual 
components of the extracellular environment that induce cancer activity, including 
metastasis. Some hypothesize that the location of a cancer's metastasis is due to the 
extracellular matrix cues. PEG-based hydrogels can incorporate specific signal or 
mechanical properties to induce a metastatic phenotype. 
Summary 
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PEG-based hydrogels represent a promising technique to induce microvascular 
formation in engineered constructs for the replacement of damaged or diseased tissues. 
Using immobilized growth factors and encapsulated cells, stable and functional vessel 
were formed throughout the hydrogel material. Furthermore, all materials were tested in 
an in vivo mouse cornea micropocket angiogenesis assay to illustrate the achievability of 
implanting angiogenic materials. This novel hydrogel-based system can be used to 
support angiogenesis for the development of clinically applicable vascularized tissues. 
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